Mutation O
of O
a O
kappa B
B I
core I
sequence I
identified O
in O
the O
IL B
- I
2 I
promoter I
( O
- O
206 O
to O
- O
195 O
) O
partially O
inhibits O
both O
mitogen O
- O
and O
HTLV O
- O
I O
Tax O
- O
mediated O
activation O
of O
this O
transcription B
unit I
and O
blocks O
the O
specific O
binding O
of O
two O
inducible B
cellular I
factors I
. O

These O
kappa B
B I
- I
specific I
proteins I
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa B
B I
enhancer I
present O
in O
the O
IL B
- I
2R I
alpha I
promoter I
. O

Different O
fragments O
of O
unrearranged B
human I
variable I
region I
of O
immunoglobulin B
kappa I
gene I
( O
V B
kappa I
) O
were O
used O
for O
cell O
- O
free O
in O
vitro O
transcription O
and O
DNA O
mobility O
shift O
assays O
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

Extracts O
of O
the O
B O
- O
cell O
line O
, O
BJA O
- O
B O
, O
contain O
high O
levels O
of O
NF B
- I
A2 I
and O
specifically O
transcribe O
Ig B
promoters I
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters B
. O

Molecules O
involved O
in O
the O
antigen O
receptor O
- O
dependent O
regulation O
of O
early B
T I
cell I
activation I
genes I
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T B
cell I
activation I
- I
specific I
enhancer I
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Molecules O
involved O
in O
the O
antigen O
receptor O
- O
dependent O
regulation O
of O
early B
T I
cell I
activation I
genes I
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T B
cell I
activation I
- I
specific I
enhancer I
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

One O
of O
these O
sequences O
forms O
a O
protein O
complex O
, O
NFAT B
- I
1 I
, O
specifically O
with O
nuclear O
extracts O
of O
activated O
T O
cells O
. O

Studies O
with O
inhibitors O
of O
protein O
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator O
of O
the O
IL B
- I
2 I
gene I
in O
Jurkat O
T O
cells O
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT B
- I
1 I
. O

NFAT B
- I
1 I
, O
or O
a O
very O
similar O
protein O
, O
bound O
functional O
sequences O
of O
the O
long B
terminal I
repeat I
( O
LTR B
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O

NFAT B
- I
1 I
, O
or O
a O
very O
similar O
protein O
, O
bound O
functional O
sequences O
of O
the O
long B
terminal I
repeat I
( O
LTR B
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O

These O
characteristics O
suggest O
that O
NFAT B
- I
1 I
transmits O
signals O
initiated O
at O
the O
T B
cell I
antigen I
receptor I
. O

Characterization O
of O
thyroid B
hormone I
receptors I
in O
human O
IM O
- O
9 O
lymphocytes O
. O

Although O
putatively O
identified O
more O
than O
10 O
years O
ago O
, O
thyroid B
hormone I
receptors I
in O
human O
tissues O
remain O
poorly O
characterized O
. O

As O
a O
first O
step O
towards O
understanding O
the O
mechanism O
of O
thyroid O
hormone O
action O
in O
man O
we O
have O
characterized O
T3 B
binding I
sites I
in O
nuclei O
of O
the O
human O
lymphoblastoid O
line O
, O
IM O
- O
9 O
cells O
. O

Under O
these O
conditions O
T3 B
binding I
sites I
in O
the O
nuclear O
extracts O
were O
present O
at O
a O
concentration O
of O
22 O
. O
4 O
+ O
/ O
- O
8 O
. O
6 O
fmol O
/ O
mg O
protein O
and O
showed O
an O
affinity O
of O
( O
Kd O
, O
room O
temperature O
) O
140 O
+ O
/ O
- O
10 O
pmol O
/ O
l O
. O

These O
results O
suggest O
that O
the O
T3 B
binding I
sites I
present O
in O
human O
IM O
- O
9 O
lymphocyte O
nuclei O
and O
extracts O
thereof O
are O
thyroid B
hormone I
receptors I
. O

These O
results O
suggest O
that O
the O
T3 B
binding I
sites I
present O
in O
human O
IM O
- O
9 O
lymphocyte O
nuclei O
and O
extracts O
thereof O
are O
thyroid B
hormone I
receptors I
. O

Formation O
of O
this O
complex O
was O
selectively O
inhibited O
by O
the O
region O
in O
HIV B
- I
1 I
containing O
a O
silencer B
element I
. O

We O
discuss O
the O
possibility O
that O
DNA B
- I
binding I
factors I
may O
coregulate O
HIV O
- O
1 O
and O
Rpt O
- O
1 O
gene O
expression O
through O
a O
common O
transcriptional B
silencer I
element I
. O

Coordinate O
regulation O
of O
HLA B
class I
II I
gene I
expression O
during O
development O
and O
coinduction O
of O
class B
II I
genes I
by O
soluble B
factors I
suggests O
that O
common O
trans B
- I
acting I
factor I
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

In O
B O
- O
lymphoblastoid O
cell O
lines O
derived O
from O
two O
independent O
class O
II O
- O
deficient O
bare O
lymphocyte O
syndrome O
patients O
, O
we O
observed O
a O
drastic O
decrease O
in O
transcription O
rates O
of O
the O
class B
II I
genes I
. O

When O
these O
cell O
lines O
are O
fused O
, O
class B
II I
genes I
are O
reexpressed O
, O
indicating O
that O
immunodeficiencies O
in O
bare O
lymphocyte O
syndrome O
patients O
are O
the O
result O
of O
two O
distinct O
mutations O
. O

Further O
studies O
show O
that O
genes O
governing O
the O
expression O
of O
class B
II I
antigens I
fall O
into O
at O
least O
three O
complementation O
groups O
; O
two O
of O
these O
were O
previously O
unidentified O
in O
mutant O
cell O
lines O
generated O
in O
vitro O
. O

In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1 B
. I
1 I
and O
NFX1 B
. I
2 I
, O
that O
bind O
to O
the O
DRA B
X I
consensus I
element I
. O

In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1 B
. I
1 I
and O
NFX1 B
. I
2 I
, O
that O
bind O
to O
the O
DRA B
X I
consensus I
element I
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2 O
. O
2 O
. O
5 O
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X B
box I
, O
clear O
alterations O
in O
either O
NFX1 B
. I
1 I
or O
NFX1 B
. I
2 I
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines O
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2 O
. O
2 O
. O
5 O
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X B
box I
, O
clear O
alterations O
in O
either O
NFX1 B
. I
1 I
or O
NFX1 B
. I
2 I
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines O
. O

Estradiol O
receptors O
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
in O
hepatitis O
B O
virus O
carriers O
treated O
with O
interferon B
- I
alpha I
. O

Estradiol B
receptors I
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
on O
estradiol B
receptors I
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

Estradiol B
receptors I
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
on O
estradiol B
receptors I
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

This O
low O
level O
of O
cytosol O
estradiol B
receptors I
in O
patients O
with O
chronic O
hepatitis O
B O
was O
increased O
by O
the O
administration O
of O
IFN B
- I
alpha I
. O

In O
addition O
, O
when O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN B
- I
alpha I
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol B
receptors I
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN B
- I
alpha I
. O

In O
addition O
, O
when O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN B
- I
alpha I
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol B
receptors I
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN B
- I
alpha I
. O

Immunoglobulin B
heavy I
- I
chain I
genes I
contain O
two O
conserved B
sequence I
elements I
5 O
' O
to O
the O
site O
of O
transcription O
initiation O
: O
the O
octamer O
ATGCAAAT O
and O
the O
heptamer O
CTCATGA O
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B
and I
lymphoid I
- I
cell I
- I
specific I
octamer I
transcription I
factors I
( O
OTF B
- I
1 I
and O
OTF B
- I
2 I
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B
sequence I
elements I
, O
forming O
either O
homo B
- I
or I
heterodimeric I
complexes I
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B
and I
lymphoid I
- I
cell I
- I
specific I
octamer I
transcription I
factors I
( O
OTF B
- I
1 I
and O
OTF B
- I
2 I
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B
sequence I
elements I
, O
forming O
either O
homo B
- I
or I
heterodimeric I
complexes I
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B
and I
lymphoid I
- I
cell I
- I
specific I
octamer I
transcription I
factors I
( O
OTF B
- I
1 I
and O
OTF B
- I
2 I
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B
sequence I
elements I
, O
forming O
either O
homo B
- I
or I
heterodimeric I
complexes I
. O

Identification O
of O
a O
novel O
lymphoid B
specific I
octamer I
binding I
protein I
( O
OTF B
- I
2B I
) O
by O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA O
) O
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin B
( I
Ig I
) I
heavy I
and I
light I
chain I
genes I
and O
in O
the O
heavy B
chain I
enhancer I
and O
is O
a O
major O
determinant O
of O
the O
cell O
type O
specific O
expression O
of O
Ig B
genes I
in O
B O
cells O
. O

The O
differential O
usage O
of O
this O
regulatory O
sequence O
motif O
is O
thought O
to O
be O
mediated O
by O
different O
species O
of O
octamer B
binding I
proteins I
. O

One O
species O
of O
100 O
kd O
, O
designated O
OTF B
- I
1 I
, O
is O
present O
in O
all O
cell O
types O
and O
may O
exert O
its O
activating O
function O
only O
when O
it O
can O
interact O
with O
additional O
adjacent O
transcription B
factors I
. O

The O
lymphoid B
cell I
specific I
octamer I
binding I
protein I
of O
60 O
kd O
( O
OTF B
- I
2A I
) O
specifically O
stimulates O
Ig B
promoters I
which O
consist O
essentially O
of O
a O
TATA B
- I
box I
and O
an O
octamer B
sequence I
upstream O
of O
it O
. O

The O
lymphoid B
cell I
specific I
octamer I
binding I
protein I
of O
60 O
kd O
( O
OTF B
- I
2A I
) O
specifically O
stimulates O
Ig B
promoters I
which O
consist O
essentially O
of O
a O
TATA B
- I
box I
and O
an O
octamer B
sequence I
upstream O
of O
it O
. O

Here O
we O
present O
evidence O
for O
yet O
another O
B B
cell I
specific I
octamer I
binding I
protein I
of O
75 O
kd O
( O
OTF B
- I
2B I
) O
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF B
- I
2B I
( O
but O
not O
OTF B
- I
2A I
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B
enhancer I
, O
we O
propose O
a O
role O
of O
the O
novel B
octamer I
factor I
in O
the O
long O
range O
activation O
by O
the O
IgH B
enhancer I
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF B
- I
2B I
( O
but O
not O
OTF B
- I
2A I
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B
enhancer I
, O
we O
propose O
a O
role O
of O
the O
novel B
octamer I
factor I
in O
the O
long O
range O
activation O
by O
the O
IgH B
enhancer I
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF B
- I
2B I
( O
but O
not O
OTF B
- I
2A I
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B
enhancer I
, O
we O
propose O
a O
role O
of O
the O
novel B
octamer I
factor I
in O
the O
long O
range O
activation O
by O
the O
IgH B
enhancer I
. O

This O
analysis O
indicates O
that O
the O
75 O
kd O
- O
species O
OTF B
- I
2B I
is O
closely O
related O
to O
the O
60 B
kd I
species I
OTF I
- I
2A I
. O

No O
significant O
reduction O
in O
the O
number O
and O
affinity O
of O
IL B
2 I
receptors I
was O
seen O
after O
6 O
h O
incubation O
with O
Dx O
. O

Blocking O
of O
IL B
2 I
synthesis O
and O
IL B
2 I
receptor I
formation O
have O
been O
proposed O
as O
one O
of O
the O
major O
mechanisms O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Identification O
and O
purification O
of O
a O
human B
lymphoid I
- I
specific I
octamer I
- I
binding I
protein I
( O
OTF B
- I
2 I
) O
that O
activates O
transcription O
of O
an O
immunoglobulin B
promoter I
in O
vitro O
. O

The O
octamer O
sequence O
5 O
' O
- O
ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream B
element I
in O
a O
variety O
of O
promoters B
and O
also O
occurs O
as O
a O
modular B
enhancer I
element I
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin B
genes I
since O
it O
is O
found O
in O
the O
upstream B
regions I
of O
all O
heavy B
and I
light I
chain I
promoters I
and O
in O
the O
heavy B
chain I
enhancer I
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell O
- O
specific O
expression O
. O

The O
B B
cell I
factor I
was O
purified O
to O
homogeneity O
using O
affinity O
chromatography O
and O
consists O
of O
three O
peptides O
of O
62 O
, O
61 O
, O
and O
58 O
. O
5 O
+ O
/ O
- O
1 O
. O
5 O
kd O
. O

We O
show O
that O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B
RNA I
accumulation O
of O
the O
multilineage B
growth I
factor I
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
. O

We O
show O
that O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B
RNA I
accumulation O
of O
the O
multilineage B
growth I
factor I
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
. O

The O
regulation O
of O
GM B
- I
CSF I
expression O
is O
seen O
in O
both O
normal O
human O
mitogen O
- O
activated O
T O
lymphocytes O
and O
T O
lymphocytes O
from O
a O
line O
( O
S O
- O
LB1 O
) O
transformed O
with O
human O
T O
cell O
lymphotropic O
virus O
1 O
( O
HTLV O
- O
1 O
) O
. O

Inhibition O
of O
GM B
- I
CSF I
expression O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
occur O
independently O
of O
interleukin B
2 I
regulation O
and O
is O
probably O
mediated O
through O
cellular B
1 I
, I
25 I
( I
OH I
) I
2D3 I
receptors I
. O

The O
influence O
of O
cortisol O
on O
thyroid B
hormone I
receptors I
discussed O
here O
might O
account O
for O
the O
clinical O
observations O
mentioned O
above O
. O

A O
nuclear B
factor I
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional B
control I
elements I
of O
immunoglobulin B
genes I
. O

Trans B
- I
acting I
factors I
that O
mediate O
B O
- O
cell O
specific O
transcription O
of O
immunoglobulin B
genes I
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin B
gene I
recombinants I
in O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

Interestingly O
, O
a O
factor O
showing O
similar O
binding O
specificity O
to O
IgNF B
- I
A I
is O
also O
present O
in O
human O
HeLa O
cells O
. O

The O
ratios O
of O
nuclear O
to O
cytosolic B
hormone I
- I
receptor I
- I
complexes I
and O
of O
cytosolic O
activated O
to O
unactivated B
receptor I
complexes I
in O
intact O
cells O
are O
similar O
to O
Old O
World O
primates O
. O

We O
find O
that O
EKLF B
is O
an O
acetylated B
transcription I
factor I
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B
, O
p300 B
, O
and O
P B
/ I
CAF I
. O

We O
find O
that O
EKLF B
is O
an O
acetylated B
transcription I
factor I
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B
, O
p300 B
, O
and O
P B
/ I
CAF I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation O
region O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
enhance O
EKLF B
' O
s O
transcriptional O
activation O
of O
the O
beta B
- I
globin I
promoter I
in O
erythroid O
cells O
. O

U937 O
cells O
differentiated O
with O
PMA O
in O
nonadherent O
culture O
were O
shown O
to O
express O
two O
fibrinogen B
- I
binding I
integrins I
, O
predominately O
CD11b B
/ I
CD18 I
, O
and O
to O
a O
lesser O
extent O
, O
CD11c B
/ I
CD18 I
. O

U937 O
cells O
differentiated O
with O
PMA O
in O
nonadherent O
culture O
were O
shown O
to O
express O
two O
fibrinogen B
- I
binding I
integrins I
, O
predominately O
CD11b B
/ I
CD18 I
, O
and O
to O
a O
lesser O
extent O
, O
CD11c B
/ I
CD18 I
. O

Fibrinogen B
also O
caused O
activation O
of O
AP B
- I
1 I
, O
but O
not O
SP1 B
or O
cAMP B
response I
element I
- I
binding I
protein I
( I
CREB I
) I
factors I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
contact O
with O
fibrinogen B
- I
derived I
proteins I
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b B
/ I
CD18 I
, O
resulting O
in O
selective O
activation O
of O
transcriptional B
regulatory I
factors I
, O
including O
NF B
- I
kappa I
B I
. O

Partial O
sequences O
from O
exons B
1 I
- I
8 I
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human B
ER I
mRNA I
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone B
binding I
domain I
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

Whether O
the O
detected O
transcripts O
are O
translated O
into O
functional B
receptor I
proteins I
remains O
to O
be O
determined O
. O

CONCLUSION O
: O
Monocytes O
, O
T O
cells O
, O
and O
B O
cells O
in O
patients O
express O
transcripts O
of O
the O
normal O
wild B
type I
ER I
and O
the O
hormone B
binding I
domain I
variants I
in O
vivo O
. O

DNA O
damaging O
agents O
induce O
expression O
of O
Fas B
ligand I
and O
subsequent O
apoptosis O
in O
T O
lymphocytes O
via O
the O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
. O

A O
nondegradable B
mutant I
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O

A O
1 O
. O
2 O
kb O
FasL B
promoter I
responded O
to O
DNA O
damage O
, O
as O
well O
as O
coexpression O
with O
p65 B
Rel I
or O
Fos B
/ I
Jun I
. O

Thus O
, O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
contributes O
to O
stress O
- O
induced O
apoptosis O
via O
the O
expression O
of O
FasL B
. O

A O
nonpeptidyl O
small O
molecule O
SB O
247464 O
, O
capable O
of O
activating O
granulocyte B
- I
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
signal O
transduction O
pathways O
, O
was O
identified O
in O
a O
high O
- O
throughput O
assay O
in O
cultured O
cells O
. O

Like O
G B
- I
CSF I
, O
SB O
247464 O
induced O
tyrosine O
phosphorylation O
of O
multiple B
signaling I
proteins I
and O
stimulated O
primary O
murine O
bone O
marrow O
cells O
to O
form O
granulocytic O
colonies O
in O
vitro O
. O

Like O
G B
- I
CSF I
, O
SB O
247464 O
induced O
tyrosine O
phosphorylation O
of O
multiple B
signaling I
proteins I
and O
stimulated O
primary O
murine O
bone O
marrow O
cells O
to O
form O
granulocytic O
colonies O
in O
vitro O
. O

The O
extracellular O
domain O
of O
the O
murine B
G I
- I
CSF I
receptor I
was O
required O
for O
the O
activity O
of O
SB O
247464 O
, O
suggesting O
that O
the O
compound O
acts O
by O
oligomerizing B
receptor I
chains I
. O

Here O
we O
studied O
minimal O
residual O
disease O
( O
MRD O
) O
of O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML O
) O
who O
have O
PML B
/ I
RAR I
alpha I
or O
AML1 B
/ I
ETO I
as O
well O
as O
the O
phenotypic O
analysis O
of O
lymphocyte O
subsets O
involved O
in O
antitumor O
immunity O
. O

Mycobacterium O
tuberculosis O
mannose O
- O
capped O
lipoarabinomannan O
can O
induce O
NF B
- I
kappaB I
- O
dependent O
activation O
of O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeat I
in O
T O
cells O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
- O
driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

The O
implication O
of O
protein B
tyrosine I
kinase I
( I
s I
) I
, O
protein B
kinase I
A I
and O
/ O
or O
protein B
kinase I
C I
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM O
- O
mediated O
activation O
of O
HIV O
- O
1 O
LTR O
- O
driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long B
terminal I
repeat I
( O
LTR B
) O
sequence O
diversity O
on O
LTR B
- I
directed I
gene I
expression O
in O
cells O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
and O
immune O
system O
, O
we O
amplified O
and O
cloned O
LTRs B
from O
proviral O
DNA O
in O
HIV O
- O
1 O
- O
infected O
peripheral O
blood O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

In O
lymphocyte O
differentiation O
, O
several O
HMG B
box I
proteins I
play O
a O
decisive O
role O
. O

Sox B
- I
4 I
is O
important O
for O
very O
early O
B O
- O
cell O
differentiation O
, O
while O
TCF B
- I
1 I
/ O
LEF B
- I
1 I
play O
a O
crucial O
role O
in O
early O
thymocyte O
development O
. O

Sox B
- I
4 I
is O
important O
for O
very O
early O
B O
- O
cell O
differentiation O
, O
while O
TCF B
- I
1 I
/ O
LEF B
- I
1 I
play O
a O
crucial O
role O
in O
early O
thymocyte O
development O
. O

Sox B
- I
4 I
is O
important O
for O
very O
early O
B O
- O
cell O
differentiation O
, O
while O
TCF B
- I
1 I
/ O
LEF B
- I
1 I
play O
a O
crucial O
role O
in O
early O
thymocyte O
development O
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF B
/ I
LEF I
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF B
/ I
LEF I
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B
box I
proteins I
in O
lymphoid O
development O

Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C B
/ I
EBP I
motif I
, O
we O
transfected O
several O
constructed O
luciferase B
reporter I
DNAs I
into O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
. O

The O
clonality O
of O
mature O
peripheral O
blood O
- O
derived O
myeloid O
and O
lymphoid O
cells O
and O
bone O
marrow O
haemopoietic O
progenitors O
from O
18 O
females O
with O
myelodysplasia O
( O
MDS O
) O
( O
five O
refractory O
anaemia O
, O
RA O
; O
one O
RA O
with O
ringed O
sideroblasts O
, O
RARS O
; O
three O
chronic O
myelomonocytic O
leukaemia O
, O
CMML O
; O
four O
RA O
with O
excess O
of O
blasts O
, O
RAEB O
; O
five O
RAEB O
in O
transformation O
, O
RAEB O
- O
t O
) O
was O
studied O
by O
X B
- I
chromosome I
inactivation O
analysis O
. O

X B
- I
chromosome I
inactivation O
patterns O
of O
CD19 O
+ O
B O
cells O
were O
highly O
concordant O
with O
CD3 O
+ O
T O
cells O
except O
for O
two O
patients O
( O
one O
RA O
, O
one O
CMML O
) O
with O
monoclonal O
B O
and O
polyclonal O
T O
lymphocytes O
, O
therefore O
suggesting O
a O
clonal O
mutation O
in O
a O
progenitor O
common O
to O
the O
myeloid O
and O
B O
- O
lymphoid O
lineages O
or O
the O
coexistence O
of O
MDS O
and O
a O
B O
- O
cell O
disorder O
in O
these O
particular O
patients O
. O

Corresponding O
enzymatic O
activity O
was O
detectable O
only O
for O
17 B
- I
hydroxysteroid I
dehydrogenase I
and O
5alpha B
- I
reductase I
, O
respectively O
producing O
testosterone O
and O
5alpha O
- O
dihydrotestosterone O
. O

Pterin B
carbinolamine I
dehydratase I
/ I
dimerization I
cofactor I
of O
HNF1 B
( O
PCD B
/ I
DCoH I
) O
is O
a O
protein O
that O
has O
a O
dual O
function O
. O

Deficiencies O
in O
the O
gene O
for O
this O
dual B
functional I
protein I
result O
in O
hyperphenylalaninemi O
. O

The O
transcription B
factor I
, O
NF B
- I
Y I
, O
plays O
a O
critical O
role O
in O
tissue O
- O
specific O
major B
histocompatibility I
complex I
class I
II I
gene I
transcription O
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

Recombination O
of O
the O
MPC11 B
plasma I
B I
- I
cell I
derived I
NF I
- I
Y I
A I
: I
B I
: I
C I
complex I
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF B
- I
Y I
- I
associated I
factors I
( O
YAFs B
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF B
- I
Y I
as O
an O
intact B
trimeric I
complex I
. O

Recombination O
of O
the O
MPC11 B
plasma I
B I
- I
cell I
derived I
NF I
- I
Y I
A I
: I
B I
: I
C I
complex I
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF B
- I
Y I
- I
associated I
factors I
( O
YAFs B
) O
, O
derived O
from O
mature O
A20 O
B O
- O
cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF B
- I
Y I
as O
an O
intact B
trimeric I
complex I
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

Interaction O
between O
PC4 B
and O
NF B
- I
Y I
was O
mapped O
to O
the O
C B
- I
terminal I
region I
of O
PC4 B
, O
and O
the O
subunit B
interaction I
subdomain I
of O
the O
highly B
conserved I
DNA I
binding I
- I
subunit I
interaction I
domain I
( O
DBD B
) O
of O
NF B
- I
YA I
. O

These O
results O
suggest O
that O
in O
class O
II O
+ O
mature O
B O
- O
cells O
NF B
- I
Y I
is O
associated O
with O
the O
protein O
cofactor O
, O
PC4 B
, O
which O
may O
play O
an O
important O
role O
in O
NF O
- O
Y O
- O
mediated O
transcriptional O
control O
of O
class B
II I
genes I
. O

These O
results O
suggest O
that O
in O
class O
II O
+ O
mature O
B O
- O
cells O
NF B
- I
Y I
is O
associated O
with O
the O
protein O
cofactor O
, O
PC4 B
, O
which O
may O
play O
an O
important O
role O
in O
NF O
- O
Y O
- O
mediated O
transcriptional O
control O
of O
class B
II I
genes I
. O

This O
arrest O
is O
manifested O
at O
a O
molecular O
level O
as O
a O
reduction O
in O
mRNA O
levels O
of O
secretory O
immunoglobulin O
gene O
products O
such O
as O
mu O
( O
s O
) O
and O
J O
chain O
as O
well O
as O
the O
loss O
of O
the O
transcriptional B
regulator I
BLIMP B
- I
1 I
. O

At O
100 O
microM O
, O
LA O
did O
not O
but O
LA O
- O
Plus O
inhibited O
H2O2 O
induced O
NF B
- I
kappaB I
activation O
and O
NF B
- I
kappaB I
directed O
IL B
- I
2 I
receptor I
expression O
. O

At O
100 O
microM O
, O
LA O
did O
not O
but O
LA O
- O
Plus O
inhibited O
H2O2 O
induced O
NF B
- I
kappaB I
activation O
and O
NF B
- I
kappaB I
directed O
IL B
- I
2 I
receptor I
expression O
. O

Both O
LA O
and O
LA O
- O
Plus O
synergised O
with O
selenium O
in O
inhibiting O
H2O2 O
induced O
NF B
- I
kappaB I
activation O
. O

At O
150 O
microM O
LA O
- O
Plus O
, O
but O
not O
LA O
, O
inhibited O
TNFalpha B
induced O
NF B
- I
kappaB I
activation O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

As O
anticipated O
, O
NRXI O
could O
be O
demonstrated O
in O
all O
lymphoid O
cells O
studied O
from O
obligate O
carriers O
of O
XSCID O
and O
an O
obligate O
carrier O
of O
XLH O
but O
not O
on O
a O
carrier O
of O
X O
- O
linked O
immunodeficiency O
with O
hyper B
- I
IgM I
. O

We O
addressed O
the O
role O
of O
hyperglycemia O
in O
leukocyte O
- O
endothelium O
interaction O
under O
flow O
conditions O
by O
exposing O
human O
umbilical O
vein O
endothelial O
cells O
for O
24 O
h O
to O
normal O
( O
5 O
mM O
) O
, O
high O
concentration O
of O
glucose O
( O
30 O
mM O
) O
, O
advanced O
glycosylation O
end O
product B
- I
albumin I
( O
100 O
microg O
/ O
ml O
) O
, O
or O
hyperglycemic O
( O
174 O
- O
316 O
mg O
/ O
dl O
) O
sera O
from O
patients O
with O
diabetes O
and O
abnormal O
hemoglobin O
A1c O
( O
8 O
. O
1 O
+ O
/ O
- O
1 O
. O
4 O
% O
) O
. O

A O
similar O
response O
was O
induced O
by O
endothelial O
stimulation O
with O
IL B
- I
1beta I
, O
here O
used O
as O
positive O
control O
( O
195 O
+ O
/ O
- O
20 O
cells O
/ O
mm2 O
) O
. O

Functional O
blocking O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
on O
endothelial O
cells O
with O
the O
corresponding O
mouse B
mAb I
significantly O
inhibited O
glucose O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
67 O
+ O
/ O
- O
16 O
, O
83 O
+ O
/ O
- O
12 O
, O
62 O
+ O
/ O
- O
8 O
versus O
144 O
+ O
/ O
- O
21 O
cells O
/ O
mm2 O
) O
. O

Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mM O
glucose O
induced O
an O
increase O
in O
endothelial O
surface O
expression O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
. O

Electrophoretic O
mobility O
shift O
assay O
of O
nuclear O
extracts O
of O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVEC O
) O
exposed O
for O
1 O
h O
to O
30 O
mM O
glucose O
revealed O
an O
intense O
NF B
- I
kB I
activation O
. O

A O
significant O
( O
P O
< O
0 O
. O
01 O
) O
inhibitory O
effect O
on O
glucose O
- O
induced O
leukocyte O
adhesion O
was O
observed O
after O
blocking O
protein B
kinase I
C I
activity O
with O
staurosporine O
( O
5 O
nM O
) O
. O

Advanced O
glycosylation O
end O
product B
- I
albumin I
significantly O
increased O
the O
number O
of O
adhering O
leukocytes O
in O
respect O
to O
native B
albumin I
used O
as O
control O
( O
110 O
+ O
/ O
- O
16 O
versus O
66 O
+ O
/ O
- O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

Sera O
from O
diabetic O
patients O
significantly O
( O
P O
< O
0 O
. O
01 O
) O
enhanced O
leukocyte O
adhesion O
as O
compared O
with O
controls O
, O
despite O
normal O
levels O
of O
IL B
- I
1beta I
and O
TNFalpha B
in O
these O
sera O
. O

These O
data O
indicate O
that O
high O
glucose O
concentration O
and O
hyperglycemia O
promote O
leukocyte O
adhesion O
to O
the O
endothelium O
through O
upregulation O
of O
cell O
surface O
expression O
of O
adhesive O
proteins O
, O
possibly O
depending O
on O
NF B
- I
kB I
activation O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B
protein O
E12 B
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B
B I
lineage I
genes I
, O
including O
EBF B
, O
IL7Ralpha B
, O
lambda5 B
, O
and O
Rag O
- O
1 O
, O
and O
the O
ability O
to O
induce O
kappa B
light I
chain I
in O
response O
to O
mitogen O
. O

Activation O
- O
induced O
down O
- O
regulation O
of O
retinoid B
receptor I
RXRalpha I
expression O
in O
human O
T O
lymphocytes O
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 B
' I
end I
of O
this O
RNA B
as O
human B
retinoid I
receptor I
RXRalpha I
mRNA I
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3 B
. I
6 I
kilobases I
of O
this O
RNA O
, O
which O
represents O
the O
3 B
' I
end I
of O
RXRalpha B
mRNA I
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

Important O
in O
the O
development O
of O
HIV O
- O
associated O
NHL O
are O
cytokines B
and O
other O
factors O
that O
induce O
B O
- O
cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c B
- I
myc I
, O
bcl B
- I
6 I
, O
and O
other O
tumor B
- I
suppressor I
genes I
with O
carcinogenic O
potential O
. O

Important O
in O
the O
development O
of O
HIV O
- O
associated O
NHL O
are O
cytokines B
and O
other O
factors O
that O
induce O
B O
- O
cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c B
- I
myc I
, O
bcl B
- I
6 I
, O
and O
other O
tumor B
- I
suppressor I
genes I
with O
carcinogenic O
potential O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

This O
study O
was O
performed O
on O
a O
series O
of O
frozen O
and O
paraffin O
sections O
from O
84 O
breast O
cancer O
specimens O
by O
immunohistochemistry O
using O
the O
monoclonal B
antibody I
MMP I
- I
3 I
( O
Ab B
- I
1 I
) O
. O

Stromelysin B
- I
1 I
( O
ST1 B
) O
was O
observed O
in O
about O
10 O
% O
of O
epithelial O
cells O
in O
the O
control O
groups O
( O
cases O
of O
fibrocystic O
and O
benign O
proliferative O
breast O
disease O
) O
, O
while O
expression O
( O
> O
10 O
% O
of O
expression O
) O
was O
detected O
in O
89 O
. O
7 O
% O
of O
tumours O
. O

There O
is O
increased O
activity O
of O
the O
proinflammatory B
cytokine I
, O
tumor B
necrosis I
factor I
( O
TNF B
) O
in O
alcoholic O
liver O
disease O
( O
ALD O
) O
. O

TNF B
can O
induce O
cellular O
oxidative O
injury O
directly O
, O
and O
indirectly O
by O
inducing O
neutrophil O
chemotactic O
factor O
( O
IL B
- I
8 I
) O
production O
by O
hepatocytes O
. O

IL B
- I
8 I
activates O
and O
chemotactically O
attracts O
neutrophils O
to O
the O
liver O
where O
they O
release O
oxidizing O
substances O
. O

Manganous B
superoxide I
dismutase I
( O
MnSOD B
) O
is O
an O
antioxidant B
protective I
factor I
. O

Manganous B
superoxide I
dismutase I
( O
MnSOD B
) O
is O
an O
antioxidant B
protective I
factor I
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B
factor I
( O
IL B
- I
8 I
) O
and O
a O
protective B
factor I
( O
MnSOD B
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

In O
the O
first O
set O
of O
experiments O
, O
IL B
- I
8 I
gene I
reporter I
constructs I
were O
used O
to O
transiently O
transfect O
a O
derivative O
( O
MVh2E1 O
- O
9 O
) O
of O
the O
HepG2 O
cell O
line O
which O
expresses O
P B
- I
4502E1 I
and O
metabolizes O
ethanol O
. O

This O
system O
may O
be O
useful O
to O
assess O
the O
effects O
of O
ethanol O
on O
TNF B
- O
induced O
hepatocyte O
IL B
- I
8 I
production O
. O

Tissue O
factor O
transcription O
driven O
by O
Egr B
- I
1 I
is O
a O
critical O
mechanism O
of O
murine B
pulmonary I
fibrin I
deposition O
in O
hypoxia O
. O

Tissue O
factor O
transcription O
driven O
by O
Egr B
- I
1 I
is O
a O
critical O
mechanism O
of O
murine B
pulmonary I
fibrin I
deposition O
in O
hypoxia O
. O

We O
now O
show O
that O
transcription B
factor I
early I
- I
growth I
- I
response I
gene I
product I
( O
Egr B
- I
1 I
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription O
and O
expression O
of O
tissue B
factor I
in O
hypoxic O
lung O
. O

MPs B
and O
HeLa O
cells O
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue B
factor I
transcripts I
( O
approximately O
18 O
- O
fold O
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15 O
- O
fold O
) O
, O
based O
on O
nuclear O
run O
- O
on O
analysis O
. O

Gel O
- O
shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic B
MPs I
and O
HeLa O
cells O
demonstrated O
increased O
DNA O
- O
binding O
activity O
at O
the O
serum B
response I
region I
( O
SRR O
; O
- O
111 O
/ O
+ O
14 O
bp O
) O
of O
the O
tissue B
factor I
promoter I
at O
Egr B
- I
1 I
motifs I
. O

Gel O
- O
shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic B
MPs I
and O
HeLa O
cells O
demonstrated O
increased O
DNA O
- O
binding O
activity O
at O
the O
serum B
response I
region I
( O
SRR O
; O
- O
111 O
/ O
+ O
14 O
bp O
) O
of O
the O
tissue B
factor I
promoter I
at O
Egr B
- I
1 I
motifs I
. O

Using O
32P O
- O
labeled O
Egr O
consensus O
oligonucleotide O
, O
we O
observed O
induction O
of O
DNA O
- O
binding O
activity O
in O
nuclear O
extracts O
from O
hypoxic O
lung O
and O
HeLa O
cells O
because O
of O
activation O
of O
Egr B
- I
1 I
, O
by O
means O
of O
supershift O
analysis O
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B
plasmids I
containing O
wild B
- I
type I
or I
mutant I
SRR I
from O
the O
tissue B
factor I
promoter I
showed O
that O
intact B
Sp1 I
sites I
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr B
- I
1 I
sites I
was O
required O
for O
hypoxia O
- O
enhanced O
expression O
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B
plasmids I
containing O
wild B
- I
type I
or I
mutant I
SRR I
from O
the O
tissue B
factor I
promoter I
showed O
that O
intact B
Sp1 I
sites I
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr B
- I
1 I
sites I
was O
required O
for O
hypoxia O
- O
enhanced O
expression O
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

These O
data O
delineate O
a O
novel O
biology O
for O
hypoxia O
- O
induced O
fibrin B
deposition O
, O
in O
which O
oxygen O
deprivation O
- O
induced O
activation O
of O
Egr B
- I
1 I
, O
resulting O
in O
expression O
of O
tissue B
factor I
, O
has O
an O
unexpected O
and O
central O
role O
. O

Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral O
blood O
- O
derived O
T O
lymphoblasts O
stimulated O
with O
anti B
- I
CD3 I
antibodies I
or O
Lens B
culinaris I
lectin I
( O
LCL B
) O
. O

T O
cells O
were O
purified O
from O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
primarily O
activated O
with O
anti B
- I
CD3 I
antibodies I
and O
cultured O
in O
the O
presence O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

T O
cells O
were O
purified O
from O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
primarily O
activated O
with O
anti B
- I
CD3 I
antibodies I
and O
cultured O
in O
the O
presence O
of O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

Anti O
- O
CD3 O
- O
restimulated O
T O
cells O
( O
mainly O
CD8 O
+ O
) O
produced O
IL B
- I
2 I
, O
interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
and O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
low O
levels O
of O
IL B
- I
4 I
and I
IL I
- I
10 I
transcripts I
and O
proteins O
. O

Steady O
- O
state O
mRNA O
levels O
of O
IL B
- I
2 I
, O
IL B
- I
10 I
and O
IFN B
- I
gamma I
peaked O
at O
3 O
hr O
after O
anti O
- O
CD3 O
stimulation O
and O
declined O
rapidly O
thereafter O
. O

Steady O
- O
state O
mRNA O
levels O
of O
IL B
- I
2 I
, O
IL B
- I
10 I
and O
IFN B
- I
gamma I
peaked O
at O
3 O
hr O
after O
anti O
- O
CD3 O
stimulation O
and O
declined O
rapidly O
thereafter O
. O

Steady O
- O
state O
mRNA O
levels O
of O
IL B
- I
2 I
, O
IL B
- I
10 I
and O
IFN B
- I
gamma I
peaked O
at O
3 O
hr O
after O
anti O
- O
CD3 O
stimulation O
and O
declined O
rapidly O
thereafter O
. O

In O
conclusion O
, O
the O
cytokines B
synthesized O
by O
IL O
- O
2 O
- O
dependent O
T O
cells O
were O
predominantly O
IL B
- I
2 I
, O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
. O

In O
conclusion O
, O
the O
cytokines B
synthesized O
by O
IL O
- O
2 O
- O
dependent O
T O
cells O
were O
predominantly O
IL B
- I
2 I
, O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
. O

In O
conclusion O
, O
the O
cytokines B
synthesized O
by O
IL O
- O
2 O
- O
dependent O
T O
cells O
were O
predominantly O
IL B
- I
2 I
, O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
. O

Both O
NF B
- I
kappaB I
- I
like I
elements I
were O
able O
to O
bind O
to O
NF B
- I
kappaB I
or O
its O
related O
factor O
( O
s O
) O
in O
a O
Tax B
- O
dependent O
manner O
. O

NF B
- I
kappaB I
- O
like O
element O
2 O
elevated O
promoter O
activity O
when O
combined O
with O
NF B
- I
kappaB I
- I
like I
element I
1 I
, O
indicating O
cooperative O
function O
of O
the O
elements O
for O
maximum O
promoter O
function O
. O

Unlike O
typical O
NF B
- I
kappaB I
elements I
, O
the O
NF B
- I
kappaB I
- I
like I
elements I
in O
gp34 B
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF B
- I
kappaB I
- O
like O
binding O
activity O
. O

The O
senile O
plaques O
of O
Alzheimer O
' O
s O
disease O
are O
foci O
of O
local O
inflammatory O
responses O
, O
as O
evidenced O
by O
the O
presence O
of O
acute B
phase I
proteins I
and O
oxidative O
damage O
. O

Fibrillar B
forms I
of O
beta B
- I
amyloid I
( O
Abeta B
) O
, O
which O
are O
the O
primary O
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate O
tyrosine O
kinase O
- O
dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O

The O
CRABP B
II I
mRNA I
was O
gradually O
upregulated O
during O
differentiation O
from O
MO O
to O
MAC O
in O
the O
presence O
of O
2 O
% O
serum O
. O

As O
MO O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP B
II I
in O
MO O
- O
derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS B
, O
IL B
- I
4 I
, O
and O
GM B
- I
CSF I
. O

As O
MO O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP B
II I
in O
MO O
- O
derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS B
, O
IL B
- I
4 I
, O
and O
GM B
- I
CSF I
. O

The O
paired B
box I
containing I
gene I
PAX B
- I
5 I
encodes O
the O
transcription B
factor I
BSAP B
( O
B B
- I
cell I
- I
specific I
activator I
protein I
) O
, O
which O
plays O
a O
key O
role O
in O
B O
- O
lymphocyte O
development O
. O

The O
high O
levels O
of O
BSAP B
, O
especially O
those O
found O
in O
large O
- O
cell O
lymphomas O
and O
in O
some O
follicular O
lymphomas O
, O
may O
be O
a O
consequence O
of O
deregulated O
gene O
expression O
and O
suggest O
a O
possible O
involvement O
of O
PAX B
- I
5 I
in O
certain O
B O
- O
cell O
malignancies O
. O

This O
article O
describes O
the O
identification O
of O
a O
putative B
STAT I
molecule I
in O
the O
channel O
catfish O
( O
Ictalurus O
punctatus O
) O
, O
the O
first O
report O
of O
such O
a O
molecule O
in O
a O
' O
lower O
' O
vertebrate O
. O

A O
monoclonal B
antibody I
against O
human B
STAT6 I
recognizes O
an O
approximately O
100 B
kDa I
molecule I
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth O
factor O
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O

In O
driving O
T O
cell O
proliferation O
, O
IL B
- I
2 I
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B
cell I
nuclear I
antigen I
( O
PCNA B
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B
polymerase I
delta I
. O

In O
driving O
T O
cell O
proliferation O
, O
IL B
- I
2 I
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B
cell I
nuclear I
antigen I
( O
PCNA B
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B
polymerase I
delta I
. O

PCNA B
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE B
sequences I
in O
the O
promoter B
and I
CRE I
binding I
proteins I
; O
IL B
- I
2 I
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

L2 O
and O
L2 O
variant O
cells O
were O
tested O
for O
IL B
- I
2 I
responsiveness O
and O
rapamycin O
sensitivity O
with O
respect O
to O
specific O
kinase O
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
cells O
, O
IL B
- I
2 I
stimulated O
and O
rapamycin O
inhibited O
the O
following O
: O
cAMP O
- O
independent O
CREB B
kinase I
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
variant O
cells O
, O
CREB B
kinase I
activity O
was O
constitutively O
high O
; O
IL B
- I
2 I
stimulated O
and O
rapamycin O
blocked O
PCNA O
expression O
and O
proliferation O
. O

These O
results O
indicate O
that O
IL B
- I
2 I
induces O
a O
rapamycin O
- O
sensitive O
, O
cAMP O
- O
independent O
CREB B
kinase I
activity O
in O
L2 O
cells O
. O

However O
, O
phosphorylation O
of O
CREB B
alone O
is O
not O
sufficient O
to O
drive O
PCNA B
expression O
and O
L2 O
cell O
proliferation O
in O
the O
absence O
of O
IL B
- I
2 I
. O

Serotonin O
derivative O
, O
N O
- O
( O
p O
- O
coumaroyl O
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
by O
endotoxin O
- O
stimulated O
human O
blood O
monocytes O
. O

Serotonin O
derivative O
, O
N O
- O
( O
p O
- O
coumaroyl O
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
by O
endotoxin O
- O
stimulated O
human O
blood O
monocytes O
. O

Serotonin O
derivative O
, O
N O
- O
( O
p O
- O
coumaroyl O
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
by O
endotoxin O
- O
stimulated O
human O
blood O
monocytes O
. O

Serotonin O
derivative O
, O
N O
- O
( O
p O
- O
coumaroyl O
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
by O
endotoxin O
- O
stimulated O
human O
blood O
monocytes O
. O

CS O
at O
50 O
- O
200 O
microM O
reduced O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
and O
IL B
- I
6 I
activities O
in O
the O
culture O
supernatants O
from O
LPS O
- O
stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

CS O
at O
50 O
- O
200 O
microM O
reduced O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
and O
IL B
- I
6 I
activities O
in O
the O
culture O
supernatants O
from O
LPS O
- O
stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

CS O
at O
50 O
- O
200 O
microM O
reduced O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
and O
IL B
- I
6 I
activities O
in O
the O
culture O
supernatants O
from O
LPS O
- O
stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

CS O
at O
50 O
- O
200 O
microM O
reduced O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
and O
IL B
- I
6 I
activities O
in O
the O
culture O
supernatants O
from O
LPS O
- O
stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
was O
inhibited O
by O
CS O
. O

ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
was O
inhibited O
by O
CS O
. O

ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
was O
inhibited O
by O
CS O
. O

ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF B
- I
alpha I
, O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
, O
and O
IL B
- I
6 I
was O
inhibited O
by O
CS O
. O

These O
findings O
indicate O
that O
CS O
has O
a O
suppressive O
effect O
on O
proinflammatory O
cytokine O
production O
from O
monocytes O
, O
and O
this O
effect O
is O
based O
in O
part O
on O
the O
suppression O
of O
cytokine B
mRNA I
expression O
through O
inhibition O
of O
NF B
- I
kappaB I
activation O
. O

Differentiation B
inhibitory I
factor I
nm23 B
gene I
has O
been O
found O
to O
be O
expressed O
in O
high O
quantities O
in O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
especially O
in O
acute O
monocytic O
leukemia O
( O
AML O
- O
M5 O
) O
and O
is O
suggested O
as O
a O
new O
prognostic O
factor O
in O
AML O
- O
M5 O
. O

The O
mRNA O
level O
of O
nm23 B
- I
H2 I
was O
slightly O
below O
the O
normal O
level O
. O

Increased O
transcription O
decreases O
the O
spontaneous O
mutation O
rate O
at O
the O
thymidine B
kinase I
locus I
in O
human O
cells O
. O

Significant O
mutations O
were O
not O
observed O
in O
c B
- I
MYC I
, I
S14 I
, I
or I
alpha I
- I
fetoprotein I
( I
AFP I
) I
genes I
, O
but O
BCL B
- I
6 I
was O
highly O
mutated O
in O
a O
large O
proportion O
of O
memory O
B O
cells O
of O
normal O
individuals O
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti O
- O
CD3 O
plus O
anti O
- O
CD28 O
) O
on O
the O
activation O
of O
NF B
- I
kappaB I
in O
CD45RA O
+ O
( O
naive O
) O
and O
CD45RO O
+ O
( O
memory O
/ O
effector O
) O
T O
cells O
. O

Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF B
- I
kappaB I
DNA O
binding O
in O
CD45RA O
+ O
cells O
than O
in O
CD45RO O
+ O
cells O
. O

Analysis O
of O
the O
nuclear B
c I
- I
Rel I
protein I
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c B
- I
Rel I
was O
higher O
in O
CD45RA O
+ O
cells O
. O

One O
member O
of O
the O
family O
( O
MNP B
- I
1 I
) O
is O
essential O
for O
promoter O
activity O
in O
monocytes O
and O
B O
- O
cells O
, O
while O
another O
( O
MNP B
- I
2 I
) O
is O
required O
for O
full O
promotor O
activity O
in O
T O
- O
cells O
. O

One O
member O
of O
the O
family O
( O
MNP B
- I
1 I
) O
is O
essential O
for O
promoter O
activity O
in O
monocytes O
and O
B O
- O
cells O
, O
while O
another O
( O
MNP B
- I
2 I
) O
is O
required O
for O
full O
promotor O
activity O
in O
T O
- O
cells O
. O

A O
third O
member O
of O
the O
family O
( O
MNP B
- I
3 I
) O
is O
expressed O
in O
PMA O
induced O
HL60 O
cells O
and O
probably O
has O
a O
role O
in O
monocyte O
differentiation O
. O

In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP B
- I
1 I
and O
MNP B
- I
2 I
are O
distinct O
but O
related O
factors O
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP B
- I
1 I
acts O
as O
a O
heterodimer B
. O

In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP B
- I
1 I
and O
MNP B
- I
2 I
are O
distinct O
but O
related O
factors O
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP B
- I
1 I
acts O
as O
a O
heterodimer B
. O

In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP B
- I
1 I
and O
MNP B
- I
2 I
are O
distinct O
but O
related O
factors O
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP B
- I
1 I
acts O
as O
a O
heterodimer B
. O

Bcl B
- I
3 I
expression O
and O
nuclear O
translocation O
are O
induced O
by O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
and O
erythropoietin B
in O
proliferating O
human O
erythroid O
precursors O
. O

Bcl B
- I
3 I
is O
a O
proto B
- I
oncogene I
involved O
in O
the O
chromosomal O
translocation O
t B
( I
14 I
; I
19 I
) I
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O

Bcl B
- I
3 I
is O
a O
proto B
- I
oncogene I
involved O
in O
the O
chromosomal O
translocation O
t B
( I
14 I
; I
19 I
) I
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O

In O
this O
report O
, O
involvement O
of O
Bcl B
- I
3 I
in O
hematopoietic O
growth O
factor O
- O
stimulated O
erythroid O
proliferation O
and O
differentiation O
was O
examined O
. O

In O
TF O
- O
1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
and O
erythropoietin B
( O
Epo B
) O
greatly O
enhanced O
Bcl B
- I
3 I
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

In O
TF O
- O
1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
and O
erythropoietin B
( O
Epo B
) O
greatly O
enhanced O
Bcl B
- I
3 I
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

Bcl B
- I
3 I
protein O
was O
also O
highly O
expressed O
in O
early O
burst O
- O
forming O
unit O
- O
erythroid O
( O
BFU O
- O
E O
) O
- O
derived O
erythroid O
precursors O
( O
day O
7 O
) O
and O
decreased O
during O
maturation O
( O
days O
10 O
and O
14 O
) O
, O
suggesting O
that O
Bcl B
- I
3 I
is O
involved O
in O
normal O
erythroid O
proliferation O
. O

Bcl B
- I
3 I
protein O
was O
also O
highly O
expressed O
in O
early O
burst O
- O
forming O
unit O
- O
erythroid O
( O
BFU O
- O
E O
) O
- O
derived O
erythroid O
precursors O
( O
day O
7 O
) O
and O
decreased O
during O
maturation O
( O
days O
10 O
and O
14 O
) O
, O
suggesting O
that O
Bcl B
- I
3 I
is O
involved O
in O
normal O
erythroid O
proliferation O
. O

In O
these O
hematopoietic O
cells O
, O
Bcl B
- I
3 I
was O
hyperphosphorylated O
. O

GM B
- I
CSF I
and O
Epo B
modulated O
the O
subcellular O
localization O
of O
Bcl B
- I
3 I
. O

GM B
- I
CSF I
and O
Epo B
modulated O
the O
subcellular O
localization O
of O
Bcl B
- I
3 I
. O

Upon O
stimulation O
of O
TF O
- O
1 O
cells O
with O
GM B
- I
CSF I
or O
Epo B
, O
the O
nuclear O
translocation O
of O
Bcl B
- I
3 I
was O
dramatically O
enhanced O
. O

Upon O
stimulation O
of O
TF O
- O
1 O
cells O
with O
GM B
- I
CSF I
or O
Epo B
, O
the O
nuclear O
translocation O
of O
Bcl B
- I
3 I
was O
dramatically O
enhanced O
. O

Overexpression O
of O
Bcl B
- I
3 I
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF B
- I
kappaB I
factors I
p50 I
or I
p52 I
resulted O
in O
significant O
induction O
of O
an O
human B
immunodeficiency I
virus I
- I
type I
1 I
( I
HIV I
- I
1 I
) I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
, O
demonstrating O
that O
Bcl B
- I
3 I
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB B
- I
containing I
genes I
in O
erythroid O
cells O
. O

Overexpression O
of O
Bcl B
- I
3 I
in O
TF O
- O
1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF B
- I
kappaB I
factors I
p50 I
or I
p52 I
resulted O
in O
significant O
induction O
of O
an O
human B
immunodeficiency I
virus I
- I
type I
1 I
( I
HIV I
- I
1 I
) I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
, O
demonstrating O
that O
Bcl B
- I
3 I
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB B
- I
containing I
genes I
in O
erythroid O
cells O
. O

Stimulation O
with O
GM B
- I
CSF I
enhanced O
c B
- I
myb I
mRNA I
expression O
in O
these O
cells O
. O

Bcl B
- I
3 I
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB B
enhancer I
in O
the O
c B
- I
myb I
promoter I
together O
with O
NF B
- I
kappaB2 I
/ I
p52 I
and O
this O
binding O
activity O
was O
enhanced O
by O
GM B
- I
CSF I
stimulation O
. O

Bcl B
- I
3 I
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB B
enhancer I
in O
the O
c B
- I
myb I
promoter I
together O
with O
NF B
- I
kappaB2 I
/ I
p52 I
and O
this O
binding O
activity O
was O
enhanced O
by O
GM B
- I
CSF I
stimulation O
. O

Furthermore O
, O
cotransfection O
of O
Bcl B
- I
3 I
with O
p52 B
or O
p50 B
in O
TF O
- O
1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c B
- I
myb I
kappaB I
- I
TATA I
- I
luceriferase I
reporter I
plasmid I
. O

These O
findings O
suggest O
that O
Bcl B
- I
3 I
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB B
- I
containing I
genes I
involved O
in O
hematopoiesis O
, O
including O
c B
- I
myb I
. O

These O
findings O
suggest O
that O
Bcl B
- I
3 I
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB B
- I
containing I
genes I
involved O
in O
hematopoiesis O
, O
including O
c B
- I
myb I
. O

5 B
- I
Lipoxygenase I
compartmentalization O
in O
granulocytic O
cells O
is O
modulated O
by O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
and O
nuclear B
factor I
kappa I
B I
complex I
formation O
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi B
fibroblast I
growth I
factor I
signal I
sequence I
fused O
to O
the O
5 B
- I
lipoxygenase639 I
- I
656 I
bipartite I
nuclear I
localizing I
sequence I
has O
a O
prominent O
inhibitory O
effect O
on O
5 B
- I
lipoxygenase I
catalysis O
in O
granulocytic O
HL O
- O
60 O
cells O
activated O
by O
calcium O
ionophor O
A23187 O
. O

Recombinant O
5 B
- I
lipoxygenase I
was O
not O
affected O
by O
the O
peptide O
. O

The O
peptide O
also O
inhibited O
redistribution O
of O
5 B
- I
lipoxygenase I
from O
the O
cytosol O
to O
the O
nuclear O
membrane O
of O
HL O
- O
60 O
cells O
stimulated O
by O
A23187 O
. O

In O
cells O
treated O
with O
agents O
that O
block O
5 B
- I
lipoxygenase I
translocation O
to O
the O
nucleus O
, O
5 B
- I
lipoxygenase I
protein O
appearing O
in O
the O
NF B
- I
kappaB I
immunoprecipitate O
was O
diminished O
. O

In O
cells O
treated O
with O
agents O
that O
block O
5 B
- I
lipoxygenase I
translocation O
to O
the O
nucleus O
, O
5 B
- I
lipoxygenase I
protein O
appearing O
in O
the O
NF B
- I
kappaB I
immunoprecipitate O
was O
diminished O
. O

In O
cells O
treated O
with O
agents O
that O
block O
5 B
- I
lipoxygenase I
translocation O
to O
the O
nucleus O
, O
5 B
- I
lipoxygenase I
protein O
appearing O
in O
the O
NF B
- I
kappaB I
immunoprecipitate O
was O
diminished O
. O

Our O
results O
implicate O
an O
internal B
bipartite I
nuclear I
localizing I
sequence I
as O
a O
regulatory O
domain O
that O
modulates O
5 B
- I
lipoxygenase I
redistribution O
and O
catalysis O
in O
granulocytic O
cells O
. O

T O
cells O
retained O
their O
physical O
parameters O
as O
measured O
by O
forward O
and O
side O
light O
scatter O
, O
and O
functional O
activity O
as O
measured O
by O
costimulation O
of O
proliferation O
and O
IL B
- I
2 I
production O
after O
being O
scraped O
off O
this O
substrate O
. O

CD28 O
/ O
CD3 O
- O
costimulated O
T O
cells O
produced O
intracellular O
IL B
- I
2 I
from O
all O
subsets O
measured O
( O
CD4 O
+ O
, O
CD4 O
- O
, O
CD45RO O
+ O
, O
and O
CD45RO O
- O
) O
. O

IL B
- I
2 I
production O
and O
intracellular O
accumulation O
in O
nonscraped O
PB O
- O
T O
cells O
activated O
with O
CD28 O
/ O
CD3 O
coligation O
were O
skewed O
favoring O
CD45RO O
+ O
and O
CD4 O
+ O
subsets O
, O
as O
was O
IL B
- I
2 I
production O
in O
scraped O
PB O
- O
T O
cells O
. O

IL B
- I
2 I
production O
and O
intracellular O
accumulation O
in O
nonscraped O
PB O
- O
T O
cells O
activated O
with O
CD28 O
/ O
CD3 O
coligation O
were O
skewed O
favoring O
CD45RO O
+ O
and O
CD4 O
+ O
subsets O
, O
as O
was O
IL B
- I
2 I
production O
in O
scraped O
PB O
- O
T O
cells O
. O

The O
intracellular O
incorporation O
of O
Abs O
specific O
for O
c B
- I
Fos I
and I
c I
- I
Jun I
family I
members I
by O
scrape O
loading O
inhibited O
the O
production O
and O
intracellular O
accumulation O
of O
IL B
- I
2 I
within O
6 O
h O
of O
costimulation O
with O
PMA O
/ O
ionomycin O
, O
or O
costimulation O
by O
CD28 O
and O
CD3 O
ligation O
. O

Scrape O
loading O
thus O
provides O
an O
efficient O
mechanism O
for O
intracellular O
incorporation O
of O
macromolecules O
, O
and O
the O
first O
direct O
evidence O
that O
c B
- I
Fos I
and O
c B
- I
Jun I
are O
involved O
in O
transcription O
of O
the O
IL B
- I
2 I
gene I
within O
its O
correct O
chromosomal O
context O
, O
in O
resting O
human O
T O
lymphocyte O
subpopulations O
. O

Scrape O
loading O
thus O
provides O
an O
efficient O
mechanism O
for O
intracellular O
incorporation O
of O
macromolecules O
, O
and O
the O
first O
direct O
evidence O
that O
c B
- I
Fos I
and O
c B
- I
Jun I
are O
involved O
in O
transcription O
of O
the O
IL B
- I
2 I
gene I
within O
its O
correct O
chromosomal O
context O
, O
in O
resting O
human O
T O
lymphocyte O
subpopulations O
. O

Differential O
expression O
of O
Nur77 B
family I
members I
in O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
- O
infected O
cells O
: O
transactivation O
of O
the O
TR3 B
/ I
nur77 I
gene I
by O
Tax B
protein I
. O

We O
have O
demonstrated O
that O
in O
both O
HTLV O
- O
1 O
- O
infected O
cells O
and O
Tax O
- O
expressing O
JPX O
- O
9 O
cells O
, O
TR3 B
/ I
nur77 I
is O
highly O
expressed O
, O
whereas O
neither O
NOR O
- O
1 O
nor O
NOT O
expression O
is O
detectable O
. O

Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax B
transactivation O
of O
the O
TR3 B
/ I
nur77 I
promoter O
but O
not O
the O
NOR B
- I
1 I
promoter I
in O
different O
cell O
types O
. O

Furthermore O
, O
expression O
of O
a O
luciferase B
reporter I
gene I
driven O
by O
the O
NGFI B
- I
B I
( I
rat I
homolog I
of I
TR3 I
/ I
Nur77 I
) I
response I
element I
( O
NBRE B
) O
provided O
evidence O
that O
Tax B
- O
mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

Cotransfection O
assays O
with O
the O
TR3 B
/ I
nur77 I
promoter I
sequence I
or O
the O
NBRE B
binding O
motif O
together O
with O
a O
series O
of O
Tax B
mutants O
have O
shown O
that O
Tax B
- O
induced O
TR3 B
/ I
nur77 I
expression O
is O
mediated O
by O
CREB B
/ I
ATF I
- I
related I
transcription I
factors I
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

To O
establish O
a O
biological O
role O
for O
HSBP1 B
, O
the O
homologous O
Caenorhabditis B
elegans I
protein I
was O
overexpressed O
in O
body O
wall O
muscle O
cells O
and O
was O
shown O
to O
block O
activation O
of O
the O
heat O
shock O
response O
from O
a O
heat B
shock I
promoter I
- I
reporter I
construct I
. O

Recent O
work O
has O
identified O
distal B
elements I
that O
mediate O
long O
- O
range O
cytokine O
gene O
regulation O
and O
has O
implicated O
chromatin O
reorganization O
in O
regulation O
of O
cytokine B
gene I
loci I
. O

A O
signaling O
complex O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
and O
protein B
phosphatase I
2A I
[ O
see O
comments O
] O

Hypoxia O
down O
- O
regulates O
MCP B
- I
1 I
expression O
: O
implications O
for O
macrophage O
distribution O
in O
tumors O
. O

Monocyte B
chemoattractant I
protein I
1 I
( O
MCP B
- I
1 I
) O
is O
likely O
to O
contribute O
to O
the O
macrophage O
infiltrate O
in O
human O
ovarian O
carcinomas O
. O

Although O
MCP B
- I
1 I
is O
predominantly O
expressed O
by O
the O
tumor O
parenchyma O
, O
macrophages O
accumulate O
at O
highest O
density O
in O
necrotic O
regions O
, O
which O
are O
associated O
with O
low O
oxygen O
tensions O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
can O
stimulate O
MCP B
- I
1 I
production O
and O
is O
also O
present O
within O
ovarian O
carcinomas O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
can O
stimulate O
MCP B
- I
1 I
production O
and O
is O
also O
present O
within O
ovarian O
carcinomas O
. O

We O
have O
investigated O
the O
effect O
of O
hypoxia O
both O
on O
MCP B
- I
1 I
expression O
in O
ovarian O
cancer O
cell O
lines O
and O
monocyte O
migration O
. O

Monocyte O
migration O
in O
response O
to O
MCP B
- I
1 I
was O
also O
diminished O
under O
hypoxic O
conditions O
. O

Down O
- O
regulation O
of O
MCP B
- I
1 I
expression O
and O
the O
inhibition O
of O
monocyte O
migration O
are O
independent O
effects O
of O
hypoxia O
that O
may O
contribute O
to O
the O
distribution O
of O
macrophages O
within O
ovarian O
tumors O
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
controls O
transcription O
of O
inflammation B
genes I
. O

On O
activation O
, O
NF B
kappa I
B I
is O
rapidly O
released O
from O
its O
cytoplasmic B
inhibitor I
( O
I B
kappa I
B I
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA B
response I
elements I
in O
gene O
promoter O
regions O
. O

On O
activation O
, O
NF B
kappa I
B I
is O
rapidly O
released O
from O
its O
cytoplasmic B
inhibitor I
( O
I B
kappa I
B I
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA B
response I
elements I
in O
gene O
promoter O
regions O
. O

On O
activation O
, O
NF B
kappa I
B I
is O
rapidly O
released O
from O
its O
cytoplasmic B
inhibitor I
( O
I B
kappa I
B I
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA B
response I
elements I
in O
gene O
promoter O
regions O
. O

AIMS O
: O
To O
investigate O
whether O
increased O
activation O
of O
NF B
kappa I
B I
is O
important O
in O
IBD O
and O
may O
be O
down O
- O
regulated O
by O
anti O
- O
inflammatory O
treatment O
. O

METHODS O
: O
Activation O
of O
NF B
kappa I
B I
was O
determined O
by O
western O
blot O
assessment O
and O
electrophoretic O
mobility O
shift O
assay O
in O
nuclear O
extracts O
of O
colonic O
biopsy O
samples O
as O
well O
as O
lamina O
propria O
mononuclear O
cells O
. O

RESULTS O
: O
Nuclear O
levels O
of O
NF B
kappa I
B I
p65 B
are O
increased O
in O
lamina O
propria O
biopsy O
specimens O
from O
patients O
with O
Crohn O
' O
s O
disease O
in O
comparison O
with O
patients O
with O
ulcerative O
colitis O
and O
controls O
. O

Increased O
activation O
of O
NF B
kappa I
B I
was O
detected O
in O
lamina O
propria O
mononuclear O
cells O
from O
patients O
with O
active O
IBD O
. O

Corticosteroids O
strongly O
inhibit O
intestinal O
NF B
kappa I
B I
activation O
in O
IBD O
in O
vivo O
and O
in O
vitro O
by O
stabilising O
the O
cytosolic B
inhibitor I
I B
kappa I
B I
alpha O
against O
activation O
induced O
degradation O
. O

Corticosteroids O
strongly O
inhibit O
intestinal O
NF B
kappa I
B I
activation O
in O
IBD O
in O
vivo O
and O
in O
vitro O
by O
stabilising O
the O
cytosolic B
inhibitor I
I B
kappa I
B I
alpha O
against O
activation O
induced O
degradation O
. O

CONCLUSIONS O
: O
In O
both O
IBDs O
, O
but O
particularly O
Crohn O
' O
s O
disease O
, O
increased O
activation O
of O
NF B
kappa I
B I
may O
be O
involved O
in O
the O
regulation O
of O
the O
inflammatory O
response O
. O

Inhibition O
of O
NF B
kappa I
B I
activation O
may O
represent O
a O
mechanism O
by O
which O
steroids O
exert O
an O
anti O
- O
inflammatory O
effect O
in O
IBD O

Synergistic O
activation O
of O
MAP B
kinase I
( O
ERK1 B
/ I
2 I
) O
by O
erythropoietin B
and O
stem B
cell I
factor I
is O
essential O
for O
expanded O
erythropoiesis O
. O

Synergistic O
activation O
of O
MAP B
kinase I
( O
ERK1 B
/ I
2 I
) O
by O
erythropoietin B
and O
stem B
cell I
factor I
is O
essential O
for O
expanded O
erythropoiesis O
. O

Stem B
cell I
factor I
( O
SCF B
) O
and O
erythropoietin B
( O
EPO B
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O

By O
using O
purified O
human O
erythroid O
colony O
- O
forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B
and O
EPO B
synergistically O
activate O
MAP B
kinase I
( O
MAPK B
, O
ERK1 B
/ I
2 I
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

Notably O
, O
among O
AIDS O
- O
related O
PCNSL O
, O
expression O
of O
BCL B
- I
6 I
was O
mutually O
exclusive O
with O
expression O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
encoded I
latent I
membrane I
protein I
( I
LMP I
) I
- I
1 I
and O
, O
with O
few O
exceptions O
, O
also O
of O
BCL B
- I
2 I
. O

Notably O
, O
among O
AIDS O
- O
related O
PCNSL O
, O
expression O
of O
BCL B
- I
6 I
was O
mutually O
exclusive O
with O
expression O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
encoded I
latent I
membrane I
protein I
( I
LMP I
) I
- I
1 I
and O
, O
with O
few O
exceptions O
, O
also O
of O
BCL B
- I
2 I
. O

These O
data O
suggest O
that O
PCNSL O
may O
be O
frequently O
related O
to O
GC O
B O
cells O
and O
may O
be O
segregated O
into O
two O
major O
biologic O
categories O
based O
on O
the O
expression O
pattern O
of O
BCL B
- I
6 I
, O
LMP B
- I
1 I
, O
and O
BCL B
- I
2 I
. O

These O
data O
suggest O
that O
PCNSL O
may O
be O
frequently O
related O
to O
GC O
B O
cells O
and O
may O
be O
segregated O
into O
two O
major O
biologic O
categories O
based O
on O
the O
expression O
pattern O
of O
BCL B
- I
6 I
, O
LMP B
- I
1 I
, O
and O
BCL B
- I
2 I
. O

These O
data O
suggest O
that O
PCNSL O
may O
be O
frequently O
related O
to O
GC O
B O
cells O
and O
may O
be O
segregated O
into O
two O
major O
biologic O
categories O
based O
on O
the O
expression O
pattern O
of O
BCL B
- I
6 I
, O
LMP B
- I
1 I
, O
and O
BCL B
- I
2 I
. O

BCL B
- I
6 I
( O
+ O
) O
/ O
LMP B
- I
1 I
( O
- O
) O
/ O
BCL B
- I
2 I
( O
- O
) O
PCNSL O
occur O
both O
in O
the O
presence O
and O
in O
the O
absence O
of O
HIV O
infection O
and O
consistently O
display O
a O
large O
noncleaved O
cell O
morphology O
. O

BCL B
- I
6 I
( O
+ O
) O
/ O
LMP B
- I
1 I
( O
- O
) O
/ O
BCL B
- I
2 I
( O
- O
) O
PCNSL O
occur O
both O
in O
the O
presence O
and O
in O
the O
absence O
of O
HIV O
infection O
and O
consistently O
display O
a O
large O
noncleaved O
cell O
morphology O
. O

BCL B
- I
6 I
( O
+ O
) O
/ O
LMP B
- I
1 I
( O
- O
) O
/ O
BCL B
- I
2 I
( O
- O
) O
PCNSL O
occur O
both O
in O
the O
presence O
and O
in O
the O
absence O
of O
HIV O
infection O
and O
consistently O
display O
a O
large O
noncleaved O
cell O
morphology O
. O

Conversely O
, O
BCL B
- I
6 I
( O
- O
) O
/ O
LMP B
- I
1 I
( O
+ O
) O
/ O
BCL B
- I
2 I
( O
+ O
) O
PCNSL O
are O
restricted O
to O
HIV O
- O
infected O
hosts O
and O
are O
represented O
by O
lymphomas O
with O
immunoblastic O
features O
. O

Conversely O
, O
BCL B
- I
6 I
( O
- O
) O
/ O
LMP B
- I
1 I
( O
+ O
) O
/ O
BCL B
- I
2 I
( O
+ O
) O
PCNSL O
are O
restricted O
to O
HIV O
- O
infected O
hosts O
and O
are O
represented O
by O
lymphomas O
with O
immunoblastic O
features O
. O

Conversely O
, O
BCL B
- I
6 I
( O
- O
) O
/ O
LMP B
- I
1 I
( O
+ O
) O
/ O
BCL B
- I
2 I
( O
+ O
) O
PCNSL O
are O
restricted O
to O
HIV O
- O
infected O
hosts O
and O
are O
represented O
by O
lymphomas O
with O
immunoblastic O
features O
. O

The O
effect O
was O
significant O
for O
ICAM B
- I
1 I
( O
p O
< O
. O
01 O
) O
and O
VCAM B
- I
1 I
( O
p O
< O
. O
01 O
) O
expression O
in O
cells O
pretreated O
with O
100 O
microM O
alpha O
- O
lipoate O
compared O
to O
PMA O
- O
activated O
untreated O
cells O
. O

The O
effect O
was O
significant O
for O
ICAM B
- I
1 I
( O
p O
< O
. O
01 O
) O
and O
VCAM B
- I
1 I
( O
p O
< O
. O
01 O
) O
expression O
in O
cells O
pretreated O
with O
100 O
microM O
alpha O
- O
lipoate O
compared O
to O
PMA O
- O
activated O
untreated O
cells O
. O

The O
regulation O
of O
adhesion O
molecule O
expression O
and O
function O
by O
low O
concentration O
of O
antioxidants O
investigated O
does O
not O
appear O
to O
be O
NF B
- I
kappaB I
regulated O
or O
transcription O
dependent O
because O
no O
change O
in O
the O
mRNA O
response O
was O
observed O
. O

Protein B
kinase I
C I
( O
PKC B
) O
has O
been O
suggested O
to O
regulate O
PMA O
- O
induced O
adhesion O
molecule O
expression O
by O
post O
- O
transcriptional O
stabilization O
of O
adhesion B
molecule I
mRNA I
. O

Protein B
kinase I
C I
( O
PKC B
) O
has O
been O
suggested O
to O
regulate O
PMA O
- O
induced O
adhesion O
molecule O
expression O
by O
post O
- O
transcriptional O
stabilization O
of O
adhesion B
molecule I
mRNA I
. O

We O
have O
previously O
shown O
that O
binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
virions O
to O
CD4 B
receptors I
stimulates O
association O
of O
Lck B
with O
Raf B
- I
1 I
and O
results O
in O
the O
activation O
of O
Raf B
- I
1 I
kinase O
in O
a O
Ras O
- O
independent O
manner O
. O

We O
have O
previously O
shown O
that O
binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
virions O
to O
CD4 B
receptors I
stimulates O
association O
of O
Lck B
with O
Raf B
- I
1 I
and O
results O
in O
the O
activation O
of O
Raf B
- I
1 I
kinase O
in O
a O
Ras O
- O
independent O
manner O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV B
- I
1 I
envelope I
glycoproteins I
of O
both O
T O
- O
cell O
- O
tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK O
/ O
mitogen O
- O
activated O
protein O
( O
MAP O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B
transcription I
factors I
( O
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
C B
/ I
EBP I
) O
and O
stimulate O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

Binding O
of O
the O
natural O
ligand O
stromal B
cell I
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
to O
CXCR4 B
, O
which O
inhibits O
entry O
of O
T O
- O
cell O
- O
tropic O
HIV O
- O
1 O
, O
activates O
also O
the O
ERK O
/ O
MAP B
kinase I
pathway O
. O

However O
, O
SDF B
- I
1 I
did O
not O
affect O
the O
CD4 O
- O
mediated O
expression O
of O
cytokine B
and I
chemokine I
genes I
. O

Antigen O
receptor O
signaling O
induces O
MAP O
kinase O
- O
mediated O
phosphorylation O
and O
degradation O
of O
the O
BCL B
- I
6 I
transcription B
factor I
. O

Deregulation O
of O
bcl B
- I
6 I
expression O
by O
chromosomal O
rearrangements O
and O
point O
mutations O
of O
the O
bcl B
- I
6 I
promoter I
region I
are O
implicated O
in O
the O
pathogenesis O
of O
B O
- O
cell O
lymphoma O
. O

The O
signals O
regulating O
bcl B
- I
6 I
expression O
are O
not O
known O
. O

Here O
we O
show O
that O
antigen O
receptor O
activation O
leads O
to O
BCL B
- I
6 I
phosphorylation O
by O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
. O

Phosphorylation O
, O
in O
turn O
, O
targets O
BCL B
- I
6 I
for O
rapid O
degradation O
by O
the O
ubiquitin B
/ O
proteasome B
pathway O
. O

These O
findings O
indicate O
that O
BCL B
- I
6 I
expression O
is O
directly O
controlled O
by O
the O
antigen O
receptor O
via O
MAPK B
activation O
. O

Cytosolic B
glucocorticoid I
receptor I
( O
GR B
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR B
protein I
than O
the O
spleen O
. O

Functional O
replacement O
of O
the O
mouse B
E2A I
gene I
with O
a O
human B
HEB I
cDNA I
. O

Functional O
replacement O
of O
the O
mouse B
E2A I
gene I
with O
a O
human B
HEB I
cDNA I
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene B
products I
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B
, O
but O
not O
HEB B
or O
E2 B
- I
2 I
, O
leads O
to O
a O
complete O
arrest O
in O
B O
- O
lymphocyte O
development O
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B
and O
HEB B
/ O
E2 B
- I
2 I
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B
and I
E47 I
exons I
and O
substitution O
of O
both O
E12 B
and I
E47 I
exons I
with O
a O
human B
HEB I
cDNA I
. O

Further O
, O
we O
find O
that O
HEB B
driven O
by O
the O
endogenous B
E2A I
promoter I
can O
functionally O
replace O
E2A B
in O
supporting O
B O
- O
cell O
commitment O
and O
differentiation O
toward O
completion O
. O

However O
, O
IL B
- I
2 I
production O
reached O
only O
suboptimal O
levels O
in O
the O
presence O
of O
CD86 B
but O
optimal O
levels O
with O
CD80 B
. O

To O
analyze O
IL B
- I
2 I
transcriptional O
activity O
in O
CD80 B
and O
CD86 B
co O
- O
stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase B
reporter I
gene I
constructs I
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Our O
results O
suggest O
that O
the O
eventual O
appearance O
of O
CD80 B
on O
recently O
activated O
CD86 O
+ O
APC O
is O
important O
for O
the O
superinduction O
of O
IL B
- I
2 I
production O
and O
to O
support O
vigorous O
T O
cell O
proliferation O
. O

Duplication O
of O
the O
DR3 B
gene I
on O
human B
chromosome I
1p36 I
and O
its O
deletion O
in O
human O
neuroblastoma O
. O

The O
human B
DR3 I
gene I
, O
whose O
product O
is O
also O
known O
as O
Wsl B
- I
1 I
/ I
APO I
- I
3 I
/ I
TRAMP I
/ I
LARD I
, O
encodes O
a O
tumor B
necrosis I
factor I
- I
related I
receptor I
that O
is O
expressed O
primarily O
on O
the O
surface O
of O
thymocytes O
and O
lymphocytes O
. O

We O
report O
here O
that O
the O
DR3 B
gene I
locus I
is O
tandemly O
duplicated O
on O
human B
chromosome I
band I
1p36 I
. I
2 I
- I
p36 I
. I
3 I
and O
that O
these O
genes O
are O
hemizygously O
deleted O
and O
/ O
or O
translocated O
to O
another O
chromosome O
in O
neuroblastoma O
( O
NB O
) O
cell O
lines O
with O
amplified O
MYCN O
. O

It O
is O
suggested O
that O
the O
presence O
of O
steroid B
- I
inducible I
GS I
in O
ALL O
cells O
may O
prove O
to O
be O
a O
marker O
for O
functional B
receptor I
sites I
. O

Aldosterone B
- I
receptor I
deficiency O
in O
pseudohypoaldosteron O
. O

We O
have O
investigated O
this O
syndrome O
for O
the O
possibility O
of O
abnormal B
Type I
I I
or O
` B
` I
mineralocorticoid I
- I
like I
' I
' I
receptors I
, O
which O
have O
intrinsic O
steroid O
specificity O
indistinguishable O
from O
that O
of O
renal B
mineralocorticoid I
receptors I
and O
are O
found O
in O
many O
tissues O
and O
cells O
, O
including O
mononuclear O
leukocytes O
. O

We O
have O
investigated O
this O
syndrome O
for O
the O
possibility O
of O
abnormal B
Type I
I I
or O
` B
` I
mineralocorticoid I
- I
like I
' I
' I
receptors I
, O
which O
have O
intrinsic O
steroid O
specificity O
indistinguishable O
from O
that O
of O
renal B
mineralocorticoid I
receptors I
and O
are O
found O
in O
many O
tissues O
and O
cells O
, O
including O
mononuclear O
leukocytes O
. O

It O
appears O
that O
pseudohypoaldosteron O
is O
caused O
by O
a O
Type O
I O
receptor O
defect O
, O
that O
the O
defect O
may O
be O
complete O
or O
partial O
, O
that O
transmission O
may O
be O
autosomal O
recessive O
, O
and O
that O
the O
study O
of O
patients O
with O
pseudohypoaldosteron O
may O
indicate O
physiologic O
roles O
for O
Type B
I I
receptors I
in O
nonepithelial O
tissues O
. O

Thus O
, O
regulation O
of O
UK B
- I
like I
PAs I
in O
HMy2 O
and O
GM4672A O
cells O
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively B
expressed I
activator I
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid B
- I
inducible I
inhibitors I
to O
the O
regulatory O
process O
in O
GM4672A O
cells O
. O

Serum O
sex O
steroid O
and O
peptide O
hormone O
concentrations O
, O
and O
endometrial O
estrogen O
and O
progestin O
receptor O
levels O
during O
administration O
of O
human B
leukocyte I
interferon I
. O

Five O
normally O
cycling O
healthy O
women O
were O
given O
daily O
subcutaneous O
injections O
of O
human B
leukocyte I
interferon I
( O
3 O
X O
10 O
( O
6 O
) O
units O
/ O
day O
) O
from O
the O
3rd O
through O
23rd O
day O
of O
the O
menstrual O
cycle O
, O
and O
serum O
steroid O
and O
peptide O
hormone O
concentrations O
monitored O
at O
3 O
- O
day O
intervals O
during O
the O
treatment O
and O
the O
preceding O
control O
cycle O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum B
alkaline I
phosphatase I
and O
gamma B
- I
glutamyltransferase I
during O
the O
interferon B
therapy O
shows O
that O
interferon B
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum B
alkaline I
phosphatase I
and O
gamma B
- I
glutamyltransferase I
during O
the O
interferon B
therapy O
shows O
that O
interferon B
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

Distinct O
increase O
in O
amount O
of O
the O
leukocyte B
glucocorticoid I
receptors I
was O
found O
in O
patients O
with O
poisoning O
by O
dichlorethane O
and O
hypnotic O
drugs O
under O
conditions O
of O
acute O
myocardial O
infarction O
. O

But O
in O
the O
patients O
with O
acute O
pancreatitis O
the O
decrease O
in O
content O
of O
leukocyte B
glucocorticoid I
receptors I
was O
not O
observed O
although O
there O
was O
an O
increase O
in O
cortisol O
concentration O
in O
blood O
. O

Proliferating O
lymphocytes O
and O
gamma B
- I
interferon I
thus O
increased O
the O
antimicrobial O
activity O
of O
phagocytes O
exposed O
to O
glucocorticoids O
over O
that O
of O
control O
cells O
. O

Macrophage O
activation O
and O
correction O
of O
the O
dexamethasone O
effect O
by O
gamma B
- I
interferon I
, O
however O
, O
was O
dependent O
on O
the O
pathogen O
. O

Suppression O
of O
macrophage O
antimicrobial O
activity O
should O
thus O
be O
considered O
when O
treating O
patients O
with O
glucocorticoids O
; O
its O
prevention O
by O
gamma B
- I
interferon I
might O
be O
beneficial O
for O
some O
but O
not O
all O
pathogens O
. O

Interleukin B
2 I
receptor I
( O
Tac B
antigen I
) O
expression O
in O
HTLV O
- O
I O
- O
associated O
adult O
T O
- O
cell O
leukemia O
. O

Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
is O
a O
lymphokine B
synthesized O
by O
some O
T O
- O
cells O
following O
activation O
. O

Interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
is O
a O
lymphokine B
synthesized O
by O
some O
T O
- O
cells O
following O
activation O
. O

Using O
anti B
- I
Tac I
, O
a O
monoclonal B
antibody I
that O
recognizes O
the O
IL B
- I
2 I
receptor I
, O
the O
receptor O
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 O
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 O
, O
000 O
mature O
form O
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B
reading I
frame I
protein I
encoded O
in O
part O
by O
the O
pX B
region I
of O
this O
virus O
may O
act O
as O
a O
transacting B
transcriptional I
activator I
that O
induces O
IL B
- I
2 I
receptor I
gene I
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL B
- I
2 I
receptor I
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

Two O
patients O
with O
Tac O
- O
positive O
adult O
T O
- O
cell O
leukemia O
have O
been O
treated O
with O
the O
anti B
- I
Tac I
. O

One O
of O
the O
patients O
had O
6 O
- O
and O
3 O
- O
mo O
remissions O
of O
his O
leukemia O
following O
two O
courses O
of O
therapy O
with O
this O
monoclonal B
antibody I
directed O
toward O
this O
growth B
factor I
receptor I
. O

Structure O
and O
regulation O
of O
the O
glucocorticoid B
hormone I
receptor I
. O

Dissociation O
of O
the O
steroid O
and O
oxidation O
of O
receptor B
thiol I
group I
( O
s O
) O
lead O
to O
the O
inactive O
receptor O
form O
( O
state O
E O
) O
. O

Thermodynamics O
of O
steroid O
binding O
to O
the O
human B
glucocorticoid I
receptor I
. O

The O
conclusions O
from O
these O
findings O
are O
: O
( O
a O
) O
the O
inhibition O
of O
mitogenic O
stimulation O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
is O
mediated O
by O
specific B
functional I
receptors I
to O
the O
hormone O
; O
and O
( O
b O
) O
the O
receptors O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
mononuclear O
cells O
are O
probably O
controlled O
genetically O
by O
the O
same O
mechanisms O
as O
the O
effector O
system O
in O
well O
- O
characterized O
target O
organs O
of O
the O
hormone O
, O
such O
as O
intestine O
and O
kidney O
. O

Reduced O
level O
of O
cellular B
glucocorticoid I
receptors I
in O
patients O
with O
anorexia O
nervosa O
. O

Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major B
histocompatibility I
antigens I
( O
HLA B
- I
A I
, O
- B
B I
, O
- O
C O
; O
Ia B
- I
like I
) O
. O

Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major B
histocompatibility I
antigens I
( O
HLA B
- I
A I
, O
- B
B I
, O
- O
C O
; O
Ia B
- I
like I
) O
. O

Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major B
histocompatibility I
antigens I
( O
HLA B
- I
A I
, O
- B
B I
, O
- O
C O
; O
Ia B
- I
like I
) O
. O

Specific O
estrogen B
binding I
sites I
in O
human O
lymphoid O
cells O
and O
thymic O
cells O
. O

Eleven O
patients O
with O
metastasized O
breast O
cancer O
received O
8 O
intramuscular O
injections O
of O
6 O
x O
10 O
( O
6 O
) O
units O
of O
human B
fibroblast I
interferon I
over O
a O
period O
of O
40 O
days O
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT B
) O
, O
adenosine B
deaminase I
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT B
) O
, O
adenosine B
deaminase I
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Adenosine B
deaminase I
and O
5 B
' I
nucleotidase I
activities O
both O
varied O
within O
two O
orders O
of O
magnitude O
. O

The O
receptor O
concentration O
of O
the O
low O
affinity O
site O
( O
0 O
. O
30 O
pmol O
/ O
mg O
protein O
) O
was O
approximately O
twice O
that O
of O
the O
high B
affinity I
site I
( O
0 O
. O
14 O
pmol O
/ O
mg O
protein O
) O
. O

In O
cytosol O
from O
a O
glucocorticoid O
- O
resistant O
cell O
line O
with O
virtually O
no O
[ O
3H O
] O
DEX O
binding O
, O
[ O
3H O
] O
CVZ O
detected O
a O
single O
high B
affinity I
binding I
site I
that O
was O
similar O
in O
dissociation O
constant O
( O
0 O
. O
8 O
nM O
) O
and O
receptor O
concentration O
( O
0 O
. O
13 O
pmol O
/ O
mg O
protein O
) O
to O
the O
high B
affinity I
site I
detected O
in O
the O
glucocorticoid O
- O
sensitive O
cell O
line O
C7 O
. O

striking O
increase O
in O
the O
expression O
by O
the O
transformed O
cells O
of O
specific O
binding O
sites O
for O
estradiol O
( O
E2 O
) O
due O
to O
an O
actual O
increase O
in O
total O
cellular B
receptor I
proteins I
and O
not O
to O
a O
change O
in O
receptor O
affinity O
for O
E2 O
. O

Since O
the O
rise O
in O
E2 B
- I
receptor I
display O
paralleled O
a O
large O
increase O
in O
the O
proliferative O
activity O
of O
the O
cells O
as O
well O
as O
a O
change O
in O
their O
maturation O
status O
the O
question O
was O
raised O
as O
to O
whether O
the O
E2 B
- I
receptor I
should O
be O
considered O
as O
a O
physiological O
marker O
of O
growth O
rate O
or O
of O
cellular O
differentiation O
. O

Since O
the O
rise O
in O
E2 B
- I
receptor I
display O
paralleled O
a O
large O
increase O
in O
the O
proliferative O
activity O
of O
the O
cells O
as O
well O
as O
a O
change O
in O
their O
maturation O
status O
the O
question O
was O
raised O
as O
to O
whether O
the O
E2 B
- I
receptor I
should O
be O
considered O
as O
a O
physiological O
marker O
of O
growth O
rate O
or O
of O
cellular O
differentiation O
. O

This O
suggests O
the O
association O
of O
E2 B
- I
receptor I
expression O
with O
control O
of O
growth O
rather O
than O
cell O
maturation O
. O

Multiple O
forms O
and O
fragments O
of O
cytosolic B
glucocorticoid I
receptors I
from O
human O
leukemic O
cells O
and O
normal O
lymphocytes O
. O

CD28 B
- O
mediated O
activation O
in O
CD45RA O
+ O
and O
CD45RO O
+ O
T O
cells O
: O
enhanced O
levels O
of O
reactive O
oxygen O
intermediates O
and O
c B
- I
Rel I
nuclear O
translocation O
in O
CD45RA O
+ O
cells O
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti B
- I
CD3 I
plus O
anti B
- I
CD28 I
) O
on O
the O
activation O
of O
NF B
- I
kappaB I
in O
CD45RA O
+ O
( O
naive O
) O
and O
CD45RO O
+ O
( O
memory O
/ O
effector O
) O
T O
cells O
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti B
- I
CD3 I
plus O
anti B
- I
CD28 I
) O
on O
the O
activation O
of O
NF B
- I
kappaB I
in O
CD45RA O
+ O
( O
naive O
) O
and O
CD45RO O
+ O
( O
memory O
/ O
effector O
) O
T O
cells O
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti B
- I
CD3 I
plus O
anti B
- I
CD28 I
) O
on O
the O
activation O
of O
NF B
- I
kappaB I
in O
CD45RA O
+ O
( O
naive O
) O
and O
CD45RO O
+ O
( O
memory O
/ O
effector O
) O
T O
cells O
. O

Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF B
- I
kappaB I
DNA O
binding O
in O
CD45RA O
+ O
cells O
than O
in O
CD45RO O
+ O
cells O
. O

Analysis O
of O
the O
nuclear B
c I
- I
Rel I
protein I
indicated O
that O
after O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
the O
level O
of O
c B
- I
Rel I
was O
higher O
in O
CD45RA O
+ O
cells O
. O

The O
role O
of O
Rel B
and O
activation B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
in O
IL B
- I
2 I
promoter I
activity O
in O
B7 O
- O
1 O
- O
and O
leukocyte O
function O
- O
associated O
Ag O
- O
3 O
( O
LFA O
. O
3 O
) O
- O
costimulated O
T O
cells O
has O
been O
evaluated O
. O

We O
demonstrate O
that O
overexpression O
of O
c B
- I
Jun I
but O
not O
c B
- I
Fos I
increases O
IL B
- I
2 I
promoter I
activity O
in O
both O
B7 O
- O
1 O
- O
and O
LFA O
- O
3 O
- O
costimulated O
Jurkat O
T O
cells O
. O

We O
demonstrate O
that O
overexpression O
of O
c B
- I
Jun I
but O
not O
c B
- I
Fos I
increases O
IL B
- I
2 I
promoter I
activity O
in O
both O
B7 O
- O
1 O
- O
and O
LFA O
- O
3 O
- O
costimulated O
Jurkat O
T O
cells O
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter I
- I
and I
CD28RE I
- I
driven I
reporter I
constructs I
in O
both O
LFA O
- O
3 O
- O
and O
B7 O
- O
1 O
- O
costimulated O
Jurkat O
cells O
. O

Mutating O
the O
CD28RE B
but O
not O
the O
upstream B
nuclear I
factor I
kappabeta I
- I
binding I
site I
in O
the O
IL B
- I
2 I
promoter I
reduced O
B7 B
- I
1 I
- O
driven O
transcription O
> O
90 O
% O
. O

The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B
in O
the O
integration O
of O
p65 B
/ O
c B
- I
Jun I
- O
mediated O
transcription O
within O
the O
IL B
- I
2 I
promoter I
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA B
- I
3 I
- O
driven O
immune O
response O
to O
a O
B7 O
- O
- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c B
- I
Jun I
and O
p65 B
, O
which O
target O
the O
CD28RE B
region O
of O
the O
IL B
- I
2 I
promoter I
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA B
- I
3 I
- O
driven O
immune O
response O
to O
a O
B7 O
- O
- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c B
- I
Jun I
and O
p65 B
, O
which O
target O
the O
CD28RE B
region O
of O
the O
IL B
- I
2 I
promoter I
. O

To O
assess O
HUVEC O
activation O
, O
E B
- I
selectin I
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E B
- I
selectin I
- I
specific I
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF B
- I
kappa I
B I
, O
a O
transcription B
factor I
necessary O
for O
E B
- I
selectin I
gene I
activation O
. O

Exposure O
of O
HUVECs O
to O
B O
. O
fragilis O
outer O
membrane O
fractions O
, O
separated O
from O
other O
components O
of O
the O
B O
. O
fragilis O
cell O
wall O
by O
isopycnic O
, O
sucrose O
gradient O
centrifugation O
, O
significantly O
increased O
surface O
expression O
of O
E B
- I
selectin I
and O
induced O
functional O
endothelial O
cell O
- O
dependent O
leukocyte O
adhesion O
. O

NF B
- I
kappaB I
protects O
HIV O
- O
1 O
- O
infected O
myeloid O
cells O
from O
apoptosis O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF B
- I
kappaB I
activity O
in O
chronically O
HIV O
- O
1 O
- O
infected O
promonocytic O
U937 O
( O
U9 O
- O
IIIB O
) O
and O
myeloblastic O
PLB O
- O
985 O
( O
PLB O
- O
IIIB O
) O
cells O
affects O
apoptotic O
signaling O
. O

Inhibition O
of O
TNFalpha B
- O
induced O
NF O
- O
kappaB O
activation O
using O
the O
antioxidant O
N O
- O
acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 O
and O
U9 O
- O
IIIB O
cells O
, O
while O
preactivation O
of O
NF B
- I
kappaB I
with O
the O
non B
- I
apoptotic I
inducer I
IL I
- I
1beta I
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

Inhibition O
of O
constitutive O
NF B
- I
kappaB I
activity O
in O
U9 O
- O
IIIB O
and O
PLB O
- O
IIIB O
cells O
also O
induced O
apoptosis O
, O
suggesting O
that O
NF O
- O
kappaB O
protects O
cells O
from O
a O
persistent O
apoptotic O
signal O
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

The O
protective O
role O
of O
NF B
- I
kappaB I
in O
blocking O
TNFalpha O
- O
and O
HIV O
- O
1 O
- O
induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB B
alpha I
repressor I
mutants I
( O
TD B
- I
IkappaB I
) O
under O
the O
control O
of O
a O
tetracycline B
- I
responsive I
promoter I
. O

The O
protective O
role O
of O
NF B
- I
kappaB I
in O
blocking O
TNFalpha O
- O
and O
HIV O
- O
1 O
- O
induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB B
alpha I
repressor I
mutants I
( O
TD B
- I
IkappaB I
) O
under O
the O
control O
of O
a O
tetracycline B
- I
responsive I
promoter I
. O

Cells O
underwent O
apoptosis O
in O
response O
to O
TNFalpha B
only O
when O
NF O
- O
kappaB O
activation O
was O
inhibited O
by O
TD B
- I
IkappaB I
expression O
. O

The O
presence O
of O
this O
faster B
migrating I
complex I
was O
restricted O
to O
B O
cells O
among O
the O
circulating O
lymphocyte O
population O
. O

Although O
the O
heterodimer B
Ku70 I
/ I
variant I
- I
Ku86 I
binds O
to O
DNA B
- I
ends I
, O
this O
altered O
form O
of O
the O
Ku B
heterodimer I
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B
component I
of O
the O
complex O
, O
DNA B
- I
PK I
( I
CS I
) I
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

Co O
- O
stimulation O
of O
human O
peripheral O
blood O
mononuclear O
cells O
with O
IL B
- I
2 I
and O
anti B
- I
CD3 I
monoclonal I
antibodies I
induces O
phosphorylation O
of O
CREB B
. O

The O
absence O
of O
P B
- I
CREB I
following O
CD3 O
cross O
- O
linking O
was O
unexpected O
, O
as O
other O
laboratories O
reported O
increased O
phosphorylation O
of O
CREB B
following O
CD3 O
cross O
- O
linking O
of O
the O
Jurkat O
lymphocyte O
cell O
line O
. O

Due O
to O
Jurkat O
T O
- O
cells O
being O
IL O
- O
2 O
- O
independent O
, O
it O
was O
postulated O
that O
IL B
- I
2 I
might O
provide O
a O
necessary O
co O
- O
stimulus O
for O
phosphorylation O
of O
CREB B
in O
primary O
lymphocytes O
. O

Therefore O
, O
P B
- I
CREB I
was O
evaluated O
following O
co O
- O
stimulation O
of O
human O
PBMC O
through O
the O
IL B
- I
2 I
and I
CD2 I
or I
CD3 I
receptors I
. O

IL B
- I
2 I
did O
not O
further O
augment O
phosphorylation O
of O
CREB B
following O
CD2 O
cross O
- O
linking O
. O

However O
, O
while O
neither O
IL B
- I
2 I
nor O
CD3 O
cross O
- O
linking O
alone O
induced O
P B
- I
CREB I
, O
a O
4 O
. O
5 O
- O
fold O
increase O
in O
phosphorylation O
of O
CREB B
within O
1 O
h O
of O
IL O
- O
2 O
/ O
CD3 O
co O
- O
stimulation O
was O
observed O
. O

However O
, O
while O
neither O
IL B
- I
2 I
nor O
CD3 O
cross O
- O
linking O
alone O
induced O
P B
- I
CREB I
, O
a O
4 O
. O
5 O
- O
fold O
increase O
in O
phosphorylation O
of O
CREB B
within O
1 O
h O
of O
IL O
- O
2 O
/ O
CD3 O
co O
- O
stimulation O
was O
observed O
. O

Phosphorylation O
was O
not O
associated O
with O
the O
induction O
of O
cAMP O
, O
and O
inhibition O
of O
PKA O
signaling O
had O
no O
effect O
on O
P B
- I
CREB I
. O

These O
data O
suggest O
that O
the O
IL B
- I
2 I
and O
CD3 B
signaling O
pathways O
provide O
a O
necessary O
and O
co O
- O
operative O
stimulus O
promoting O
phosphorylation O
of O
CREB B
following O
receptor O
cross O
- O
linking O
. O

Transcription B
factor I
LKLF I
is O
sufficient O
to O
program O
T O
cell O
quiescence O
via O
a O
c O
- O
Myc O
- O
- O
dependent O
pathway O
. O

LKLF B
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto B
- I
oncogene I
encoding O
c B
- I
Myc I
. O

LKLF B
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto B
- I
oncogene I
encoding O
c B
- I
Myc I
. O

Forced O
expression O
of O
LKLF B
was O
associated O
with O
markedly O
decreased O
c B
- I
Myc I
expression O
. O

In O
addition O
, O
many O
effects O
of O
LKLF B
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant B
- I
negative I
MadMyc I
protein I
and O
rescued O
by O
overexpression O
of O
c B
- I
Myc I
. O

HTLV B
- I
1 I
p12 I
( I
I I
) I
protein I
enhances O
STAT5 O
activation O
and O
decreases O
the O
interleukin B
- I
2 I
requirement O
for O
proliferation O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
. O

In O
addition O
, O
the O
proliferative O
advantage O
of O
p12 O
( O
I O
) O
- O
transduced O
PBMCs O
was O
evident O
mainly O
at O
low O
concentrations O
of O
IL B
- I
2 I
. O

Critical O
downregulatory O
role O
of O
IL B
- I
4 I
. O

To O
determine O
the O
mechanisms O
by O
which O
IL B
- I
18 I
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines B
in O
the O
regulation O
of O
IL B
- I
18 I
receptor I
alpha I
chain I
( O
IL B
- I
18Ralpha I
) O
expression O
. O

To O
determine O
the O
mechanisms O
by O
which O
IL B
- I
18 I
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines B
in O
the O
regulation O
of O
IL B
- I
18 I
receptor I
alpha I
chain I
( O
IL B
- I
18Ralpha I
) O
expression O
. O

The O
majority O
of O
peripheral O
CD4 O
( O
+ O
) O
T O
cells O
constitutively O
expressed O
the O
IL B
- I
18Ralpha I
. O

Upon O
antigen O
stimulation O
in O
the O
presence O
of O
IL B
- I
12 I
, O
marked O
enhancement O
of O
IL B
- I
18Ralpha I
expression O
was O
observed O
. O

Upon O
antigen O
stimulation O
in O
the O
presence O
of O
IL B
- I
12 I
, O
marked O
enhancement O
of O
IL B
- I
18Ralpha I
expression O
was O
observed O
. O

IL B
- I
12 I
- O
mediated O
upregulation O
of O
IL B
- I
18Ralpha I
required O
IFN B
- I
gamma I
. O

IL B
- I
12 I
- O
mediated O
upregulation O
of O
IL B
- I
18Ralpha I
required O
IFN B
- I
gamma I
. O

IL B
- I
12 I
- O
mediated O
upregulation O
of O
IL B
- I
18Ralpha I
required O
IFN B
- I
gamma I
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL B
- I
18 I
alone O
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL B
- I
18 I
alone O
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL B
- I
18 I
alone O
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL B
- I
18 I
alone O
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL B
- I
18 I
alone O
. O

Activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL B
- I
18Ralpha I
could O
produce O
IFN B
- I
gamma I
when O
stimulated O
with O
the O
combination O
of O
IL B
- I
12 I
and O
IL B
- I
18 I
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL B
- I
18Ralpha I
could O
respond O
to O
IL B
- I
18 I
alone O
. O

In O
contrast O
, O
T O
cell O
stimulation O
in O
the O
presence O
of O
IL B
- I
4 I
resulted O
in O
a O
downregulation O
of O
IL B
- I
18Ralpha I
expression O
. O

In O
contrast O
, O
T O
cell O
stimulation O
in O
the O
presence O
of O
IL B
- I
4 I
resulted O
in O
a O
downregulation O
of O
IL B
- I
18Ralpha I
expression O
. O

Both O
IL O
- O
4 O
( O
- O
/ O
) O
- O
and O
signal O
transducer O
and O
activator O
of O
transcription O
( O
Stat O
) O
6 O
( O
- O
/ O
) O
- O
T O
cells O
expressed O
higher O
levels O
of O
IL B
- I
18Ralpha I
after O
TCR O
stimulation O
. O

Furthermore O
, O
activated O
T O
cells O
from O
Stat6 O
( O
- O
/ O
) O
- O
mice O
produced O
more O
IFN B
- I
gamma I
in O
response O
to O
IL B
- I
18 I
than O
wild O
- O
type O
controls O
. O

Furthermore O
, O
activated O
T O
cells O
from O
Stat6 O
( O
- O
/ O
) O
- O
mice O
produced O
more O
IFN B
- I
gamma I
in O
response O
to O
IL B
- I
18 I
than O
wild O
- O
type O
controls O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL B
- I
18Ralpha I
by O
the O
major O
inductive O
cytokines B
( O
IL B
- I
12 I
and O
IL B
- I
4 I
) O
determines O
the O
capacity O
of O
IL B
- I
18 I
to O
polarize O
an O
immune O
response O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL B
- I
18Ralpha I
by O
the O
major O
inductive O
cytokines B
( O
IL B
- I
12 I
and O
IL B
- I
4 I
) O
determines O
the O
capacity O
of O
IL B
- I
18 I
to O
polarize O
an O
immune O
response O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL B
- I
18Ralpha I
by O
the O
major O
inductive O
cytokines B
( O
IL B
- I
12 I
and O
IL B
- I
4 I
) O
determines O
the O
capacity O
of O
IL B
- I
18 I
to O
polarize O
an O
immune O
response O
. O

Thus O
, O
positive O
/ O
negative O
regulation O
of O
the O
IL B
- I
18Ralpha I
by O
the O
major O
inductive O
cytokines B
( O
IL B
- I
12 I
and O
IL B
- I
4 I
) O
determines O
the O
capacity O
of O
IL B
- I
18 I
to O
polarize O
an O
immune O
response O
. O

Acetylation O
of O
histones B
allows O
unwinding O
of O
the O
local B
DNA I
structure I
and O
enables O
RNA B
polymerase I
II I
to O
enhance O
gene O
transcription O
. O

Acetylation O
of O
histones B
allows O
unwinding O
of O
the O
local B
DNA I
structure I
and O
enables O
RNA B
polymerase I
II I
to O
enhance O
gene O
transcription O
. O

Upon O
exposure O
to O
ultraviolet O
B O
, O
only O
XPA O
mice O
are O
very O
sensitive O
to O
ultraviolet O
- O
B O
- O
induced O
inhibition O
of O
Th1 O
- O
mediated O
contact O
hypersensitivity O
responses O
and O
interferon B
- I
gamma I
production O
in O
skin O
draining O
lymph O
nodes O
. O

Lipopolysaccharide O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
and O
interleukin B
- I
10 I
production O
are O
significantly O
augmented O
in O
both O
XPA O
and O
CSB O
mice O
after O
ultraviolet O
B O
exposure O
. O

Peritoneal O
macrophages O
seem O
to O
participate O
in O
the O
process O
of O
peritoneal O
fibrosis O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
plays O
a O
key O
role O
in O
the O
recruitment O
of O
monocytes O
toward O
the O
peritoneal O
cavity O
. O

However O
, O
little O
is O
known O
about O
the O
effect O
of O
high O
glucose O
on O
MCP B
- I
1 I
expression O
and O
its O
signal O
transduction O
pathway O
in O
human O
peritoneal O
mesothelial O
cells O
. O

MCP B
- I
1 I
expression O
of O
mRNA O
and O
protein O
was O
measured O
by O
Northern O
blot O
analysis O
and O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

To O
examine O
the O
roles O
of O
the O
transcription B
factors I
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

To O
examine O
the O
roles O
of O
the O
transcription B
factors I
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

EMSA O
revealed O
that O
glucose O
increased O
the O
AP B
- I
1 I
binding O
activity O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
, O
but O
not O
NF B
- I
kappaB I
. O

EMSA O
revealed O
that O
glucose O
increased O
the O
AP B
- I
1 I
binding O
activity O
in O
a O
time O
- O
and O
dose O
- O
dependent O
manner O
, O
but O
not O
NF B
- I
kappaB I
. O

Curcumin O
, O
an O
inhibitor O
of O
AP B
- I
1 I
, O
dose O
- O
dependently O
suppressed O
the O
induction O
of O
MCP B
- I
1 I
mRNA I
by O
high O
glucose O
. O

Tyrosine O
kinase O
inhibitors O
such O
as O
genistein O
( O
12 O
. O
5 O
to O
50 O
micromol O
/ O
L O
) O
and O
herbimycin O
A O
( O
0 O
. O
1 O
to O
1 O
micromol O
/ O
L O
) O
inhibited O
the O
high O
- O
glucose O
- O
induced O
MCP B
- I
1 I
mRNA I
expression O
in O
a O
dose O
- O
dependent O
manner O
, O
and O
also O
suppressed O
the O
high O
- O
glucose O
- O
induced O
AP B
- I
1 I
binding O
activity O
. O

CONCLUSIONS O
: O
: O
High O
glucose O
induced O
mesothelial O
MCP B
- I
1 I
expression O
partly O
via O
the O
tyrosine O
kinase O
- O
AP B
- I
1 I
pathway O
. O

CONCLUSIONS O
: O
: O
High O
glucose O
induced O
mesothelial O
MCP B
- I
1 I
expression O
partly O
via O
the O
tyrosine O
kinase O
- O
AP B
- I
1 I
pathway O
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti B
- I
CD54 I
. O

Whereas O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
cross O
- O
linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B
, O
up O
- O
regulation O
of O
CD80 B
required O
dual O
stimulation O
with O
anti B
- I
IgM I
and O
anti B
- I
CD54 I
. O

LMP1 B
acts O
like O
a O
constitutively B
activated I
receptor I
of O
the O
tumor B
necrosis I
factor I
receptor I
family I
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor B
necrosis I
factor I
receptor I
- I
associated I
factor I
( I
TRAF I
) I
family I
. O

TRAF2 B
- O
mediated O
NF B
- I
kappaB I
activation O
, O
AP B
- I
1 I
induction O
and O
JAK3 B
/ O
STAT B
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

TRAF2 B
- O
mediated O
NF B
- I
kappaB I
activation O
, O
AP B
- I
1 I
induction O
and O
JAK3 B
/ O
STAT B
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

Cytotoxic O
T O
lymphocytes O
directed O
against O
well O
- O
characterized O
epitopes O
of O
EBV B
latency I
genes I
represent O
an O
already O
successful O
and O
promising O
therapeutic O
approach O
to O
EBV O
- O
associated O
lymphomas O
, O
in O
particular O
PTLDs O

Interferon B
- I
alpha I
drives O
T O
cell O
- O
mediated O
immunopathology O
in O
the O
intestine O
. O

We O
have O
recently O
described O
enhanced O
expression O
of O
IFN B
- I
alpha I
in O
the O
mucosa O
of O
patients O
with O
celiac O
disease O
( O
CD O
) O
, O
a O
gluten O
- O
sensitive O
Th1 O
- O
mediated O
enteropathy O
, O
characterized O
by O
villous O
atrophy O
and O
crypt O
cell O
hyperplasia O
. O

We O
have O
, O
therefore O
, O
examined O
changes O
that O
take O
place O
in O
explant O
cultures O
of O
human O
fetal O
gut O
after O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
and O
/ O
or O
IFN B
- I
alpha I
. O

We O
have O
, O
therefore O
, O
examined O
changes O
that O
take O
place O
in O
explant O
cultures O
of O
human O
fetal O
gut O
after O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
and O
/ O
or O
IFN B
- I
alpha I
. O

We O
show O
that O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
alone O
elicits O
a O
small O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
response O
with O
no O
tissue O
injury O
. O

We O
show O
that O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
alone O
elicits O
a O
small O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
response O
with O
no O
tissue O
injury O
. O

We O
show O
that O
activation O
of O
T O
cells O
with O
anti B
- I
CD3 I
alone O
elicits O
a O
small O
IFN B
- I
gamma I
and O
TNF B
- I
alpha I
response O
with O
no O
tissue O
injury O
. O

Similarly O
, O
no O
changes O
are O
seen O
in O
explants O
cultured O
with O
IFN B
- I
alpha I
alone O
. O

However O
, O
addition O
of O
IFN B
- I
alpha I
with O
anti B
- I
CD3 I
results O
in O
enhanced O
Th1 O
response O
and O
crypt O
cell O
hyperplasia O
. O

However O
, O
addition O
of O
IFN B
- I
alpha I
with O
anti B
- I
CD3 I
results O
in O
enhanced O
Th1 O
response O
and O
crypt O
cell O
hyperplasia O
. O

Together O
these O
data O
indicate O
that O
IFN B
- I
alpha I
can O
facilitate O
activation O
of O
Th1 O
- O
reactive O
cells O
in O
the O
gut O
and O
drive O
immunopathology O
. O

Suppression O
of O
tumor B
necrosis I
factor I
alpha I
production O
by O
cAMP O
in O
human O
monocytes O
: O
dissociation O
with O
mRNA O
level O
and O
independent O
of O
interleukin B
- I
10 I
. O

BACKGROUND O
: O
Elevation O
of O
cellular O
cAMP O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
production O
and O
increases O
the O
expression O
of O
interleukin B
( I
IL I
) I
- I
10 I
in O
mononuclear O
cells O
. O

TNF B
- I
alpha I
gene I
expression O
obligates O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
. O

TNF B
- I
alpha I
gene I
expression O
obligates O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
. O

Exogenous O
IL B
- I
10 I
inhibits O
NF B
- I
kappaB I
in O
monocytes O
and O
thus O
attenuates O
TNF B
- I
alpha I
production O
. O

Exogenous O
IL B
- I
10 I
inhibits O
NF B
- I
kappaB I
in O
monocytes O
and O
thus O
attenuates O
TNF B
- I
alpha I
production O
. O

Exogenous O
IL B
- I
10 I
inhibits O
NF B
- I
kappaB I
in O
monocytes O
and O
thus O
attenuates O
TNF B
- I
alpha I
production O
. O

We O
examined O
the O
role O
of O
endogenous O
IL B
- I
10 I
in O
the O
regulation O
of O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
in O
human O
monocytes O
by O
cAMP O
. O

We O
examined O
the O
role O
of O
endogenous O
IL B
- I
10 I
in O
the O
regulation O
of O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
in O
human O
monocytes O
by O
cAMP O
. O

We O
examined O
the O
role O
of O
endogenous O
IL B
- I
10 I
in O
the O
regulation O
of O
NF B
- I
kappaB I
activation O
and O
TNF B
- I
alpha I
production O
in O
human O
monocytes O
by O
cAMP O
. O

Cytokine B
( O
TNF B
- I
alpha I
and O
IL B
- I
10 I
) O
release O
was O
measured O
by O
immunoassay O
. O

Cytokine B
( O
TNF B
- I
alpha I
and O
IL B
- I
10 I
) O
release O
was O
measured O
by O
immunoassay O
. O

TNF B
- I
alpha I
mRNA I
was O
measured O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
, O
and O
NF B
- I
kappaB I
DNA O
binding O
activity O
was O
assessed O
by O
gel O
mobility O
shift O
assay O
. O

RESULTS O
: O
cAMP O
- O
elevating O
agents O
inhibited O
LPS O
- O
stimulated O
TNF B
- I
alpha I
release O
( O
0 O
. O
77 O
+ O
/ O
- O
0 O
. O
13 O
ng O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
dbcAMP O
and O
0 O
. O
68 O
+ O
/ O
- O
0 O
. O
19 O
ng O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
FSK O
, O
both O
P O
< O
0 O
. O
05 O
vs O
1 O
. O
61 O
+ O
/ O
- O
0 O
. O
34 O
ng O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
alone O
) O
. O

Conversely O
, O
cAMP O
enhanced O
LPS O
- O
stimulated O
IL B
- I
10 I
release O
( O
100 O
+ O
/ O
- O
21 O
. O
5 O
pg O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
dbcAMP O
and O
110 O
+ O
/ O
- O
25 O
. O
2 O
pg O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
FSK O
, O
both O
P O
< O
0 O
. O
05 O
vs O
53 O
. O
3 O
+ O
/ O
- O
12 O
. O
8 O
pg O
/ O
10 O
( O
6 O
) O
cells O
in O
LPS O
alone O
) O
. O

Neither O
TNF B
- I
alpha I
mRNA I
expression O
nor O
NF B
- I
kappaB I
activation O
stimulated O
by O
LPS O
was O
inhibited O
by O
the O
cAMP O
- O
elevating O
agents O
. O

Neutralization O
of O
IL B
- I
10 I
with O
a O
specific O
antibody B
did O
not O
attenuate O
the O
effect O
of O
cAMP O
- O
elevating O
agents O
on O
TNF B
- I
alpha I
production O
. O

Neutralization O
of O
IL B
- I
10 I
with O
a O
specific O
antibody B
did O
not O
attenuate O
the O
effect O
of O
cAMP O
- O
elevating O
agents O
on O
TNF B
- I
alpha I
production O
. O

CONCLUSION O
: O
The O
results O
indicate O
that O
cAMP O
inhibits O
LPS O
- O
stimulated O
TNF B
- I
alpha I
production O
through O
a O
posttranscriptional O
mechanism O
that O
is O
independent O
of O
endogenous O
IL B
- I
10 I
. O

CONCLUSION O
: O
The O
results O
indicate O
that O
cAMP O
inhibits O
LPS O
- O
stimulated O
TNF B
- I
alpha I
production O
through O
a O
posttranscriptional O
mechanism O
that O
is O
independent O
of O
endogenous O
IL B
- I
10 I
. O

We O
have O
previously O
reported O
that O
BMP B
- I
2 I
inhibited O
the O
growth O
of O
HS O
- O
72 O
mouse O
hybridoma O
cells O
by O
inducing O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
expression O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29 B
- I
b I
region I
was O
found O
to O
be O
associated O
with O
Smad4 B
and O
phosphorylated B
Smad1 I
in O
the O
nuclear O
extract O
of O
BMP B
- I
2 I
- O
stimulated O
HS O
- O
72 O
cells O
. O

These O
results O
suggested O
that O
BMP B
- I
2 I
might O
activate O
p21 O
( O
CIP1 O
/ O
WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 B
and O
Smad1 B
to O
the O
29 B
- I
b I
region I
in O
HS O
- O
72 O
cells O
. O

Dendritic O
cells O
( O
DCs O
) O
are O
professional O
antigen O
- O
presenting O
cells O
which O
both O
initiate O
adaptive O
immune O
responses O
and O
control O
tolerance O
to O
self B
- I
antigens I
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV O
- O
suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
, O
C B
/ I
EBPbeta I
and O
STAT1 B
: O
role O
of O
CD14 B
and O
Toll B
- I
like I
receptors I
2 I
and I
4 I
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B
surface I
receptors I
, O
including O
CD14 B
and O
Toll B
- I
like I
receptor I
2 I
( O
TLR2 B
) O
or O
TLR4 B
that O
are O
known O
to O
be O
signal B
- I
transducing I
receptors I
for O
other O
bacterial O
cell O
wall O
components O
. O

Using O
MonoMac6 O
cells O
, O
we O
observed O
high O
C B
/ I
EBPbeta I
and O
AP B
- I
1 I
but O
weaker O
and O
transient O
NF B
- I
kappaB I
activation O
by O
MB O
. O

Using O
MonoMac6 O
cells O
, O
we O
observed O
high O
C B
/ I
EBPbeta I
and O
AP B
- I
1 I
but O
weaker O
and O
transient O
NF B
- I
kappaB I
activation O
by O
MB O
. O

Using O
MonoMac6 O
cells O
, O
we O
observed O
high O
C B
/ I
EBPbeta I
and O
AP B
- I
1 I
but O
weaker O
and O
transient O
NF B
- I
kappaB I
activation O
by O
MB O
. O

Moreover O
, O
the O
truncated O
form O
of O
C B
/ I
EBPbeta I
, O
known O
to O
repress O
HIV O
- O
1 O
transcription O
, O
was O
detected O
in O
extracts O
from O
MB O
- O
treated O
THP O
- O
1 O
cells O
. O

Surprisingly O
, O
neither O
MB O
nor O
MDP O
were O
able O
to O
transduce O
signals O
via O
CD14 B
and O
TLR2 B
or I
4 I
. O

These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co B
- I
receptors I
other O
than O
TLR2 B
and O
TLR4 B
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O

We O
conclude O
that O
peritoneal O
fluid O
of O
endometriosis O
patients O
contains O
activators O
of O
PPAR B
- I
alpha I
that O
stimulate O
macrophage O
chemotaxis O
. O

Inhibitors O
of O
PPAR B
- I
alpha I
or O
activators O
of O
PPAR B
- I
gamma I
could O
be O
developed O
for O
the O
treatment O
of O
inflammation O
associated O
with O
endometriosis O
. O

Inhibitors O
of O
PPAR B
- I
alpha I
or O
activators O
of O
PPAR B
- I
gamma I
could O
be O
developed O
for O
the O
treatment O
of O
inflammation O
associated O
with O
endometriosis O
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin B
- I
10 I
or O
transforming B
growth I
factor I
- I
beta I
and O
NF B
- I
kappa I
B I
, O
these O
immunosuppressive B
cytokines I
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

Although O
IL B
- I
12 I
together O
with O
IFN B
- I
gamma I
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL B
- I
12 I
p70 I
protein I
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O

Although O
IL B
- I
12 I
together O
with O
IFN B
- I
gamma I
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL B
- I
12 I
p70 I
protein I
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O

The O
inhibition O
was O
induced O
by O
interaction O
with O
macrophages O
that O
had O
contacted O
with O
P O
. O
berghei O
- O
infected O
erythrocytes O
and O
was O
mediated O
by O
a O
soluble O
factor O
, O
IL B
- I
10 I
. O

There O
was O
comparable O
activation O
of O
NF B
- I
kappaB I
in O
uninfected O
and O
infected O
cells O
. O

The O
Friend B
of I
GATA I
proteins I
U O
- O
shaped O
, O
FOG B
- I
1 I
, O
and O
FOG B
- I
2 I
function O
as O
negative O
regulators O
of O
blood O
, O
heart O
, O
and O
eye O
development O
in O
Drosophila O
. O

The O
Friend B
of I
GATA I
proteins I
U O
- O
shaped O
, O
FOG B
- I
1 I
, O
and O
FOG B
- I
2 I
function O
as O
negative O
regulators O
of O
blood O
, O
heart O
, O
and O
eye O
development O
in O
Drosophila O
. O

In O
this O
report O
, O
we O
show O
that O
Ush B
is O
expressed O
in O
hemocyte O
precursors O
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA B
factor I
Serpent I
is O
essential O
for O
Ush B
embryonic O
expression O
. O

Murine B
FOG I
- I
1 I
and I
FOG I
- I
2 I
also O
can O
repress O
crystal O
cell O
production O
, O
but O
a O
mutant O
version O
of O
FOG B
- I
2 I
lacking O
a O
conserved O
motif O
that O
binds O
the O
corepressor B
C I
- I
terminal I
binding I
protein I
fails O
to O
affect O
the O
cell O
lineage O
. O

The O
GATA B
factor I
Pannier I
( O
Pnr B
) O
is O
required O
for O
eye O
and O
heart O
development O
in O
Drosophila O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

When O
Ush B
, O
FOG B
- I
1 I
, O
FOG B
- I
2 I
, O
or O
mutant B
FOG I
- I
2 I
is O
coexpressed O
with O
Pnr B
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B
function O
. O

The O
RING B
finger I
protein I
Siah B
- I
1 I
regulates O
the O
level O
of O
the O
transcriptional B
coactivator I
OBF B
- I
1 I
. O

The O
RING B
finger I
protein I
Siah B
- I
1 I
regulates O
the O
level O
of O
the O
transcriptional B
coactivator I
OBF B
- I
1 I
. O

The O
RING B
finger I
protein I
Siah B
- I
1 I
regulates O
the O
level O
of O
the O
transcriptional B
coactivator I
OBF B
- I
1 I
. O

The O
transcriptional B
coactivator I
OBF B
- I
1 I
, O
which O
interacts O
with O
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
the O
octamer B
site I
DNA I
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

The O
transcriptional B
coactivator I
OBF B
- I
1 I
, O
which O
interacts O
with O
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
the O
octamer B
site I
DNA I
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

The O
transcriptional B
coactivator I
OBF B
- I
1 I
, O
which O
interacts O
with O
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
the O
octamer B
site I
DNA I
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

The O
transcriptional B
coactivator I
OBF B
- I
1 I
, O
which O
interacts O
with O
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
the O
octamer B
site I
DNA I
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

Here O
we O
have O
identified O
the O
RING B
finger I
protein I
Siah B
- I
1 I
as O
a O
protein O
interacting O
specifically O
with O
OBF B
- I
1 I
. O

Here O
we O
have O
identified O
the O
RING B
finger I
protein I
Siah B
- I
1 I
as O
a O
protein O
interacting O
specifically O
with O
OBF B
- I
1 I
. O

Here O
we O
have O
identified O
the O
RING B
finger I
protein I
Siah B
- I
1 I
as O
a O
protein O
interacting O
specifically O
with O
OBF B
- I
1 I
. O

This O
interaction O
is O
mediated O
by O
the O
C B
- I
terminal I
part O
of O
Siah B
- I
1 I
and O
by O
residues O
in O
the O
N B
- I
terminus I
of O
OBF B
- I
1 I
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B
POU I
domains I
and O
the O
DNA O
. O

This O
interaction O
is O
mediated O
by O
the O
C B
- I
terminal I
part O
of O
Siah B
- I
1 I
and O
by O
residues O
in O
the O
N B
- I
terminus I
of O
OBF B
- I
1 I
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B
POU I
domains I
and O
the O
DNA O
. O

This O
interaction O
is O
mediated O
by O
the O
C B
- I
terminal I
part O
of O
Siah B
- I
1 I
and O
by O
residues O
in O
the O
N B
- I
terminus I
of O
OBF B
- I
1 I
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B
POU I
domains I
and O
the O
DNA O
. O

This O
interaction O
is O
mediated O
by O
the O
C B
- I
terminal I
part O
of O
Siah B
- I
1 I
and O
by O
residues O
in O
the O
N B
- I
terminus I
of O
OBF B
- I
1 I
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B
POU I
domains I
and O
the O
DNA O
. O

This O
interaction O
is O
mediated O
by O
the O
C B
- I
terminal I
part O
of O
Siah B
- I
1 I
and O
by O
residues O
in O
the O
N B
- I
terminus I
of O
OBF B
- I
1 I
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B
POU I
domains I
and O
the O
DNA O
. O

Interaction O
between O
Siah B
- I
1 I
and O
OBF B
- I
1 I
leads O
to O
downregulation O
of O
OBF O
- O
1 O
protein O
level O
but O
not O
mRNA O
, O
and O
to O
a O
corresponding O
reduction O
in O
octamer O
site O
- O
dependent O
transcription O
activation O
. O

Interaction O
between O
Siah B
- I
1 I
and O
OBF B
- I
1 I
leads O
to O
downregulation O
of O
OBF O
- O
1 O
protein O
level O
but O
not O
mRNA O
, O
and O
to O
a O
corresponding O
reduction O
in O
octamer O
site O
- O
dependent O
transcription O
activation O
. O

These O
data O
suggest O
that O
Siah B
- I
1 I
is O
part O
of O
a O
novel O
regulatory O
loop O
controlling O
the O
level O
of O
OBF B
- I
1 I
protein I
in O
B O
cells O
. O

The O
association O
of O
trans B
- I
acting I
T I
cell I
factors I
( O
TCFs B
) O
or O
lymphoid B
enhancer I
factor I
1 I
( O
LEF B
- I
1 I
) O
with O
their O
coactivator O
beta O
- O
catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

We O
show O
here O
that O
T O
cell O
maturation O
depends O
on O
the O
presence O
of O
the O
beta B
- I
catenin I
- I
- I
binding I
domain I
in O
TCF B
- I
1 I
. O

Accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF B
- I
1 I
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti B
- I
apoptotic I
protein I
Bcl B
- I
x I
( I
L I
) I
. O

Thus O
, O
TCF B
- I
1 I
, O
upon O
association O
with O
beta O
- O
catenin O
, O
transiently O
ensures O
the O
survival O
of O
immature O
T O
cells O
, O
which O
enables O
them O
to O
generate O
and O
edit O
T B
cell I
receptor I
( I
TCR I
) I
alpha I
chains I
and O
attempt O
TCR B
- O
mediated O
positive O
selection O
. O

Preclinical O
in O
vitro O
and O
in O
vivo O
evaluations O
were O
performed O
to O
assess O
the O
potential O
therapeutic O
applications O
of O
human O
recombinant O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
related I
apoptosis I
- I
inducing I
ligand I
/ I
Apo2 I
ligand I
( O
TRAIL B
/ I
Apo2L I
) O
in O
MM O
. O

TRAIL B
/ I
Apo2L I
potently O
induced O
apoptosis O
of O
MM O
cells O
from O
patients O
and O
the O
majority O
of O
MM O
cell O
lines O
, O
including O
cells O
sensitive O
or O
resistant O
to O
dexamethasone O
( O
Dex O
) O
, O
doxorubicin O
( O
Dox O
) O
, O
melphalan O
, O
and O
mitoxantrone O
. O

TRAIL B
/ I
Apo2L I
also O
overcame O
the O
survival O
effect O
of O
interleukin B
6 I
on O
MM O
cells O
and O
did O
not O
affect O
the O
survival O
of O
peripheral O
blood O
and O
bone O
marrow O
mononuclear O
cells O
and O
purified O
B O
cells O
from O
healthy O
donors O
. O

The O
anti O
- O
MM O
activity O
of O
TRAIL B
/ I
Apo2L I
was O
confirmed O
in O
nu O
/ O
xid O
/ O
bg O
mice O
xenografted O
with O
human O
MM O
cells O
; O
TRAIL B
( O
500 O
microg O
intraperitoneally O
daily O
for O
14 O
days O
) O
was O
well O
tolerated O
and O
significantly O
suppressed O
the O
growth O
of O
plasmacytomas O
. O

Dox O
up O
- O
regulated O
the O
expression O
of O
the O
TRAIL B
receptor I
death B
receptor I
5 I
( O
DR5 B
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL B
not O
only O
against O
MM O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex O
- O
or O
Dox O
- O
induced O
apoptosis O
. O

Nuclear O
factor O
( O
NF O
) O
- O
kappaB O
inhibitors O
, O
such O
as O
SN50 O
( O
a O
cell O
- O
permeable O
inhibitor O
of O
the O
nuclear O
translocation O
and O
transcriptional O
activity O
of O
NF B
- I
kappaB I
) O
or O
the O
proteasome O
inhibitor O
PS O
- O
341 O
, O
enhanced O
the O
proapoptotic O
activity O
of O
TRAIL B
/ I
Apo2L I
against O
TRAIL O
- O
sensitive O
MM O
cells O
, O
whereas O
SN50 O
reversed O
the O
TRAIL O
resistance O
of O
ARH O
- O
77 O
and O
IM O
- O
9 O
MM O
cells O
. O

Nuclear O
factor O
( O
NF O
) O
- O
kappaB O
inhibitors O
, O
such O
as O
SN50 O
( O
a O
cell O
- O
permeable O
inhibitor O
of O
the O
nuclear O
translocation O
and O
transcriptional O
activity O
of O
NF B
- I
kappaB I
) O
or O
the O
proteasome O
inhibitor O
PS O
- O
341 O
, O
enhanced O
the O
proapoptotic O
activity O
of O
TRAIL B
/ I
Apo2L I
against O
TRAIL O
- O
sensitive O
MM O
cells O
, O
whereas O
SN50 O
reversed O
the O
TRAIL O
resistance O
of O
ARH O
- O
77 O
and O
IM O
- O
9 O
MM O
cells O
. O

These O
preclinical O
studies O
suggest O
that O
TRAIL B
/ I
Apo2L I
can O
overcome O
conventional O
drug O
resistance O
and O
provide O
the O
basis O
for O
clinical O
trials O
of O
TRAIL B
- O
based O
treatment O
regimens O
to O
improve O
outcome O
in O
patients O
with O
MM O
. O

CD28 B
costimulation O
is O
required O
not O
only O
to O
induce O
IL B
- I
12 I
receptor I
but O
also O
to O
render O
janus B
kinases I
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
in O
TCR O
- O
triggered O
T O
cells O
. O

Here O
, O
we O
investigated O
how O
CD28 O
costimulation O
functions O
to O
allow O
TCR B
- O
triggered O
resting O
T O
cells O
to O
acquire O
IL B
- I
12 I
responsiveness O
. O

When O
T O
cells O
are O
stimulated O
with O
low O
doses O
of O
anti B
- I
CD3 I
mAb I
, O
CD28 O
costimulation O
was O
required O
for O
the O
optimal O
levels O
of O
IL B
- I
12 I
receptor I
( O
IL B
- I
12R I
) O
expression O
. O

However O
, O
stimulation O
of O
T O
cells O
with O
high O
doses O
of O
anti B
- I
CD3 I
alone O
induced O
comparable O
levels O
of O
IL B
- I
12R I
expression O
to O
those O
induced O
upon O
CD28 O
costimulation O
. O

However O
, O
stimulation O
of O
T O
cells O
with O
high O
doses O
of O
anti B
- I
CD3 I
alone O
induced O
comparable O
levels O
of O
IL B
- I
12R I
expression O
to O
those O
induced O
upon O
CD28 O
costimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

These O
resutls O
indicate O
that O
CD28 O
costimulation O
not O
only O
contributes O
to O
up O
- O
regulating O
IL B
- I
12R I
expression O
but O
is O
also O
required O
to O
render O
JAKs B
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
. O

These O
resutls O
indicate O
that O
CD28 O
costimulation O
not O
only O
contributes O
to O
up O
- O
regulating O
IL B
- I
12R I
expression O
but O
is O
also O
required O
to O
render O
JAKs B
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
. O

These O
resutls O
indicate O
that O
CD28 O
costimulation O
not O
only O
contributes O
to O
up O
- O
regulating O
IL B
- I
12R I
expression O
but O
is O
also O
required O
to O
render O
JAKs B
/ I
STAT4 I
responsive O
to O
IL B
- I
12 I
stimulation O
. O

Constitutively O
activated O
Akt B
- I
1 I
is O
vital O
for O
the O
survival O
of O
human O
monocyte O
- O
differentiated O
macrophages O
. O

Role O
of O
Mcl B
- I
1 I
, O
independent O
of O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
, O
Bad B
, O
or O
caspase O
activation O
. O

Here O
, O
we O
focused O
on O
the O
role O
of O
the O
PI3K B
- I
regulated I
serine I
/ I
threonine I
kinase I
Akt B
- I
1 I
in O
modulating O
macrophage O
survival O
. O

Akt B
- I
1 I
was O
constitutively O
activated O
in O
human O
macrophages O
and O
addition O
of O
the O
PI3K B
inhibitor O
, O
LY294002 O
, O
suppressed O
the O
activation O
of O
Akt B
- I
1 I
and O
induced O
cell O
death O
. O

Akt B
- I
1 I
was O
constitutively O
activated O
in O
human O
macrophages O
and O
addition O
of O
the O
PI3K B
inhibitor O
, O
LY294002 O
, O
suppressed O
the O
activation O
of O
Akt B
- I
1 I
and O
induced O
cell O
death O
. O

Furthermore O
, O
suppression O
of O
Akt B
- I
1 I
by O
inhibition O
of O
PI3K B
or O
a O
dominant B
negative I
( I
DN I
) I
Akt I
- I
1 I
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases B
- I
9 I
and I
- I
3 I
, O
and O
DNA O
fragmentation O
. O

The O
effects O
of O
PI3K B
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt B
- I
1 I
or O
Bcl B
- I
x I
( I
L I
) I
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

Further O
, O
inhibition O
of O
Mcl B
- I
1 I
by O
antisense O
oligonucleotides O
, O
also O
resulted O
in O
macrophage O
apoptosis O
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt B
- I
1 I
regulates O
macrophage O
survival O
through O
Mcl B
- I
1 I
, O
which O
is O
independent O
of O
caspases B
, O
NF B
- I
kappaB I
, O
or O
Bad B
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt B
- I
1 I
regulates O
macrophage O
survival O
through O
Mcl B
- I
1 I
, O
which O
is O
independent O
of O
caspases B
, O
NF B
- I
kappaB I
, O
or O
Bad B
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt B
- I
1 I
regulates O
macrophage O
survival O
through O
Mcl B
- I
1 I
, O
which O
is O
independent O
of O
caspases B
, O
NF B
- I
kappaB I
, O
or O
Bad B
. O

An O
inverse O
correlation O
was O
observed O
between O
the O
baseline O
inflammatory O
cell O
GRbeta B
expression O
and O
the O
reduction O
after O
FP O
treatment O
in O
EG2 O
- O
positive O
eosinophils O
, O
CD4 O
- O
positive O
T O
lymphocytes O
, O
endothelial O
VCAM B
- I
1 I
expression O
, O
and O
IL O
- O
4 O
mRNA O
- O
positive O
cells O
. O

NPs O
that O
were O
` O
` O
FP O
- O
insensitive O
' O
' O
in O
terms O
of O
suppression O
of O
eosinophil O
numbers O
( O
major B
basic I
protein I
- O
positive O
) O
had O
a O
significantly O
greater O
percentage O
of O
GRbeta O
- O
positive O
inflammatory O
cells O
, O
a O
higher O
ratio O
of O
GRbeta O
- O
positive O
/ O
GRalpha O
- O
positive O
cells O
, O
and O
increased O
numbers O
of O
GRbeta O
- O
positive O
eosinophils O
and O
macrophages O
in O
comparison O
with O
those O
that O
were O
` O
` O
FP O
- O
sensitive O
. O
' O
' O

Transcriptional O
regulation O
of O
galectin B
- I
10 I
( O
eosinophil B
Charcot I
- I
Leyden I
crystal I
protein I
) O
: O
a O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
controls O
butyric O
acid O
induction O
of O
gene O
expression O
. O

Galectin B
- I
10 I
( O
gal B
- I
10 I
, O
also O
known O
as O
Charcot B
- I
Leyden I
crystal I
protein I
) O
is O
a O
member O
of O
the O
galectin B
family I
of O
beta B
- I
galactoside I
binding I
proteins I
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

Galectin B
- I
10 I
( O
gal B
- I
10 I
, O
also O
known O
as O
Charcot B
- I
Leyden I
crystal I
protein I
) O
is O
a O
member O
of O
the O
galectin B
family I
of O
beta B
- I
galactoside I
binding I
proteins I
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

To O
gain O
a O
better O
understanding O
of O
galectin O
gene O
expression O
, O
we O
present O
an O
analysis O
of O
the O
transcriptional O
regulation O
of O
the O
gene O
encoding O
gal B
- I
10 I
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B
factors I
Sp1 B
and O
Oct1 B
to O
the O
consensus B
GC I
box I
and O
the O
Oct B
site I
, O
respectively O
. O

Similar O
to O
gal B
- I
1 I
, O
gal O
- O
10 O
expression O
is O
induced O
by O
butyric O
acid O
, O
an O
effect O
that O
is O
lost O
upon O
ablation O
of O
the O
GC B
box I
. O

Additionally O
, O
we O
demonstrate O
AML3 O
binding O
to O
the O
consensus B
AML I
site I
and O
YY1 B
binding I
to O
the O
Inr B
sequence I
, O
both O
elements O
functioning O
as O
silencers O
in O
the O
gal B
- I
10 I
promoter I
. O

Enzymatically B
modified I
low I
- I
density I
lipoprotein I
( O
E B
- I
LDL I
) O
induces O
rapid O
foam O
cell O
formation O
in O
monocytes O
and O
upregulates O
adipophilin B
mRNA O
and O
protein O
within O
2 O
h O
of O
incubation O
. O

This O
rapid O
induction O
of O
adipophilin B
is O
accompanied O
by O
a O
significant O
increase O
of O
free O
fatty O
acids O
in O
monocytes O
incubated O
with O
E B
- I
LDL I
. O

Constitutive O
expression O
of O
MHC B
class I
II I
genes I
in O
melanoma O
cell O
lines O
results O
from O
the O
transcription O
of O
class B
II I
transactivator I
abnormally O
initiated O
from O
its O
B B
cell I
- I
specific I
promoter I
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma O
- O
inducible O
expression O
of O
HLA B
- I
DR I
and O
HLA B
- I
DP I
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA B
- I
DQ I
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i O
. O
e O
. O
, O
IFN O
- O
gamma O
independent O
, O
of O
all O
three O
HLA B
- I
D I
isotypes I
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma O
- O
inducible O
expression O
of O
HLA B
- I
DR I
and O
HLA B
- I
DP I
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA B
- I
DQ I
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i O
. O
e O
. O
, O
IFN O
- O
gamma O
independent O
, O
of O
all O
three O
HLA B
- I
D I
isotypes I
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma O
- O
inducible O
expression O
of O
HLA B
- I
DR I
and O
HLA B
- I
DP I
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA B
- I
DQ I
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i O
. O
e O
. O
, O
IFN O
- O
gamma O
independent O
, O
of O
all O
three O
HLA B
- I
D I
isotypes I
. O

This O
expression O
was O
further O
shown O
to O
occur O
through O
factor O
( O
s O
) O
acting O
on O
the O
enhancer O
located O
upstream O
of O
CIITA B
promoter I
III I
, O
which O
was O
previously O
described O
in O
epithelioid O
cells O
as O
an O
IFN O
- O
gamma O
- O
response O
sequence O
. O

Caspase B
- O
mediated O
calcineurin O
activation O
contributes O
to O
IL B
- I
2 I
release O
during O
T O
cell O
activation O
. O

It O
has O
been O
previously O
reported O
that O
IL B
- I
2 I
release O
in O
activated O
Jurkat O
T O
requires O
caspase O
- O
like O
activity O
( O
Posmantur O
et O
al O
. O
( O
1998 O
) O
Exp O
. O
Cell O
. O
Res O
. O
244 O
, O
302 O
- O
309 O
) O
. O

We O
report O
here O
that O
the O
60 B
- I
kDa I
catalytic I
subunit I
of O
calcineurin B
A I
( O
Cn B
A I
) O
was O
partially O
cleaved O
to O
a O
45 B
- I
kDa I
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

Cn B
A I
cleavage O
was O
also O
observed O
when O
purified O
calcineurin B
was O
digested O
in O
vitro O
with O
caspase B
- I
3 I
. O

Truncated B
Cn I
A I
was O
associated O
with O
enhanced O
phosphatase O
activity O
and O
reduced O
calmodulin O
sensitivity O
. O

A O
specific O
proteasome B
defect O
has O
been O
identified O
in O
NOD O
mouse O
in O
select O
lymphocytic O
and O
monocytic O
lineages O
that O
results O
from O
down O
- O
regulation O
of O
expression O
of O
the O
proteasome B
subunit I
LMP2 I
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC B
genomic I
region I
. O

A O
specific O
proteasome B
defect O
has O
been O
identified O
in O
NOD O
mouse O
in O
select O
lymphocytic O
and O
monocytic O
lineages O
that O
results O
from O
down O
- O
regulation O
of O
expression O
of O
the O
proteasome B
subunit I
LMP2 I
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC B
genomic I
region I
. O

This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected O
cells O
to O
apoptosis O
induced O
by O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
. O

This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected O
cells O
to O
apoptosis O
induced O
by O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
. O

Mutations O
that O
selectively O
disrupt O
Ikaros O
binding O
to O
an O
integrated B
TdT I
promoter I
had O
no O
effect O
on O
promoter O
function O
in O
a O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
. O

Surprisingly O
, O
in O
the O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
, O
overexpression O
of O
a O
small B
Ikaros I
isoform I
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA O
- O
binding O
properties O
of O
Ikaros B
. O

The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros B
dimers I
bound O
to O
the O
TdT B
promoter I
and O
those O
bound O
to O
pericentromeric B
repeat I
sequences I
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B
gene I
. O

Type B
I I
interferons I
and O
IL B
- I
12 I
: O
convergence O
and O
cross O
- O
regulation O
among O
mediators O
of O
cellular O
immunity O
. O

Type B
I I
interferons I
and O
IL B
- I
12 I
: O
convergence O
and O
cross O
- O
regulation O
among O
mediators O
of O
cellular O
immunity O
. O

Therapeutic O
use O
of O
type B
I I
IFN I
( O
IFN B
- I
alpha I
/ I
beta I
) O
has O
become O
common O
. O

It O
is O
thus O
notable O
that O
the O
pleiotropic O
effects O
of O
type B
I I
IFN I
on O
CMI O
remain O
poorly O
understood O
. O

We O
characterized O
the O
effects O
of O
type B
I I
IFN I
on O
the O
production O
of O
IL B
- I
12 I
, O
the O
central B
immunoregulatory I
cytokine I
of O
the O
CD4 B
( I
+ I
) I
T I
cell I
arm I
of O
CMI O
. O

We O
characterized O
the O
effects O
of O
type B
I I
IFN I
on O
the O
production O
of O
IL B
- I
12 I
, O
the O
central B
immunoregulatory I
cytokine I
of O
the O
CD4 B
( I
+ I
) I
T I
cell I
arm I
of O
CMI O
. O

We O
characterized O
the O
effects O
of O
type B
I I
IFN I
on O
the O
production O
of O
IL B
- I
12 I
, O
the O
central B
immunoregulatory I
cytokine I
of O
the O
CD4 B
( I
+ I
) I
T I
cell I
arm I
of O
CMI O
. O

We O
show O
that O
type B
I I
IFN I
are O
potent O
inhibitors O
of O
IL O
- O
12 O
production O
by O
human O
monocytes O
/ O
macrophages O
. O

The O
underlying O
mechanism O
involves O
transcriptional O
inhibition O
of O
the O
IL B
- I
12p40 I
gene I
, O
marked O
by O
down O
- O
regulation O
of O
PU O
. O
1 O
binding O
activity O
at O
the O
upstream B
Ets I
site I
of O
the O
IL B
- I
12p40 I
promoter I
. O

Type B
I I
IFN I
have O
previously O
been O
shown O
to O
be O
able O
to O
substitute O
for O
IL B
- I
12 I
in O
driving O
IFN O
- O
gamma O
production O
from O
T O
and O
NK O
cells O
. O

Type B
I I
IFN I
have O
previously O
been O
shown O
to O
be O
able O
to O
substitute O
for O
IL B
- I
12 I
in O
driving O
IFN O
- O
gamma O
production O
from O
T O
and O
NK O
cells O
. O

Nuclear B
factor I
- I
kappaB I
suppressive O
and O
inhibitor B
- I
kappaB I
stimulatory O
effects O
of O
troglitazone O
in O
obese O
patients O
with O
type O
2 O
diabetes O
: O
evidence O
of O
an O
antiinflammatory O
action O
? O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B
transcription I
factor I
nuclear I
factor I
- I
kappaB I
and O
its O
inhibitory B
protein I
IkappaB I
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B
soluble I
intracellular I
adhesion I
molecule I
- I
1 I
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
plasminogen B
activator I
inhibitor I
- I
1 I
, O
and O
C B
- I
reactive I
protein I
. O

Endogenous O
TNF B
alpha I
( O
TNF B
- I
alpha I
) O
and O
TNF B
- I
beta I
production O
were O
not O
involved O
in O
the O
enhanced O
HIV O
- O
1 O
production O
. O

Endogenous O
TNF B
alpha I
( O
TNF B
- I
alpha I
) O
and O
TNF B
- I
beta I
production O
were O
not O
involved O
in O
the O
enhanced O
HIV O
- O
1 O
production O
. O

Furthermore O
, O
enhanced O
HIV O
- O
1 O
transcription O
in O
gp34 B
- O
stimulated O
ACH O
- O
2 O
/ O
OX40 O
cells O
was O
dependent O
on O
the O
kappa B
B I
site I
of O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
, O
and O
the O
OX40 O
- O
gp34 O
interaction O
activated O
NF B
- I
kappa I
B I
consisting O
of O
p50 B
and I
p65 I
subunits I
. O

Peroxizome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
is O
a O
member O
of O
the O
nuclear B
receptor I
family I
of O
transcription B
factors I
that O
regulate O
adipocyte O
differentiation O
. O

Transient O
transfection O
assays O
of O
the O
human B
osteopontin I
promoter I
/ I
luciferase I
construct I
which O
contains O
a O
5 B
' I
- I
flanking I
region I
between O
- O
1500 O
and O
+ O
87 O
relative O
to O
the O
transcription B
start I
site I
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B
expression I
vector I
inhibits O
osteopontin O
promoter O
activity O
. O

Transient O
transfection O
assays O
of O
the O
human B
osteopontin I
promoter I
/ I
luciferase I
construct I
which O
contains O
a O
5 B
' I
- I
flanking I
region I
between O
- O
1500 O
and O
+ O
87 O
relative O
to O
the O
transcription B
start I
site I
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B
expression I
vector I
inhibits O
osteopontin O
promoter O
activity O
. O

Directed O
alterations O
in O
the O
accessibility O
of O
V B
, I
D I
, I
and I
J I
gene I
segments I
target O
the O
recombinase B
to O
specific O
Ag B
receptor I
loci I
. O

Accessibility O
within O
a O
given O
locus B
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B
factors I
with O
cognate B
enhancer I
elements I
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene B
segments I
. O

As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa B
locus I
is O
regulated O
by O
the O
inducible B
transcription I
factor I
NF B
- I
kappaB I
. O

As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa B
locus I
is O
regulated O
by O
the O
inducible B
transcription I
factor I
NF B
- I
kappaB I
. O

In O
contrast O
to O
the O
Igkappa B
locus I
, O
known O
transcriptional B
control I
elements I
in O
the O
Iglambda B
locus I
lack O
functional O
NF B
- I
kappaB I
binding I
sites I
. O

Consistent O
with O
this O
observation O
, O
the O
expression O
of O
assembled O
Iglambda B
genes I
in O
mature O
B O
cells O
has O
been O
shown O
to O
be O
NF B
- I
kappaB I
independent O
. O

Nonetheless O
, O
we O
now O
show O
that O
specific O
repression O
of O
NF B
- I
kappaB I
inhibits O
germline O
transcription O
and O
recombination O
of O
Iglambda B
gene I
segments I
in O
precursor O
B O
cells O
. O

Nonetheless O
, O
we O
now O
show O
that O
specific O
repression O
of O
NF B
- I
kappaB I
inhibits O
germline O
transcription O
and O
recombination O
of O
Iglambda B
gene I
segments I
in O
precursor O
B O
cells O
. O

Molecular O
analyses O
indicate O
that O
the O
block O
in O
NF B
- I
kappaB I
impairs O
Iglambda O
rearrangement O
at O
the O
level O
of O
recombinase B
accessibility O
. O

These O
findings O
expand O
the O
range O
of O
NF B
- I
kappaB I
action O
in O
precursor O
B O
cells O
beyond O
Igkappa B
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L B
chain I
loci I
. O

These O
findings O
expand O
the O
range O
of O
NF B
- I
kappaB I
action O
in O
precursor O
B O
cells O
beyond O
Igkappa B
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L B
chain I
loci I
. O

Moreover O
, O
our O
results O
strongly O
suggest O
the O
existence O
of O
a O
novel O
Iglambda B
regulatory I
element I
that O
is O
either O
directly O
or O
indirectly O
activated O
by O
NF B
- I
kappaB I
during O
the O
early O
stages O
of O
B O
cell O
development O
. O

Moreover O
, O
our O
results O
strongly O
suggest O
the O
existence O
of O
a O
novel O
Iglambda B
regulatory I
element I
that O
is O
either O
directly O
or O
indirectly O
activated O
by O
NF B
- I
kappaB I
during O
the O
early O
stages O
of O
B O
cell O
development O
. O

Purified B
recombinant I
BTK I
was O
capable O
of O
directly O
binding O
purified B
recombinant I
STAT5A I
with O
high O
affinity O
( O
K O
( O
d O
) O
= O
44 O
nm O
) O
, O
as O
determined O
by O
surface O
plasmon O
resonance O
using O
a O
BIAcore O
biosensor O
system O
. O

Purified B
recombinant I
BTK I
was O
capable O
of O
directly O
binding O
purified B
recombinant I
STAT5A I
with O
high O
affinity O
( O
K O
( O
d O
) O
= O
44 O
nm O
) O
, O
as O
determined O
by O
surface O
plasmon O
resonance O
using O
a O
BIAcore O
biosensor O
system O
. O

BTK B
was O
also O
capable O
of O
tyrosine O
- O
phosphorylating O
ectopically O
expressed O
recombinant B
STAT5A I
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus B
kinase I
3 I
- O
independent O
fashion O
. O

Recombinant B
BTK I
proteins I
with O
mutant O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
were O
capable O
of O
phosphorylating O
STAT5A B
, O
whereas O
recombinant B
BTK I
proteins I
with O
SH1 O
/ O
kinase O
domain O
mutations O
were O
not O
. O

Recombinant B
BTK I
proteins I
with O
mutant O
pleckstrin O
homology O
, O
SH2 B
, I
or I
SH3 I
domains I
were O
capable O
of O
phosphorylating O
STAT5A B
, O
whereas O
recombinant B
BTK I
proteins I
with O
SH1 O
/ O
kinase O
domain O
mutations O
were O
not O
. O

Ectopically O
expressed O
BTK B
kinase I
domain I
was O
capable O
of O
tyrosine O
- O
phosphorylating O
STAT5A B
both O
in O
vitro O
and O
in O
vivo O
. O

Role O
of O
T B
- I
bet I
in O
commitment O
of O
TH1 O
cells O
before O
IL B
- I
12 I
- O
dependent O
selection O
. O

Role O
of O
T B
- I
bet I
in O
commitment O
of O
TH1 O
cells O
before O
IL B
- I
12 I
- O
dependent O
selection O
. O

We O
show O
that O
T B
- I
bet I
, O
without O
apparent O
assistance O
from O
interleukin B
12 I
( I
IL I
- I
12 I
) I
/ O
STAT4 B
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon B
- I
gamma I
( I
IFN I
- I
gamma I
) I
alleles I
and O
by O
inducing O
IL B
- I
12 I
receptor I
beta2 I
expression O
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

IL B
- I
4 I
plays O
a O
critical O
role O
in O
the O
differentiation O
of O
T O
CR O
- O
stimulated O
naive O
CD4 O
T O
cells O
to O
the O
Th2 O
phenotype O
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

In O
response O
to O
IL B
- I
4 I
, O
the O
IL B
- I
4R I
activates O
a O
set O
of O
phosphotyrosine B
binding I
domain I
- I
containing I
proteins I
, O
including O
insulin B
receptor I
substrate I
1 I
/ I
2 I
, O
Shc B
, O
and O
IL B
- I
4R I
interacting I
protein I
, O
as O
well O
as O
Stat6 B
. O

To O
determine O
the O
roles O
of O
the O
phosphotyrosine B
binding I
adaptors I
in O
Th2 O
differentiation O
, O
we O
prepared O
a O
retrovirus O
containing O
a O
mutant O
of O
the O
human B
( I
h I
) I
IL I
- I
4R I
alpha I
- I
chain I
, O
Y497F B
, O
which O
is O
unable O
to O
recruit O
these O
adaptors O
. O

These O
results O
suggest O
that O
the O
signal O
pathway O
mediated O
by O
Y497 B
is O
dispensable O
for O
both O
IL B
- I
4 I
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
. O

Thus O
, O
activated B
Stat6 I
is O
necessary O
and O
sufficient O
to O
mediate O
both O
IL B
- I
4 I
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
in O
CD4 O
T O
cells O
. O

Increase O
secretion O
of O
IL B
- I
2 I
, O
the O
major O
T O
cell O
growth O
and O
differentiation O
cytokine B
, O
may O
play O
a O
decisive O
role O
in O
sensitization O
of O
T O
cells O
for O
activation O
induced O
apoptosis O
and O
indirect O
death O
of O
activated O
T O
cells O
through O
augmented O
virus O
replication O
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF B
- I
IL6 I
, O
JunB B
, O
c B
- I
Fos I
and O
Fra B
- I
1 I
is O
formed O
on O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
and O
represses O
IL B
- I
2 I
promoter I
activity O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric B
activator I
containing O
p65 B
and O
c B
- I
Jun I
binds O
to O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

HIV B
Tat I
enhances O
activation O
of O
NF B
- I
kappaB I
and O
consequently O
, O
activates O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

MATERIALS O
AND O
METHODS O
: O
The O
cells O
were O
stimulated O
by O
100 O
ng O
/ O
mL O
TPO B
and O
/ O
or O
100 O
ng O
/ O
mL O
TGF B
- I
beta1 I
and O
analyzed O
for O
proliferation O
( O
3H O
thymidine O
incorporation O
) O
, O
viability O
( O
trypan O
blue O
exclusion O
) O
, O
and O
protein O
expression O
and O
phosphorylation O
( O
Western O
blot O
) O
. O

RESULTS O
: O
TPO B
enhanced O
the O
proliferation O
of O
Mo O
- O
7e O
cells O
as O
determined O
by O
3H O
- O
thymidine O
incorporation O
, O
whereas O
TGF B
- I
beta1 I
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO B
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF B
- I
beta1 I
reduced O
the O
TPO B
- O
stimulated O
ERK1 B
/ O
ERK2 B
and O
STAT5 O
phosphorylation O
in O
Mo O
- O
7e O
and O
HEL O
cells O
. O

This O
effect O
was O
completely O
reversed O
by O
preincubation O
with O
a O
tyrosine O
phosphatase O
inhibitor O
( O
Na3VO4 O
) O
, O
which O
suggests O
that O
TGF B
- I
beta1 I
activated O
a O
phosphatase B
. O

Although O
STAT3 B
also O
was O
activated O
by O
TPO B
, O
STAT3 B
activation O
remained O
unaltered O
by O
TGF B
- I
beta1 I
. O

CONCLUSION O
: O
Taken O
together O
, O
these O
data O
suggest O
that O
TGF B
- I
beta1 I
modulates O
TPO B
- O
mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO B
- O
induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK B
ERK1 I
/ I
ERK2 I
and I
STAT5 I
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

Inhibition O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappaB I
in O
CD4 O
T O
cells O
by O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
ligands I
. O

Inhibition O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappaB I
in O
CD4 O
T O
cells O
by O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
ligands I
. O

Our O
study O
shows O
PPARgamma B
to O
be O
preferentially O
expressed O
in O
the O
nuclei O
of O
resting O
T O
cells O
and O
to O
increase O
upon O
activation O
of O
T O
cells O
by O
either O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
phorbol O
myristyl O
acetate O
( O
PMA O
) O
. O

Our O
study O
shows O
PPARgamma B
to O
be O
preferentially O
expressed O
in O
the O
nuclei O
of O
resting O
T O
cells O
and O
to O
increase O
upon O
activation O
of O
T O
cells O
by O
either O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
phorbol O
myristyl O
acetate O
( O
PMA O
) O
. O

We O
also O
found O
the O
PPARgamma B
ligand I
ciglitizone O
to O
attenuate O
the O
activation O
of O
T O
cells O
by O
inhibiting O
cytokine O
gene O
expression O
and O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
PMA O
- O
induced O
proliferative O
responses O
. O

We O
also O
found O
the O
PPARgamma B
ligand I
ciglitizone O
to O
attenuate O
the O
activation O
of O
T O
cells O
by O
inhibiting O
cytokine O
gene O
expression O
and O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
PMA O
- O
induced O
proliferative O
responses O
. O

Inhibition O
of O
both O
the O
proliferative O
response O
and O
inflammatory O
cytokine O
expression O
in O
CD4 O
T O
cells O
was O
correlated O
with O
suppression O
of O
the O
activated O
transcription B
factors I
AP1 B
and O
NF B
- I
kappaB I
. O

We O
have O
recently O
identified O
CD48 B
as O
the O
high B
affinity I
counterreceptor I
for O
2B4 B
in O
both O
mice O
and O
humans O
. O

We O
isolated O
h2B4 B
genomic I
clones I
and O
PCR O
amplified O
the O
5 B
' I
untranslated I
region I
containing O
the O
promoter B
elements I
. O

These O
results O
demonstrate O
a O
significant O
role O
for O
AP B
- I
1 I
in O
the O
transcriptional O
regulation O
of O
the O
h2B4 B
gene I
. O

High O
constitutive O
expression O
of O
the O
IFNgamma B
- I
inducible I
genes I
, O
IFN B
- I
stimulated I
gene I
factor I
3 I
gamma I
subunit I
( O
ISGF3gamma B
) O
, O
IFN B
regulatory I
factor I
- I
1 I
( O
IRF B
- I
1 I
) O
, O
and O
the O
cyclin B
- I
dependent I
kinase I
inhibitor I
p21 I
( O
WAF1 B
) O
was O
found O
in O
FANCC B
mutant O
B O
lymphoblasts O
, O
low O
- O
density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

However O
, O
enforced O
expression O
of O
ICSBP B
failed O
to O
down O
- O
regulate O
IRF B
- I
1 I
, O
ISGF3gamma B
, O
and O
p21 B
( I
WAF1 I
) I
. O

Here O
, O
we O
only O
discuss O
some O
of O
the O
genetic O
approaches O
our O
laboratory O
( O
except O
where O
it O
is O
noted O
) O
has O
undertaken O
to O
investigate O
the O
molecular O
pathways O
mediated O
by O
E2A B
transcription I
factors I
in O
lymphocyte O
development O

Inhibition O
of O
AP B
- I
1 I
by O
the O
glucocorticoid O
- O
inducible O
protein B
GILZ I
. O

The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine O
gene O
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid B
receptor I
and O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

GILZ B
also O
potently O
inhibited O
AP B
- I
1 I
- I
driven I
and I
IL I
- I
2 I
promoter I
- I
driven I
reporter I
constructs I
, O
and O
recombinant O
GILZ B
specifically O
interacted O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B
AP I
- I
1 I
to O
its O
target O
DNA O
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Thus O
, O
GILZ B
represents O
a O
glucocorticoid O
- O
induced O
gene O
product O
that O
can O
inhibit O
a O
variety O
of O
activation O
- O
induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP B
- I
1 I
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

We O
examined O
the O
involvement O
of O
Smad B
proteins I
in O
TGF B
- I
beta1 I
- O
induced O
IgA O
expression O
. O

First O
, O
we O
found O
that O
TGF B
- I
beta1 I
significantly O
increases O
endogenous B
germ I
- I
line I
( I
GL I
) I
alpha I
transcripts I
by O
LPS O
- O
stimulated O
CH12 O
. O
LX O
. O
4933 O
( O
mu O
( O
+ O
) O
) O
B O
lymphoma O
cells O
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 B
that O
contains O
the O
TGF B
- I
beta I
- I
responsive I
element I
of O
the O
GLalpha B
promoter I
, O
and O
stimulated O
with O
TGF B
- I
beta1 I
. O

Similar O
to O
endogenous B
GLalpha I
transcripts I
, O
TGF B
- I
beta1 I
induces O
GLalpha B
promoter I
activity O
and O
overexpression O
of O
Smad3 B
markedly O
enhances O
the O
promoter O
activity O
. O

Similar O
to O
endogenous B
GLalpha I
transcripts I
, O
TGF B
- I
beta1 I
induces O
GLalpha B
promoter I
activity O
and O
overexpression O
of O
Smad3 B
markedly O
enhances O
the O
promoter O
activity O
. O

On O
the O
other O
hand O
, O
Smad7 B
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3 B
/ I
4 I
on O
GLalpha B
promoter I
activity O
. O

In O
addition O
, O
overexpression O
of O
Smad3 B
/ I
4 I
enhances O
TGF B
- I
beta1 I
- O
induced O
endogenous B
GLalpha I
transcripts I
in O
normal O
spleen O
B O
cell O
s O
. O

In O
addition O
, O
overexpression O
of O
Smad3 B
/ I
4 I
enhances O
TGF B
- I
beta1 I
- O
induced O
endogenous B
GLalpha I
transcripts I
in O
normal O
spleen O
B O
cell O
s O
. O

In O
addition O
, O
overexpression O
of O
Smad3 B
/ I
4 I
enhances O
TGF B
- I
beta1 I
- O
induced O
endogenous B
GLalpha I
transcripts I
in O
normal O
spleen O
B O
cell O
s O
. O

Finally O
, O
in O
the O
presence O
of O
TGF B
- I
beta1 I
, O
overexpression O
of O
Smad3 B
/ I
4 I
selectively O
increases O
both O
surface O
IgA O
expression O
and O
IgA O
production O
. O

Finally O
, O
in O
the O
presence O
of O
TGF B
- I
beta1 I
, O
overexpression O
of O
Smad3 B
/ I
4 I
selectively O
increases O
both O
surface O
IgA O
expression O
and O
IgA O
production O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B
, O
Smad4 B
, O
and O
Smad7 B
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF B
- I
beta1 I
to O
transcriptional O
regulation O
of O
IgA B
switching I
related I
gene I
and O
regulation O
of O
IgA O
class O
switching O
. O

We O
show O
that O
human O
B O
cells O
constitutively O
express O
the O
translesion B
pol I
zeta I
, O
which O
effectively O
extends O
DNA O
past O
mismatched O
bases O
( O
mispair O
extender O
) O
, O
and O
pol B
eta I
, O
which O
bypasses O
DNA O
lesions O
in O
an O
error O
- O
free O
fashion O
. O

Upon O
B B
cell I
receptor I
( O
BCR B
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B
zeta I
, O
downregulated O
pol B
eta I
, O
and O
mutated O
the O
Ig B
and I
bcl I
- I
6 I
genes I
. O

Inhibition O
of O
the O
pol B
zeta I
REV3 B
catalytic I
subunit I
by O
specific O
phosphorothioate O
- O
modified O
oligonucleotides O
impaired O
Ig O
and O
bcl O
- O
6 O
hypermutation O
and O
UV O
damage O
- O
induced O
DNA O
mutagenesis O
, O
without O
affecting O
cell O
cycle O
or O
viability O
. O

Molecular O
mechanism O
of O
cell O
cycle O
progression O
induced O
by O
the O
oncogene B
product I
Tax I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
. O

Introduction O
of O
Tax B
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1 O
/ O
S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin B
dependent I
kinase I
2 I
( O
CDK2 B
) O
and O
CDK4 B
, O
phosphorylation O
of O
the O
Rb B
family I
proteins I
and O
an O
increase O
in O
free O
E2F B
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

Cyclooxygenase B
- I
2 I
( O
COX B
- I
2 I
) O
is O
induced O
in O
human O
T O
lymphocytes O
upon O
T B
cell I
receptor I
triggering O
. O

Cyclooxygenase B
- I
2 I
( O
COX B
- I
2 I
) O
is O
induced O
in O
human O
T O
lymphocytes O
upon O
T B
cell I
receptor I
triggering O
. O

Cyclooxygenase B
- I
2 I
( O
COX B
- I
2 I
) O
is O
induced O
in O
human O
T O
lymphocytes O
upon O
T B
cell I
receptor I
triggering O
. O

Mutation O
of O
the O
distal B
( I
- I
105 I
/ I
- I
97 I
) I
and O
proximal B
( I
- I
76 I
/ I
- I
61 I
) I
NFAT B
response I
elements I
in O
the O
COX B
- I
2 I
promoter I
abolished O
the O
activation O
induced O
by O
Cot B
kinase I
. O

These O
data O
indicate O
that O
Cot B
kinase I
up O
- O
regulates O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
through O
the O
NFAT B
response I
elements I
, O
being O
the O
Cot B
kinase I
- O
induced O
NFAT B
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

The O
acquisition O
of O
one O
Ly B
- I
49 I
receptor I
, O
Ly B
- I
49A I
is O
strictly O
dependent O
on O
the O
transcriptional B
trans I
- I
acting I
factor I
T B
cell I
- I
specific I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
. O

The O
acquisition O
of O
one O
Ly B
- I
49 I
receptor I
, O
Ly B
- I
49A I
is O
strictly O
dependent O
on O
the O
transcriptional B
trans I
- I
acting I
factor I
T B
cell I
- I
specific I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
. O

Indeed O
, O
TCF B
- I
1 I
binds O
to O
two O
sites O
in O
the O
Ly B
- I
49a I
promoter I
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly B
- I
49a I
gene I
is O
a O
direct O
TCF B
- I
1 I
target O
. O

Indeed O
, O
TCF B
- I
1 I
binds O
to O
two O
sites O
in O
the O
Ly B
- I
49a I
promoter I
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly B
- I
49a I
gene I
is O
a O
direct O
TCF B
- I
1 I
target O
. O

TCF B
- I
1 I
deficiency O
resulted O
in O
the O
altered O
usage O
of O
additional O
Ly B
- I
49 I
receptors I
. O

Our O
findings O
rather O
suggest O
a O
TCF B
- I
1 I
- O
dependent O
, O
cell O
autonomous O
effect O
on O
the O
acquisition O
of O
multiple O
Ly B
- I
49 I
receptors I
. O

Besides O
reduced O
receptor O
usage O
( O
Ly B
- I
49A I
and I
D I
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly B
- I
49C I
) O
and O
significantly O
expanded O
( O
Ly B
- I
49G I
and I
I I
) O
receptor O
usage O
in O
the O
absence O
of O
TCF B
- I
1 I
. O

Besides O
reduced O
receptor O
usage O
( O
Ly B
- I
49A I
and I
D I
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly B
- I
49C I
) O
and O
significantly O
expanded O
( O
Ly B
- I
49G I
and I
I I
) O
receptor O
usage O
in O
the O
absence O
of O
TCF B
- I
1 I
. O

These O
effects O
did O
not O
in O
all O
cases O
correlate O
with O
the O
presence O
of O
TCF B
binding I
sites I
in O
the O
respective O
proximal B
promoter I
. O

Therefore O
, O
besides O
TCF B
- I
1 I
binding O
to O
the O
proximal B
promoter I
, O
Ly O
- O
49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF B
- I
1 I
binding O
to O
more O
distant O
cis B
- I
acting I
elements I
and O
/ O
or O
by O
regulating O
the O
expression O
of O
additional O
trans B
- I
acting I
factors I
. O

Therefore O
, O
besides O
TCF B
- I
1 I
binding O
to O
the O
proximal B
promoter I
, O
Ly O
- O
49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF B
- I
1 I
binding O
to O
more O
distant O
cis B
- I
acting I
elements I
and O
/ O
or O
by O
regulating O
the O
expression O
of O
additional O
trans B
- I
acting I
factors I
. O

Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF B
- I
1 I
for O
Ly B
- I
49 I
receptor I
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF B
site I
in O
certain O
proximal O
Ly B
- I
49 I
promoters I
. O

These O
findings O
reveal O
an O
important O
role O
of O
TCF B
- I
1 I
for O
the O
formation O
of O
the O
NK B
cell I
receptor I
repertoire O
. O

These O
findings O
reveal O
an O
important O
role O
of O
TCF B
- I
1 I
for O
the O
formation O
of O
the O
NK B
cell I
receptor I
repertoire O
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

Because O
the O
promoters B
of O
these O
chemokine B
genes I
contain O
kappaB B
binding I
sites I
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Because O
the O
promoters B
of O
these O
chemokine B
genes I
contain O
kappaB B
binding I
sites I
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B
or O
antibodies B
to O
CD11b B
or O
to O
CD11c B
up O
- O
regulated O
DNA O
- O
binding O
activity O
of O
NF B
- I
kappaB I
. O

Activation O
of O
NF B
- I
kappaB I
was O
accompanied O
by O
degradation O
of O
its O
cytosolic B
inhibitor I
IkappaB I
- I
alpha I
. O

Blockade O
of O
depletion O
of O
IkappaB B
- I
alpha I
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I O
or O
acetyl O
- O
leucinyl O
- O
leucinyl O
- O
norleucinal O
) O
led O
to O
concomitant O
inhibition O
of O
NF O
- O
kappaB O
DNA O
- O
binding O
activity O
and O
expression O
of O
MIP B
- I
1alpha I
and I
MIP I
- I
1beta I
messenger I
RNA I
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O

These O
results O
suggest O
that O
triggering O
of O
CD11b B
or O
CD11c B
beta I
( I
2 I
) I
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF B
- I
kappaB I
and O
subsequent O
secretion O
of O
MIP B
- I
1alpha I
and O
MIP B
- I
1beta I
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

These O
results O
suggest O
that O
triggering O
of O
CD11b B
or O
CD11c B
beta I
( I
2 I
) I
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF B
- I
kappaB I
and O
subsequent O
secretion O
of O
MIP B
- I
1alpha I
and O
MIP B
- I
1beta I
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

These O
results O
suggest O
that O
triggering O
of O
CD11b B
or O
CD11c B
beta I
( I
2 I
) I
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF B
- I
kappaB I
and O
subsequent O
secretion O
of O
MIP B
- I
1alpha I
and O
MIP B
- I
1beta I
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O

Synergistic O
transcriptional O
activation O
of O
human B
Acyl I
- I
coenzyme I
A I
: I
cholesterol I
acyltransterase I
- I
1 I
gene I
by O
interferon B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
THP O
- O
1 O
cells O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
a O
cytokine B
that O
exerts O
many O
pro O
- O
atherosclerotic O
effects O
in O
vivo O
, O
causes O
up O
- O
regulation O
of O
ACAT B
- I
1 I
mRNA I
in O
human O
blood O
monocyte O
- O
derived O
macrophages O
and O
macrophage O
- O
like O
cells O
but O
not O
in O
other O
cell O
types O
. O

Interferon B
- I
gamma I
( O
IFN B
- I
gamma I
) O
, O
a O
cytokine B
that O
exerts O
many O
pro O
- O
atherosclerotic O
effects O
in O
vivo O
, O
causes O
up O
- O
regulation O
of O
ACAT B
- I
1 I
mRNA I
in O
human O
blood O
monocyte O
- O
derived O
macrophages O
and O
macrophage O
- O
like O
cells O
but O
not O
in O
other O
cell O
types O
. O

In O
the O
monocytic O
cell O
line O
THP O
- O
1 O
cell O
, O
the O
combination O
of O
IFN B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT B
- I
1 I
P1 I
promoter I
but O
not O
the O
P7 B
promoter I
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B
factor I
STAT1 I
, O
while O
IFN B
- I
gamma I
causes O
activation O
of O
STAT1 B
such O
that O
it O
binds O
to O
the O
GAS B
/ I
Sp1 I
site I
in O
the O
ACAT B
- I
1 I
P1 I
promoter I
. O

Additional O
experiments O
showed O
that O
all O
- O
trans O
- O
retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B
factor I
STAT1 I
, O
while O
IFN B
- I
gamma I
causes O
activation O
of O
STAT1 B
such O
that O
it O
binds O
to O
the O
GAS B
/ I
Sp1 I
site I
in O
the O
ACAT B
- I
1 I
P1 I
promoter I
. O

Our O
work O
provides O
a O
molecular O
mechanism O
to O
account O
for O
the O
effect O
of O
IFN B
- I
gamma I
in O
causing O
transcriptional O
activation O
of O
ACAT B
- I
1 I
in O
macrophage O
- O
like O
cells O
. O

Our O
work O
provides O
a O
molecular O
mechanism O
to O
account O
for O
the O
effect O
of O
IFN B
- I
gamma I
in O
causing O
transcriptional O
activation O
of O
ACAT B
- I
1 I
in O
macrophage O
- O
like O
cells O
. O

Treatment O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
by O
antisense O
- O
induced O
local O
blockade O
of O
GATA B
- I
3 I
expression O
. O

However O
, O
it O
remains O
unclear O
whether O
GATA B
- I
3 I
plays O
a O
role O
in O
the O
effector O
phase O
of O
allergic O
airway O
inflammation O
and O
whether O
antagonizing O
the O
expression O
and O
/ O
or O
function O
of O
GATA B
- I
3 I
can O
be O
used O
for O
the O
therapy O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
. O

However O
, O
it O
remains O
unclear O
whether O
GATA B
- I
3 I
plays O
a O
role O
in O
the O
effector O
phase O
of O
allergic O
airway O
inflammation O
and O
whether O
antagonizing O
the O
expression O
and O
/ O
or O
function O
of O
GATA B
- I
3 I
can O
be O
used O
for O
the O
therapy O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
. O

Here O
, O
we O
analyzed O
the O
effects O
of O
locally O
antagonizing O
GATA B
- I
3 I
function O
in O
a O
murine O
model O
of O
asthma O
. O

We O
could O
suppress O
GATA O
- O
3 O
expression O
in O
interleukin B
( I
IL I
) I
- I
4 I
- O
producing O
T O
cells O
in O
vitro O
and O
in O
vivo O
by O
an O
antisense O
phosphorothioate O
oligonucleotide O
overlapping O
the O
translation B
start I
site I
of O
GATA B
- I
3 I
, O
whereas O
nonsense O
control O
oligonucleotides O
were O
virtually O
inactive O
. O

We O
could O
suppress O
GATA O
- O
3 O
expression O
in O
interleukin B
( I
IL I
) I
- I
4 I
- O
producing O
T O
cells O
in O
vitro O
and O
in O
vivo O
by O
an O
antisense O
phosphorothioate O
oligonucleotide O
overlapping O
the O
translation B
start I
site I
of O
GATA B
- I
3 I
, O
whereas O
nonsense O
control O
oligonucleotides O
were O
virtually O
inactive O
. O

These O
data O
indicate O
a O
critical O
role O
for O
GATA B
- I
3 I
in O
the O
effector O
phase O
of O
a O
murine O
asthma O
model O
and O
suggest O
that O
local O
delivery O
of O
GATA O
- O
3 O
antisense O
oligonucleotides O
may O
be O
a O
novel O
approach O
for O
the O
treatment O
of O
airway O
hyperresponsiveness O
such O
as O
in O
asthma O
. O

This O
approach O
has O
the O
potential O
advantage O
of O
suppressing O
the O
expression O
of O
various O
proinflammatory B
Th2 I
cytokines I
simultaneously O
rather O
than O
suppressing O
the O
activity O
of O
a O
single O
cytokine B
. O

Decreasing O
Th1 O
cells O
by O
antibodies B
( O
alpha B
- I
CD4 I
) O
or O
cytokines B
( O
IL B
- I
4 I
) O
also O
caused O
> O
/ O
= O
80 O
% O
reductions O
in O
lesion O
size O
. O

Decreasing O
Th1 O
cells O
by O
antibodies B
( O
alpha B
- I
CD4 I
) O
or O
cytokines B
( O
IL B
- I
4 I
) O
also O
caused O
> O
/ O
= O
80 O
% O
reductions O
in O
lesion O
size O
. O

Immunohistology O
revealed O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
colocalized O
with O
activated O
macrophages O
. O

Immunohistology O
revealed O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
colocalized O
with O
activated O
macrophages O
. O

IFN B
- I
gamma I
may O
participate O
through O
macrophage O
activation O
, O
whereas O
IL B
- I
4 I
may O
act O
to O
limit O
Th1 O
- O
cell O
response O
. O

IFN B
- I
gamma I
may O
participate O
through O
macrophage O
activation O
, O
whereas O
IL B
- I
4 I
may O
act O
to O
limit O
Th1 O
- O
cell O
response O
. O

Requirement O
for O
p38 B
and O
p44 B
/ I
p42 I
mitogen B
- I
activated I
protein I
kinases I
in O
RAGE B
- O
mediated O
nuclear B
factor I
- I
kappaB I
transcriptional O
activation O
and O
cytokine O
secretion O
. O

Signal O
transduction O
from O
RAGE B
to O
NF B
- I
kappaB I
involved O
the O
generation O
of O
reactive O
oxygen O
species O
, O
since O
reporter O
gene O
expression O
was O
blocked O
with O
the O
antioxidant O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

These O
results O
indicate O
that O
p38 B
MAPK I
activation O
mediates O
RAGE B
- O
induced O
NF B
- I
kappaB I
- O
dependent O
secretion O
of O
proinflammatory B
cytokines I
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

Despite O
the O
importance O
of O
NF B
- I
kappaB I
to O
B O
cell O
function O
, O
little O
is O
known O
about O
the O
signaling O
pathways O
leading O
to O
NF O
- O
kappaB O
activation O
. O

Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B
3 I
- I
kinase I
, O
Wortmannin O
and O
LY294002 O
, O
we O
demonstrate O
that O
PI B
3 I
- I
kinase I
activity O
is O
vital O
for O
BCR B
- O
induced O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
. O

Furthermore O
, O
we O
show O
that O
this O
is O
achieved O
via O
protein B
kinase I
C I
- O
dependent O
degradation O
of O
IkappaBalpha B
. O

Similar O
analyses O
reveal O
that O
PI B
3 I
- I
kinase I
is O
also O
critical O
in O
triggering O
NF B
- I
kappaB I
DNA O
- O
binding O
activity O
and O
IkappaBalpha B
degradation O
following O
LPS O
stimulation O
. O

Taken O
together O
, O
our O
results O
indicate O
the O
involvement O
of O
PI B
3 I
- I
kinase I
in O
at O
least O
two O
distinct O
signaling O
pathways O
leading O
to O
activation O
of O
NF B
- I
kappaB I
in O
B O
cells O
. O

Transcription B
factor I
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
is O
activated O
in O
cerulein O
pancreatitis O
and O
mediates O
cytokine O
expression O
. O

Here O
we O
report O
upregulation O
of O
NF B
- I
kappaB I
and O
inflammatory B
molecules I
, O
and O
their O
correlation O
with O
local O
pancreatic O
injury O
, O
in O
a O
model O
of O
severe O
pancreatitis O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

NF B
- I
kappaB I
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin B
- I
6 I
, O
tumor B
necrosis I
factor I
- I
alpha I
, O
KC O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
, O
and O
inducible B
nitric I
oxide I
synthase I
was O
assessed O
by O
semiquantitative O
RT O
- O
PCR O
. O

AP B
- I
1 I
was O
strongly O
activated O
in O
both O
pancreatic O
segments O
after O
either O
taurocholate O
or O
saline O
infusion O
. O

NF B
- I
kappaB I
inhibition O
with O
N O
- O
acetylcysteine O
ameliorated O
the O
local O
inflammatory O
response O
. O

Correlation O
between O
localized O
NF B
- I
kappaB I
activation O
, O
cytokine O
upregulation O
, O
and O
tissue O
damage O
suggests O
a O
key O
role O
for O
NF B
- I
kappaB I
in O
the O
development O
of O
the O
inflammatory O
response O
of O
acute O
pancreatitis O
. O

Correlation O
between O
localized O
NF B
- I
kappaB I
activation O
, O
cytokine O
upregulation O
, O
and O
tissue O
damage O
suggests O
a O
key O
role O
for O
NF B
- I
kappaB I
in O
the O
development O
of O
the O
inflammatory O
response O
of O
acute O
pancreatitis O
. O

CD45 B
tyrosine I
phosphatase I
controls O
common O
gamma B
- I
chain I
cytokine I
- O
mediated O
STAT B
and O
extracellular O
signal O
- O
related O
kinase O
phosphorylation O
in O
activated O
human O
lymphoblasts O
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O

In O
experiments O
with O
the O
CD45R0 B
mAb I
UCHL I
- I
1 I
, O
but O
not O
control B
CD45 I
mAbs I
, O
we O
found O
significant O
inhibition O
of O
proliferation O
. O

Addition O
of O
CD3 B
mAb I
OKT I
- I
3 I
had O
no O
influence O
on O
IL O
- O
2 O
- O
mediated O
proliferation O
( O
with O
or O
without O
UCHL B
- I
1 I
) O
. O

In O
contrast O
, O
after O
addition O
of O
OKT B
- I
3 I
to O
IL B
- I
4 I
- O
and O
IL B
- I
7 I
- O
stimulated O
proliferation O
assays O
, O
UCHL B
- I
1 I
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

In O
contrast O
, O
after O
addition O
of O
OKT B
- I
3 I
to O
IL B
- I
4 I
- O
and O
IL B
- I
7 I
- O
stimulated O
proliferation O
assays O
, O
UCHL B
- I
1 I
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

In O
contrast O
, O
after O
addition O
of O
OKT B
- I
3 I
to O
IL B
- I
4 I
- O
and O
IL B
- I
7 I
- O
stimulated O
proliferation O
assays O
, O
UCHL B
- I
1 I
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

In O
contrast O
, O
after O
addition O
of O
OKT B
- I
3 I
to O
IL B
- I
4 I
- O
and O
IL B
- I
7 I
- O
stimulated O
proliferation O
assays O
, O
UCHL B
- I
1 I
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

Using O
RT O
- O
PCR O
, O
we O
found O
that O
CD45R0 O
signaling O
inhibited O
IL O
- O
2 O
mRNA O
production O
without O
major O
influence O
on O
IL B
- I
13 I
, O
IL B
- I
5 I
, O
or O
IFN B
- I
gamma I
mRNA I
levels O
. O

Using O
RT O
- O
PCR O
, O
we O
found O
that O
CD45R0 O
signaling O
inhibited O
IL O
- O
2 O
mRNA O
production O
without O
major O
influence O
on O
IL B
- I
13 I
, O
IL B
- I
5 I
, O
or O
IFN B
- I
gamma I
mRNA I
levels O
. O

Costimulation O
with O
OKT B
- I
3 I
and O
IL B
- I
2 I
optimally O
induced O
secretion O
of O
IFN B
- I
gamma I
, O
TNF B
- I
alpha I
, O
and O
IL B
- I
5 I
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Costimulation O
with O
OKT B
- I
3 I
and O
IL B
- I
2 I
optimally O
induced O
secretion O
of O
IFN B
- I
gamma I
, O
TNF B
- I
alpha I
, O
and O
IL B
- I
5 I
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Costimulation O
with O
OKT B
- I
3 I
and O
IL B
- I
2 I
optimally O
induced O
secretion O
of O
IFN B
- I
gamma I
, O
TNF B
- I
alpha I
, O
and O
IL B
- I
5 I
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Costimulation O
with O
OKT B
- I
3 I
and O
IL B
- I
2 I
optimally O
induced O
secretion O
of O
IFN B
- I
gamma I
, O
TNF B
- I
alpha I
, O
and O
IL B
- I
5 I
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Costimulation O
with O
OKT B
- I
3 I
and O
IL B
- I
2 I
optimally O
induced O
secretion O
of O
IFN B
- I
gamma I
, O
TNF B
- I
alpha I
, O
and O
IL B
- I
5 I
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

Furthermore O
, O
we O
show O
the O
existence O
of O
CD45 B
epitopes I
( O
GAP8 B
. I
3 I
) O
, O
which O
are O
active O
and O
critical O
for O
signaling O
in O
quiescent O
lymphocytes O
, O
but O
are O
nonfunctional O
in O
activated O
human O
lymphoblasts O
. O

The O
Pax5 B
gene I
encoding O
the O
transcription B
factor I
BSAP I
is O
required O
for O
progression O
of O
B O
- O
lymphopoiesis O
beyond O
the O
pro O
- O
B O
cell O
stage O
. O

Pax5 B
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors B
of O
the O
Groucho B
protein I
family I
or O
with O
positive O
regulators O
such O
as O
the O
TATA B
- I
binding I
protein I
. O

Partners O
in O
transcription O
: O
NFAT B
and O
AP B
- I
1 I
. O

Concomitant O
induction O
of O
NFAT B
and O
AP B
- I
1 I
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B
kinase I
C I
( I
PKC I
) I
/ I
Ras I
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B
and I
Jun I
families I
of O
transcription B
factors I
. O

A O
fifth O
member O
of O
the O
NFAT B
family I
, O
NFAT5 B
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B
or O
of O
interaction O
with O
AP B
- I
1 I
. O

Balanced O
activation O
of O
NFAT B
and O
AP B
- I
1 I
is O
known O
to O
be O
required O
for O
productive O
immune O
responses O
, O
but O
the O
role O
of O
NFAT O
: O
AP O
- O
1 O
interactions O
in O
other O
cell O
types O
and O
biological O
processes O
remains O
to O
be O
understood O
. O

Two O
coxsackievirus O
B3 O
( O
CVB3 O
) O
variants O
( O
H3 O
and O
H310A1 O
) O
differ O
by O
a O
single O
amino O
acid O
mutation O
in O
the O
VP2 B
capsid I
protein I
. O

Infection O
with O
H3 O
, O
but O
not O
H310A1 O
, O
preferentially O
activates O
Vgamma4 O
Vdelta4 O
cells O
, O
which O
are O
strongly O
positive O
for O
gamma B
interferon I
( O
IFN B
- I
gamma I
) O
, O
whereas O
Vgamma1 O
Vdelta4 O
cells O
are O
increased O
in O
both O
H3 O
and O
H310A1 O
virus O
- O
infected O
animals O
. O

Depletion O
of O
Vgamma1 O
( O
+ O
) O
cells O
using O
monoclonal B
anti I
- I
Vgamma1 I
antibody I
enhanced O
myocarditis O
and O
CD4 O
( O
+ O
) O
- O
, O
IFN B
- I
gamma I
( O
+ O
) O
- O
cell O
responses O
in O
both O
H3 O
- O
and O
H310A1 O
- O
infected O
mice O
yet O
decreased O
the O
CD4 O
( O
+ O
) O
- O
, O
IL O
- O
4 O
( O
+ O
) O
- O
cell O
response O
. O

The O
role O
of O
cytokine O
production O
by O
Vgamma1 O
( O
+ O
) O
and O
Vgamma4 O
( O
+ O
) O
T O
cells O
was O
investigated O
by O
adoptively O
transferring O
these O
cells O
isolated O
from O
H3 O
- O
infected O
BALB O
/ O
c O
Stat4 O
knockout O
( O
Stat4ko O
) O
( O
defective O
in O
IFN B
- I
gamma I
expression O
) O
or O
BALB O
/ O
c O
Stat6ko O
( O
defective O
in O
IL O
- O
4 O
expression O
) O
mice O
into O
H3 O
virus O
- O
infected O
wild O
- O
type O
BALB O
/ O
c O
recipients O
. O

Vgamma4 O
and O
Vgamma1 O
( O
+ O
) O
T O
cells O
from O
Stat4ko O
mice O
expressed O
IL B
- I
4 I
but O
no O
or O
minimal O
IFN B
- I
gamma I
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN B
- I
gamma I
but O
no O
IL B
- I
4 I
. O

Vgamma4 O
and O
Vgamma1 O
( O
+ O
) O
T O
cells O
from O
Stat4ko O
mice O
expressed O
IL B
- I
4 I
but O
no O
or O
minimal O
IFN B
- I
gamma I
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN B
- I
gamma I
but O
no O
IL B
- I
4 I
. O

Vgamma4 O
and O
Vgamma1 O
( O
+ O
) O
T O
cells O
from O
Stat4ko O
mice O
expressed O
IL B
- I
4 I
but O
no O
or O
minimal O
IFN B
- I
gamma I
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN B
- I
gamma I
but O
no O
IL B
- I
4 I
. O

Vgamma4 O
and O
Vgamma1 O
( O
+ O
) O
T O
cells O
from O
Stat4ko O
mice O
expressed O
IL B
- I
4 I
but O
no O
or O
minimal O
IFN B
- I
gamma I
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN B
- I
gamma I
but O
no O
IL B
- I
4 I
. O

Plasmin B
- O
induced O
expression O
of O
cytokines B
and O
tissue B
factor I
in O
human O
monocytes O
involves O
AP B
- I
1 I
and O
IKKbeta B
- O
mediated O
NF O
- O
kappaB O
activation O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B
0 O
. O
043 O
to O
1 O
. O
43 O
CTA O
U O
/ O
mL O
, O
but O
not O
active B
site I
- I
blocked I
plasmin I
, O
triggered O
concentration O
- O
dependent O
expression O
of O
mRNA O
for O
interleukin B
- I
1alpha I
( O
IL B
- I
1alpha I
) O
, O
IL B
- I
1beta I
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
and O
TF B
with O
maximum O
responses O
after O
4 O
hours O
. O

Increases O
in O
mRNA O
levels O
were O
followed O
by O
concentration O
- O
and O
time O
- O
dependent O
release O
of O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
and O
by O
TF B
expression O
on O
monocyte O
surfaces O
. O

Increases O
in O
mRNA O
levels O
were O
followed O
by O
concentration O
- O
and O
time O
- O
dependent O
release O
of O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
and O
by O
TF B
expression O
on O
monocyte O
surfaces O
. O

Increases O
in O
mRNA O
levels O
were O
followed O
by O
concentration O
- O
and O
time O
- O
dependent O
release O
of O
IL B
- I
1alpha I
, O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
and O
by O
TF B
expression O
on O
monocyte O
surfaces O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B
- O
induced O
activation O
of O
NF B
- I
kappaB I
; O
DNA B
- I
binding I
complexes I
were O
composed O
of O
p50 B
, O
p65 B
, O
and O
c B
- I
Rel I
, O
as O
shown O
by O
supershift O
experiments O
. O

In O
addition O
, O
AP O
- O
1 O
binding O
was O
increased O
in O
plasmin B
- O
treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD B
, O
c B
- I
Fos I
, O
and O
FosB B
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P O
. O
vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B
, O
insulin B
- I
like I
growth I
factor I
- I
1 I
, O
thrombopoietin B
, O
interleukin B
- I
3 I
, O
and O
granulocyte B
/ I
monocyte I
colony I
- I
stimulating I
factor I
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

Constitutively B
active I
STAT3 I
may O
contribute O
to O
the O
growth O
factor O
hypersensitivity O
of O
P O
. O
vera O
cells O
. O

Interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
induces O
ICSBP B
expression O
and O
is O
an O
effective O
therapy O
for O
CML O
. O

Interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
induces O
ICSBP B
expression O
and O
is O
an O
effective O
therapy O
for O
CML O
. O

Both O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
that O
produce O
IL B
- I
2 I
in O
response O
to O
Ag O
recognition O
have O
been O
isolated O
. O

However O
, O
most O
effector O
CD8 O
+ O
T O
cells O
recovered O
after O
exposure O
to O
Ag B
do O
not O
produce O
sufficient O
IL B
- I
2 I
to O
sustain O
growth O
, O
and O
depend O
on O
CD4 O
+ O
T O
helper O
cells O
for O
this O
obligate O
growth O
factor O
. O

These O
results O
suggest O
that O
the O
defect O
at O
the O
- B
150 I
site I
may O
reflect O
the O
absence O
or O
inactivity O
of O
a O
required O
factor O
rather O
than O
repression O
of O
the O
IL B
- I
2 I
promoter I
. O

Stem B
cell I
factor I
and O
interleukin B
- I
3 I
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast B
growth I
factor I
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
. O

Stem B
cell I
factor I
and O
interleukin B
- I
3 I
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast B
growth I
factor I
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
. O

Stem B
cell I
factor I
and O
interleukin B
- I
3 I
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast B
growth I
factor I
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B
fibroblast I
growth I
factor I
( O
bFGF B
) O
- O
dependent O
hematopoietic O
stem O
cell O
line O
, O
A O
- O
6 O
, O
when O
cultured O
with O
stem B
cell I
factor I
( O
SCF B
) O
replacing O
bFGF B
. O

Those O
cells O
were O
positive O
for O
stem B
cell I
markers I
, O
c B
- I
kit I
and O
CD34 B
, O
and O
a O
myeloid B
cell I
marker I
, I
F4 I
/ I
80 I
. O

Those O
cells O
were O
positive O
for O
stem B
cell I
markers I
, O
c B
- I
kit I
and O
CD34 B
, O
and O
a O
myeloid B
cell I
marker I
, I
F4 I
/ I
80 I
. O

Some O
cell O
fractions O
were O
also O
positive O
for O
Mac B
- I
1 I
, I
a I
macrophage I
marker I
or O
Gr B
- I
1 I
, I
a I
granulocytic I
maker I
, O
but O
negative O
for O
an O
erythroid B
marker I
TER119 I
. O

Among O
various O
cytokines B
, O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
and O
beta B
- I
major I
globin I
. O

Among O
various O
cytokines B
, O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid B
- I
specific I
GATA I
- I
1 I
and O
beta B
- I
major I
globin I
. O

The O
quantitative O
analysis O
showed O
that O
erythroid O
precursor O
cells O
were O
newly O
produced O
from O
the O
immature O
myeloid O
cells O
by O
cultivation O
with O
IL B
- I
3 I
. O

SCF B
and O
IL B
- I
3 I
induced O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
an O
A O
- O
6 O
hematopoietic O
stem O
cell O
line O
. O

Distinct O
BMI B
- I
1 I
and O
EZH2 B
expression O
patterns O
in O
thymocytes O
and O
mature O
T O
cells O
suggest O
a O
role O
for O
Polycomb B
genes I
in O
human O
T O
cell O
differentiation O
. O

BMI B
- I
1 I
and O
EZH2 B
Polycomb B
- I
group I
( I
PcG I
) I
proteins I
belong O
to O
two O
distinct O
protein O
complexes O
involved O
in O
the O
regulation O
of O
hematopoiesis O
. O

Using O
unique O
PcG O
- O
specific O
antisera O
and O
triple O
immunofluorescence O
, O
we O
found O
that O
mature O
resting O
peripheral O
T O
cells O
expressed O
BMI B
- I
1 I
, O
whereas O
dividing O
blasts O
were O
EZH2 O
( O
+ O
) O
. O

By O
contrast O
, O
subcapsular O
immature O
double O
- O
negative O
( O
DN O
) O
( O
CD4 O
( O
- O
) O
/ O
CD8 O
( O
- O
) O
) O
T O
cells O
in O
the O
thymus O
coexpressed O
BMI B
- I
1 I
and O
EZH2 B
or O
were O
BMI O
- O
1 O
single O
positive O
. O

Their O
descendants O
, O
double O
- O
positive O
( O
DP O
; O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
+ O
) O
) O
cortical O
thymocytes O
, O
expressed O
EZH2 B
without O
BMI B
- I
1 I
. O

Maturation O
of O
DP O
cortical O
thymocytes O
to O
single O
- O
positive O
( O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
- O
) O
or O
CD8 O
( O
+ O
) O
/ O
CD4 O
( O
- O
) O
) O
medullar O
thymocytes O
correlated O
with O
decreased O
detectability O
of O
EZH2 B
and O
continued O
relative O
absence O
of O
BMI B
- I
1 I
. O

Our O
data O
show O
that O
BMI B
- I
1 I
and O
EZH2 B
expression O
in O
mature O
peripheral O
T O
cells O
is O
mutually O
exclusive O
and O
linked O
to O
proliferation O
status O
, O
and O
that O
this O
pattern O
is O
not O
yet O
established O
in O
thymocytes O
of O
the O
cortex O
and O
medulla O
. O

Epstein O
- O
Barr O
Virus O
and O
its O
glycoprotein B
- I
350 I
upregulate O
IL B
- I
6 I
in O
human O
B O
- O
lymphocytes O
via O
CD21 B
, O
involving O
activation O
of O
NF B
- I
kappaB I
and O
different O
signaling O
pathways O
. O

Epstein O
- O
Barr O
Virus O
and O
its O
glycoprotein B
- I
350 I
upregulate O
IL B
- I
6 I
in O
human O
B O
- O
lymphocytes O
via O
CD21 B
, O
involving O
activation O
of O
NF B
- I
kappaB I
and O
different O
signaling O
pathways O
. O

Epstein O
- O
Barr O
Virus O
and O
its O
glycoprotein B
- I
350 I
upregulate O
IL B
- I
6 I
in O
human O
B O
- O
lymphocytes O
via O
CD21 B
, O
involving O
activation O
of O
NF B
- I
kappaB I
and O
different O
signaling O
pathways O
. O

EBV O
utilizes O
CD21 B
/ I
CR2 I
as O
its O
receptor O
on O
B O
cells O
to O
initiate O
the O
infection O
process O
. O

Both O
EBV O
and O
gp350 B
enhance O
the O
binding O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
as O
determined O
by O
band O
- O
shift O
and O
augment O
NF B
- I
kappaB I
- O
mediated O
activation O
of O
a O
CAT B
reporter I
plasmid I
. O

Both O
EBV O
and O
gp350 B
enhance O
the O
binding O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
as O
determined O
by O
band O
- O
shift O
and O
augment O
NF B
- I
kappaB I
- O
mediated O
activation O
of O
a O
CAT B
reporter I
plasmid I
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus B
envelope I
glycoprotein I
to O
CR2 B
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
leading O
to O
the O
upregulation O
of O
IL O
- O
6 O
gene O
expression O
in O
these O
lymphocytes O
. O

Caspase B
- O
dependent O
cleavage O
of O
the O
hematopoietic B
specific I
adaptor I
protein I
Gads I
alters O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
is O
a O
SH2 B
and I
SH3 I
domain I
- O
containing O
, O
hematopoietic B
- I
specific I
adaptor I
protein I
that O
functions O
in O
signalling O
from O
the O
T B
cell I
receptor I
. O

Gads B
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

Gads B
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

Gads B
acts O
by O
linking O
SLP B
- I
76 I
, O
bound O
by O
the O
carboxy B
- I
terminal I
Gads I
SH3 I
domain I
, O
to O
tyrosine B
phosphorylated I
LAT I
which O
contains O
binding O
sites O
for O
the O
Gads B
SH2 I
domain I
. O

Here O
we O
demonstrate O
that O
the O
unique O
region O
of O
Gads B
contains O
a O
capase B
cleavage I
site I
. O

The O
Gads B
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP B
- I
76 I
and O
LAT B
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B
cell I
receptor I
by O
disrupting O
cross O
talk O
between O
SLP B
- I
76 I
and O
LAT B
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B
cell I
receptor I
by O
disrupting O
cross O
talk O
between O
SLP B
- I
76 I
and O
LAT B
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B
is O
dispensable O
for O
activation O
of O
the O
IL B
- I
2 I
promoter I
, O
and O
the O
N B
- I
terminal I
743 I
residues I
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE B
- I
TRE I
, O
the O
IL B
- I
2 I
promoter I
, O
and O
endogenous O
IL B
- I
2 I
gene I
expression O
. O

Mutational O
analysis O
of O
p300 B
reveals O
differential O
structural O
requirements O
for O
the O
N O
- O
terminal O
p300 O
module O
by O
individual O
cis B
- I
elements I
within O
the O
IL B
- I
2 I
promoter I
. O

Regulation O
of O
cytokine O
production O
in O
T O
- O
cell O
responses O
to O
inhalant O
allergen O
: O
GATA B
- I
3 I
expression O
distinguishes O
between O
Th1 O
- O
and O
Th2 O
- O
polarized O
immunity O
. O

RESULTS O
: O
Cytokine B
- O
driven O
Th2 O
polarization O
of O
naive O
T O
cells O
is O
associated O
with O
marked O
upregulation O
of O
GATA B
- I
3 I
expression O
, O
whereas O
a O
reciprocal O
expression O
pattern O
accompanies O
differentiation O
towards O
the O
Th1 O
cytokine O
phenotype O
. O

In O
T O
cells O
from O
HDM O
skin O
prick O
test O
- O
positive O
( O
HDM O
- O
SPT O
+ O
/ O
HDM O
- O
IgE O
+ O
) O
volunteers O
, O
overnight O
stimulation O
results O
in O
marked O
upregulation O
of O
GATA B
- I
3 I
expression O
, O
compared O
to O
an O
equally O
marked O
downregulation O
of O
expression O
in O
T O
cells O
from O
SPT O
- O
/ O
IgE O
- O
subjects O
. O

In O
subjects O
who O
are O
HDM O
- O
SPT O
+ O
but O
IgE O
- O
, O
GATA B
- I
3 I
expression O
levels O
remained O
relatively O
stable O
during O
culture O
with O
HDM O
. O

CONCLUSIONS O
: O
Upregulation O
of O
GATA B
- I
3 I
expression O
in O
PBMC O
is O
a O
hallmark O
of O
the O
early O
phase O
of O
Th2 O
recall O
responses O
to O
specific O
allergen O
in O
atopics O
. O

The O
heat O
shock O
response O
reduces O
myelin B
oligodendrocyte I
glycoprotein I
- O
induced O
experimental O
autoimmune O
encephalomyelitis O
in O
mice O
. O

The O
stress O
response O
( O
SR O
) O
can O
block O
inflammatory O
gene O
expression O
by O
preventing O
activation O
of O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappaB I
) O
. O

EAE O
was O
actively O
induced O
in O
C57BL O
/ O
6 O
mice O
using O
an O
encephalitogenic O
myelin B
oligodendrocyte I
glycoprotein I
( O
MOG B
( I
35 I
- I
55 I
) I
) O
peptide O
. O

The O
HSR O
reduced O
inflammatory O
gene O
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE O
, O
including O
the O
early O
increase O
in O
RANTES B
( O
regulated B
on I
activation I
of I
normal I
T I
- I
cell I
expressed I
and I
secreted I
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric B
oxide I
synthase I
. O

The O
early O
activation O
of O
transcription B
factor I
NF B
- I
kappaB I
was O
also O
blocked O
by O
the O
HSR O
. O

This O
approach O
uses O
reporter B
- I
plasmids I
for O
the O
detection O
of O
intracellular O
signals O
mediated O
by O
the O
mitogen B
- I
activated I
protein I
kinase I
or O
cyclic B
AMP I
- I
dependent I
protein I
kinase I
. O

Reporter B
- I
plasmids I
are O
transfected O
into O
thymocytes O
in O
fetal O
thymic O
organ O
culture O
by O
accelerated O
DNA O
/ O
particle O
bombardment O
( O
gene O
gun O
) O
, O
and O
the O
activation O
of O
a O
signaling O
pathway O
is O
determined O
in O
the O
form O
of O
a O
standard O
luciferase O
assay O
. O

Genes B
encoding I
CBFbeta I
( O
CBFB B
) O
, O
and O
one O
of O
the O
DNA B
- I
binding I
CBFalpha I
subunits I
, I
Runx1 I
( O
also O
known O
as O
CBFalpha2 B
, O
AML1 B
, O
and O
PEBP2alphaB B
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

CBFbeta B
- I
SMMHC I
preferentially O
inhibits O
the O
differentiation O
of O
myeloid O
lineage O
cells O
, O
while O
increasing O
the O
number O
of O
blastlike O
cells O
in O
culture O
. O

The O
latency O
pattern O
of O
Epstein O
- O
Barr O
virus O
infection O
and O
viral O
IL B
- I
10 I
expression O
in O
cutaneous O
natural O
killer O
/ O
T O
- O
cell O
lymphomas O
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV B
- I
DNA I
, O
EBV B
- I
encoded I
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV B
- I
DNA I
fragments I
containing O
the O
terminal B
repeats I
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
- I
1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q B
promoter I
, O
whereas O
both O
the O
Q B
promoter I
and O
another O
upstream B
promoter I
( O
Cp B
/ I
Wp I
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Latent B
BHRF1 I
transcripts I
encoding O
bcl B
- I
2 I
homologue I
and O
BCRF1 B
transcripts I
encoding O
viral B
interleukin I
( I
vIL I
) I
- I
10 I
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

The O
scavenger B
receptor I
CD36 I
is O
encoded O
by O
a O
PPRE B
- I
responsive I
gene I
, O
and O
azPC O
enhanced O
expression O
of O
CD36 B
in O
primary O
human O
monocytes O
. O

We O
found O
that O
anti B
- I
CD36 I
inhibited O
azPC O
uptake O
, O
and O
it O
inhibited O
PPRE O
reporter O
induction O
. O

Results O
with O
a O
small O
molecule O
phospholipid B
flippase I
mimetic I
suggest O
azPC O
acts O
intracellularly O
and O
that O
cellular O
azPC O
accumulation O
was O
efficient O
. O

Regulation O
of O
the O
human B
MAT2B I
gene I
encoding O
the O
regulatory B
beta I
subunit I
of O
methionine B
adenosyltransferase I
, O
MAT B
II I
. O

Methionine B
adenosyltransferase I
( O
MAT B
) O
catalyzes O
the O
biosynthesis O
of O
S B
- I
adenosylmethionine I
( O
AdoMet B
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

The O
MAT B
II I
isozyme I
consists O
of O
a O
catalytic B
alpha2 I
and I
a I
regulatory I
beta I
subunit I
. O

Transcription O
of O
the O
MAT2B B
gene I
initiates O
at O
position O
- O
203 O
relative O
to O
the O
translation B
start I
site I
. O

Promoter B
deletion I
analysis I
defined O
a O
minimal B
promoter I
between O
positions B
+ I
52 I
and I
+ I
93 I
base O
pairs O
, O
a O
GC B
- I
rich I
region I
. O

Inclusion O
of O
the O
sequences O
between O
- O
4 O
and O
+ O
52 O
enhanced O
promoter O
activity O
; O
this O
was O
primarily O
because O
of O
an O
Sp1 B
recognition I
site I
at O
+ O
9 O
/ O
+ O
15 O
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B
, O
MIP B
- I
1 I
alpha I
, O
MCP B
- I
1 I
, O
MCP B
- I
3 I
, O
and O
IP B
- I
10 I
) O
, O
pro O
- O
inflammatory O
( O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
18 I
, O
and O
TNF B
- I
alpha I
) O
, O
and O
antiviral B
( I
IFN I
- I
alpha I
/ I
beta I
) I
cytokines I
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
STAT B
and O
IRF B
signal I
transducing I
molecules I
in O
influenza O
A O
virus O
- O
infected O
cells O
. O

In O
addition O
of O
upregulating O
cytokine B
gene I
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase B
- I
1 I
enzyme I
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL B
- I
1 I
beta I
and O
proIL B
- I
18 I
into O
their O
biologically O
active O
forms O
. O

IFN B
- I
alpha I
/ I
beta I
also O
prolongs O
T O
cell O
survival O
, O
upregulates O
IL O
- O
12 O
and O
IL O
- O
18 O
receptor O
gene O
expression O
and O
together O
with O
IL B
- I
18 I
stimulates O
NK O
and O
T O
cell O
IFN O
- O
gamma O
production O
and O
the O
development O
of O
Th1 O
- O
type O
immune O
response O
. O

To O
investigate O
Mad1 B
function O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
that O
express O
a O
Mad1 B
transgene I
in O
T O
lineage O
cells O
under O
the O
control O
of O
the O
proximal B
lck I
promoter I
. O

PU B
. I
1 I
is O
a O
member O
of O
the O
Ets B
family I
of I
transcription I
factors I
required O
for O
the O
development O
of O
various O
lymphoid O
and O
myeloid O
cell O
lineages O
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O

The O
study O
shows O
that O
PU B
. I
1 I
is O
expressed O
in O
NK O
cells O
and O
that O
, O
on O
cell O
transfer O
into O
alymphoid O
Rag2 O
/ O
gammac O
( O
- O
/ O
- O
) O
mice O
, O
hematopoietic O
progenitors O
of O
PU O
. O
1 O
( O
- O
/ O
- O
) O
fetal O
liver O
cells O
could O
generate O
functional O
NK O
cells O
but O
not O
B O
or O
T O
cells O
. O

Moreover O
, O
PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem B
cell I
factor I
and O
interleukin B
( I
IL I
) I
- I
7 I
, O
suggesting O
a O
nonredundant O
role O
for O
PU B
. I
1 I
in O
regulating O
the O
expression O
of O
these O
cytokine B
receptor I
genes I
during O
NK O
cell O
development O
. O

Moreover O
, O
PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem B
cell I
factor I
and O
interleukin B
( I
IL I
) I
- I
7 I
, O
suggesting O
a O
nonredundant O
role O
for O
PU B
. I
1 I
in O
regulating O
the O
expression O
of O
these O
cytokine B
receptor I
genes I
during O
NK O
cell O
development O
. O

Moreover O
, O
PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem B
cell I
factor I
and O
interleukin B
( I
IL I
) I
- I
7 I
, O
suggesting O
a O
nonredundant O
role O
for O
PU B
. I
1 I
in O
regulating O
the O
expression O
of O
these O
cytokine B
receptor I
genes I
during O
NK O
cell O
development O
. O

PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 B
family I
and O
failed O
to O
proliferate O
in O
response O
to O
IL B
- I
2 I
and O
IL B
- I
12 I
. O

PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 B
family I
and O
failed O
to O
proliferate O
in O
response O
to O
IL B
- I
2 I
and O
IL B
- I
12 I
. O

Thus O
, O
despite O
the O
less O
stringent O
requirement O
for O
PU B
. I
1 I
in O
NK O
cell O
development O
compared O
to O
B O
and O
T O
cells O
, O
PU B
. I
1 I
regulates O
NK O
cell O
differentiation O
and O
homeostasis O
. O

Thus O
, O
despite O
the O
less O
stringent O
requirement O
for O
PU B
. I
1 I
in O
NK O
cell O
development O
compared O
to O
B O
and O
T O
cells O
, O
PU B
. I
1 I
regulates O
NK O
cell O
differentiation O
and O
homeostasis O
. O

Benzene O
- O
extracted O
components O
showed O
effects O
mimicking O
DEPs O
on O
IL O
- O
8 O
gene O
expression O
, O
release O
of O
several O
cytokines B
( O
IL B
- I
8 I
; O
granulocyte B
macrophage I
colony I
- I
stimulating I
factor I
; O
and O
regulated O
on O
activation O
, O
normal O
T O
cells O
expressed O
and O
secreted O
) O
and O
nuclear O
factor O
( O
NF O
) O
- O
kappa O
B O
activation O
. O

Peroxisome B
proliferator I
- I
activated I
receptor I
( I
PPAR I
) I
- I
gamma I
is O
a O
nuclear B
hormone I
receptor I
that O
serves O
as O
a O
trans O
factor O
to O
regulate O
lipid O
metabolism O
. O

Intense O
interest O
is O
focused O
on O
PPAR B
- I
gamma I
and O
its O
ligands O
owing O
to O
its O
putative O
role O
in O
adipocyte O
differentiation O
. O

Little O
is O
known O
, O
however O
, O
about O
the O
functions O
of O
PPAR B
- I
gamma I
in O
the O
immune O
system O
, O
especially O
in O
T O
lymphocytes O
. O

We O
demonstrate O
that O
both O
naive O
and O
activated O
ovalbumin O
- O
specific O
T O
cells O
from O
DO11 O
. O
10 O
- O
transgenic O
mice O
express O
PPAR B
- I
gamma I
mRNA O
and O
protein O
. O

In O
order O
to O
determine O
the O
function O
of O
PPAR B
- I
gamma I
, O
T O
cells O
were O
stimulated O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
ionomycin O
or O
antigen O
and O
antigen O
- O
presenting O
cells O
. O

The O
decrease O
in O
cell O
viability O
was O
due O
to O
apoptosis O
of O
the O
T O
lymphocytes O
, O
and O
occurred O
only O
when O
cells O
were O
treated O
with O
PPAR B
- I
gamma I
, O
and O
not O
PPAR O
- O
alpha O
agonists O
, O
revealing O
specificity O
of O
this O
response O
for O
PPAR B
- I
gamma I
. O

The O
decrease O
in O
cell O
viability O
was O
due O
to O
apoptosis O
of O
the O
T O
lymphocytes O
, O
and O
occurred O
only O
when O
cells O
were O
treated O
with O
PPAR B
- I
gamma I
, O
and O
not O
PPAR O
- O
alpha O
agonists O
, O
revealing O
specificity O
of O
this O
response O
for O
PPAR B
- I
gamma I
. O

Activation O
of O
NF B
- I
kappaB I
and O
production O
of O
NF B
- I
kappaB I
- O
dependent O
chemokines B
are O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
neutrophilic O
lung O
inflammation O
. O

Activation O
of O
NF B
- I
kappaB I
and O
production O
of O
NF B
- I
kappaB I
- O
dependent O
chemokines B
are O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
neutrophilic O
lung O
inflammation O
. O

Calpain O
- O
1 O
inhibitor O
( O
CI O
- O
1 O
) O
blocks O
activation O
of O
NF B
- I
kappaB I
by O
preventing O
proteolysis O
of O
the O
inhibitory O
protein O
IkappaB B
- I
alpha I
by O
the O
ubiquitin O
/ O
proteasome O
pathway O
. O

Calpain O
- O
1 O
inhibitor O
( O
CI O
- O
1 O
) O
blocks O
activation O
of O
NF B
- I
kappaB I
by O
preventing O
proteolysis O
of O
the O
inhibitory O
protein O
IkappaB B
- I
alpha I
by O
the O
ubiquitin O
/ O
proteasome O
pathway O
. O

Treatment O
with O
Cl O
- O
1 O
prevented O
degradation O
of O
IkappaB B
- I
alpha I
and O
activation O
of O
NF B
- I
kappaB I
in O
the O
liver O
in O
response O
to O
LPS O
; O
however O
, O
Cl O
- O
1 O
treatment O
had O
no O
detected O
effect O
on O
NF O
- O
kappaB O
activation O
in O
lung O
tissue O
. O

Treatment O
with O
Cl O
- O
1 O
prevented O
degradation O
of O
IkappaB B
- I
alpha I
and O
activation O
of O
NF B
- I
kappaB I
in O
the O
liver O
in O
response O
to O
LPS O
; O
however O
, O
Cl O
- O
1 O
treatment O
had O
no O
detected O
effect O
on O
NF O
- O
kappaB O
activation O
in O
lung O
tissue O
. O

Two O
cognate B
Sp1 I
binding I
sites I
located O
at O
- O
279 O
and O
- O
45 O
relative O
to O
the O
transcriptional B
start I
site I
proved O
crucial O
for O
Rta O
- O
mediated O
activation O
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B
factor I
Zif268 I
and O
the O
viral B
transactivator I
ZEBRA I
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B
by O
Rta B
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B
factor I
Zif268 I
and O
the O
viral B
transactivator I
ZEBRA I
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B
by O
Rta B
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

Hypoxia B
inducible I
factor I
- I
1 I
( O
HIF B
- I
1 I
) O
is O
a O
constitutively O
expressed O
basic O
helix B
- I
loop I
- I
helix I
transcription I
factor I
, O
formed O
by O
the O
assembly O
of O
HIF B
- I
1alpha I
and O
HIF B
- I
1beta I
( O
Arnt B
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

Here O
, O
we O
demonstrate O
that O
engineered O
down O
- O
regulation O
of O
HIF B
- I
1alpha I
by O
intratumoral O
gene O
transfer O
of O
an O
antisense B
HIF I
- I
1alpha I
plasmid I
leads O
to O
the O
down O
- O
regulation O
of O
VEGF B
, O
and O
decreased O
tumor O
microvessel O
density O
. O

In O
summary O
, O
whilst O
intensive O
investigations O
are O
in O
progress O
to O
target O
the O
many O
HIF B
- I
1 I
effectors O
, O
the O
results O
herein O
indicate O
that O
blocking O
hypoxia O
- O
inducible O
pathways O
and O
enhancing O
NK O
- O
mediated O
antitumor O
immunity O
by O
targeting O
HIF B
- I
1 I
itself O
may O
be O
advantageous O
, O
especially O
when O
combined O
with O
cancer O
immunotherapy O
. O

In O
summary O
, O
whilst O
intensive O
investigations O
are O
in O
progress O
to O
target O
the O
many O
HIF B
- I
1 I
effectors O
, O
the O
results O
herein O
indicate O
that O
blocking O
hypoxia O
- O
inducible O
pathways O
and O
enhancing O
NK O
- O
mediated O
antitumor O
immunity O
by O
targeting O
HIF B
- I
1 I
itself O
may O
be O
advantageous O
, O
especially O
when O
combined O
with O
cancer O
immunotherapy O
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

Analysis O
of O
known O
Moloney B
MLV I
target I
genes I
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c B
- I
Myc I
or O
N B
- I
Myc I
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B
or O
Pim2 B
( O
23 O
% O
) O
, O
and O
at O
Pal1 B
/ I
Gfi1 I
( O
18 O
% O
) O
. O

The O
involvement O
of O
TNF B
- I
alpha I
- O
related O
apoptosis O
- O
inducing O
ligand O
in O
the O
enhanced O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
human O
dendritic O
cells O
to O
tumor O
cells O
. O

The O
involvement O
of O
TNF B
- I
alpha I
- O
related O
apoptosis O
- O
inducing O
ligand O
in O
the O
enhanced O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
human O
dendritic O
cells O
to O
tumor O
cells O
. O

TNF B
- I
alpha I
- O
related O
apoptosis O
- O
inducing O
ligand O
( O
TRAIL O
) O
is O
characterized O
by O
its O
preferential O
induction O
of O
apoptosis O
of O
tumor O
cells O
but O
not O
normal O
cells O
. O

TRAIL O
expression O
on O
immature O
CD34DCs O
or O
MoDCs O
was O
greatly O
up O
- O
regulated O
after O
IFN B
- I
beta I
stimulation O
. O

Moreover O
, O
IFN B
- I
beta I
could O
strikingly O
enhance O
the O
ability O
of O
CD34DCs O
or O
MoDCs O
to O
kill O
TRAIL O
- O
sensitive O
tumor O
cells O
, O
but O
LPS O
did O
not O
have O
such O
an O
effect O
. O

The O
up O
- O
regulation O
of O
TRAIL O
on O
IFN B
- I
beta I
- O
stimulated O
DCs O
partially O
contributed O
to O
the O
increased O
cytotoxicity O
of O
DCS O
: O
Pretreatment O
of O
TRAIL O
- O
sensitive O
tumor O
cells O
with O
caspase O
- O
3 O
inhibitor O
could O
significantly O
increase O
their O
resistance O
to O
the O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
DCS O
: O
In O
contrast O
, O
NF O
- O
kappaB O
inhibitor O
could O
significantly O
increase O
the O
sensitivity O
of O
tumor O
cells O
to O
the O
killing O
by O
nonstimulated O
or O
LPS O
- O
stimulated O
DCS O
: O
Our O
studies O
demonstrate O
that O
IFN B
- I
beta I
- O
stimulated O
DCs O
are O
functionally O

The O
up O
- O
regulation O
of O
TRAIL O
on O
IFN B
- I
beta I
- O
stimulated O
DCs O
partially O
contributed O
to O
the O
increased O
cytotoxicity O
of O
DCS O
: O
Pretreatment O
of O
TRAIL O
- O
sensitive O
tumor O
cells O
with O
caspase O
- O
3 O
inhibitor O
could O
significantly O
increase O
their O
resistance O
to O
the O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
DCS O
: O
In O
contrast O
, O
NF O
- O
kappaB O
inhibitor O
could O
significantly O
increase O
the O
sensitivity O
of O
tumor O
cells O
to O
the O
killing O
by O
nonstimulated O
or O
LPS O
- O
stimulated O
DCS O
: O
Our O
studies O
demonstrate O
that O
IFN B
- I
beta I
- O
stimulated O
DCs O
are O
functionally O

The O
up O
- O
regulation O
of O
TRAIL O
on O
IFN B
- I
beta I
- O
stimulated O
DCs O
partially O
contributed O
to O
the O
increased O
cytotoxicity O
of O
DCS O
: O
Pretreatment O
of O
TRAIL O
- O
sensitive O
tumor O
cells O
with O
caspase O
- O
3 O
inhibitor O
could O
significantly O
increase O
their O
resistance O
to O
the O
cytotoxicity O
of O
IFN B
- I
beta I
- O
stimulated O
DCS O
: O
In O
contrast O
, O
NF O
- O
kappaB O
inhibitor O
could O
significantly O
increase O
the O
sensitivity O
of O
tumor O
cells O
to O
the O
killing O
by O
nonstimulated O
or O
LPS O
- O
stimulated O
DCS O
: O
Our O
studies O
demonstrate O
that O
IFN B
- I
beta I
- O
stimulated O
DCs O
are O
functionally O

Subsequently O
, O
DCs O
act O
as O
APCs O
involved O
in O
the O
uptake O
, O
processing O
, O
and O
presentation O
of O
apoptotic B
tumor I
Ags I
to O
cross O
- O
prime O
CD8 O
( O
+ O
) O
CTL O
cells O
. O

We O
found O
that O
fresh O
CD34 O
( O
+ O
) O
Lin O
( O
- O
) O
cells O
that O
are O
human O
leukocyte O
antigen O
( O
HLA O
) O
- O
DR O
( O
- O
) O
or O
CD38 O
( O
- O
) O
constitutively O
express O
GATA B
- I
3 I
but O
not O
T B
- I
cell I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
or O
Id B
- I
3 I
. O

We O
found O
that O
fresh O
CD34 O
( O
+ O
) O
Lin O
( O
- O
) O
cells O
that O
are O
human O
leukocyte O
antigen O
( O
HLA O
) O
- O
DR O
( O
- O
) O
or O
CD38 O
( O
- O
) O
constitutively O
express O
GATA B
- I
3 I
but O
not O
T B
- I
cell I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
or O
Id B
- I
3 I
. O

We O
found O
that O
fresh O
CD34 O
( O
+ O
) O
Lin O
( O
- O
) O
cells O
that O
are O
human O
leukocyte O
antigen O
( O
HLA O
) O
- O
DR O
( O
- O
) O
or O
CD38 O
( O
- O
) O
constitutively O
express O
GATA B
- I
3 I
but O
not O
T B
- I
cell I
factor I
- I
1 I
( O
TCF B
- I
1 I
) O
or O
Id B
- I
3 I
. O

Id B
- I
3 I
, O
a O
basic B
helix I
loop I
helix I
factor I
with O
dominant O
negative O
function O
for O
T O
- O
cell O
differentiation O
transcription B
factors I
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T O
- O
cell O
maturation O
. O

CD56 O
( O
+ O
bright O
) O
, O
but O
not O
CD56 O
( O
+ O
dim O
) O
, O
NK O
cells O
constitutively O
express O
TCF B
- I
1 I
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
and O
Western O
blot O
analysis O
. O

The O
TCF B
- I
1 I
isoform I
found O
in O
CD56 O
( O
+ O
bright O
) O
cells O
, O
which O
express O
lectin B
but O
not O
immunoglobulin B
class I
I I
recognizing O
inhibitory B
receptors I
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

These O
results O
suggest O
that O
TCF B
- I
1 I
does O
not O
target O
human B
killer I
immunoglobulin I
receptor I
genes I
, O
TCF B
- I
1 I
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+ O
bright O
) O
NK O
cells O
, O
and O
specific O
TCF B
- I
1 I
isoforms I
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK O
/ O
T O
- O
cell O
progenitor O
. O

These O
results O
suggest O
that O
TCF B
- I
1 I
does O
not O
target O
human B
killer I
immunoglobulin I
receptor I
genes I
, O
TCF B
- I
1 I
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+ O
bright O
) O
NK O
cells O
, O
and O
specific O
TCF B
- I
1 I
isoforms I
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK O
/ O
T O
- O
cell O
progenitor O
. O

Bright B
( O
B B
cell I
regulator I
of I
IgH I
transcription I
) O
is O
a O
B O
cell O
- O
specific O
, O
matrix B
associating I
region I
- I
binding I
protein I
that O
transactivates O
gene O
expression O
from O
the O
IgH B
intronic I
enhancer I
( O
E B
mu I
) O
. O

Bright B
can O
not O
transactivate O
via O
out O
of O
context O
, O
concatenated B
binding I
sites I
. O

BCL B
- I
6 I
is O
essential O
for O
germinal O
center O
formation O
and O
thus O
for O
affinity O
maturation O
of O
immunoglobulin B
( I
Ig I
) I
genes I
by O
somatic O
mutations O
. O

Translocations O
of O
the O
BCL B
- I
6 I
gene I
to O
heterologous B
promoters I
and O
mutations O
of O
its O
5 B
' I
- I
noncoding I
regulatory I
region I
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL B
- I
6 I
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non O
- O
Hodgkin O
lymphoma O
. O

Gadd45gamma B
, O
a O
family O
member O
of O
the O
growth B
arrest I
and I
DNA I
damage I
- I
inducible I
gene I
family I
45 I
( O
Gadd45 B
) O
, O
is O
strongly O
induced O
by O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
peripheral O
T O
cells O
. O

Gadd45gamma B
, O
a O
family O
member O
of O
the O
growth B
arrest I
and I
DNA I
damage I
- I
inducible I
gene I
family I
45 I
( O
Gadd45 B
) O
, O
is O
strongly O
induced O
by O
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
in O
peripheral O
T O
cells O
. O

While O
in O
most O
tissues O
all O
Gadd45 B
family I
members I
are O
expressed O
, O
Gadd45gamma B
is O
the O
only O
member O
that O
is O
induced O
by O
IL B
- I
2 I
. O

While O
in O
most O
tissues O
all O
Gadd45 B
family I
members I
are O
expressed O
, O
Gadd45gamma B
is O
the O
only O
member O
that O
is O
induced O
by O
IL B
- I
2 I
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma B
is O
not O
impaired O
and O
Gadd45gamma B
- O
deficient O
T O
lymphocytes O
show O
normal O
responses O
to O
IL B
- I
2 I
. O

These O
data O
demonstrate O
that O
Gadd45gamma B
is O
not O
essential O
for O
normal O
mouse O
development O
and O
hematopoiesis O
, O
possibly O
due O
to O
functional O
redundancy O
among O
the O
Gadd45 B
family I
members I
. O

Gadd45gamma B
is O
also O
dispensable O
for O
IL B
- I
2 I
- O
induced O
T O
- O
cell O
proliferation O
. O

We O
studied O
the O
expression O
of O
apoptosis O
- O
associated O
genes O
, O
bcl B
- I
xL I
, O
bad B
, O
caspase B
- I
3 I
, O
and O
c B
- I
myc I
family I
genes I
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

We O
studied O
the O
expression O
of O
apoptosis O
- O
associated O
genes O
, O
bcl B
- I
xL I
, O
bad B
, O
caspase B
- I
3 I
, O
and O
c B
- I
myc I
family I
genes I
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

We O
observed O
that O
the O
mRNA O
levels O
of O
myc B
family I
genes I
, O
c B
- I
myc I
and O
max B
, O
were O
markedly O
reduced O
in O
MG O
thymuses O
. O

We O
observed O
that O
the O
mRNA O
levels O
of O
myc B
family I
genes I
, O
c B
- I
myc I
and O
max B
, O
were O
markedly O
reduced O
in O
MG O
thymuses O
. O

These O
results O
indicate O
that O
c B
- I
myc I
- O
mediated O
signaling O
is O
abnormal O
in O
MG O
thymuses O
. O

The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc B
, O
such O
as O
STAM B
, O
prothymosin B
- I
alpha I
, O
and O
NFkappaB B

The O
pattern O
of O
IFN B
- I
gamma I
staining O
appeared O
to O
be O
intracellular O
in O
mononuclear O
lymphoid O
cells O
. O

Th1 O
response O
, O
which O
is O
characterized O
by O
IFN B
- I
gamma I
release O
, O
is O
thought O
to O
be O
involved O
in O
the O
host O
defense O
against O
dermatophytes O
and O
to O
reflect O
cutaneous O
reaction O
in O
dermatophytosis O
. O

The O
basic B
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
proteins I
E12 B
and O
E47 B
and O
an O
inhibitor B
HLH I
protein I
, O
Id3 B
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

Investigation O
of O
mast O
cell O
responsiveness O
toward O
retinoic O
acid O
( O
RA O
) O
revealed O
selective O
promotion O
of O
ICAM B
- I
3 I
expression O
in O
the O
human O
mast O
cell O
line O
HMC O
- O
1 O
. O

ICAM B
- I
3 I
modulation O
was O
found O
to O
be O
cell O
- O
type O
dependent O
, O
detectable O
also O
for O
HL O
- O
60 O
cells O
and O
monocytes O
but O
not O
U O
- O
937 O
and O
only O
weakly O
for O
KU812 O
cells O
. O

Terminally O
differentiated O
skin O
mast O
cells O
also O
failed O
to O
up O
- O
modulate O
their O
ICAM B
- I
3 I
, O
suggesting O
the O
requirement O
for O
some O
degree O
of O
immaturity O
for O
the O
process O
. O

RA O
- O
mediated O
effects O
on O
ICAM B
- I
1 I
expression O
, O
studied O
in O
parallel O
, O
were O
clearly O
distinct O
from O
those O
on O
ICAM B
- I
3 I
. O

RA O
- O
mediated O
effects O
on O
ICAM B
- I
1 I
expression O
, O
studied O
in O
parallel O
, O
were O
clearly O
distinct O
from O
those O
on O
ICAM B
- I
3 I
. O

RAR B
beta I
, O
not O
expressed O
at O
baseline O
, O
was O
induced O
by O
RA O
in O
a O
fashion O
obviously O
correlating O
with O
ICAM B
- I
3 I
up O
- O
regulation O
. O

Increased O
ICAM B
- I
3 I
expression O
was O
of O
functional O
significance O
, O
such O
that O
processes O
stimulated O
or O
co O
- O
stimulated O
via O
ICAM B
- I
3 I
( O
homotypic O
aggregation O
, O
IL O
- O
8 O
secretion O
) O
were O
clearly O
enhanced O
upon O
RA O
pretreatment O
, O
suggesting O
that O
RA O
may O
contribute O
via O
hitherto O
unrecognized O
pathways O
to O
immune O
function O
and O
host O
defense O
. O

Increased O
ICAM B
- I
3 I
expression O
was O
of O
functional O
significance O
, O
such O
that O
processes O
stimulated O
or O
co O
- O
stimulated O
via O
ICAM B
- I
3 I
( O
homotypic O
aggregation O
, O
IL O
- O
8 O
secretion O
) O
were O
clearly O
enhanced O
upon O
RA O
pretreatment O
, O
suggesting O
that O
RA O
may O
contribute O
via O
hitherto O
unrecognized O
pathways O
to O
immune O
function O
and O
host O
defense O
. O

The O
transcriptional O
events O
that O
control O
T O
cell O
tolerance O
to O
peripheral B
self I
Ags I
are O
still O
unknown O
. O

In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP B
- I
1 I
- O
and O
NF B
- I
kappa I
B I
- O
mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self B
Ag I
expressed O
exclusively O
on O
hepatocytes O
. O

In O
contrast O
to O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP B
- I
1 I
and O
high O
NF B
- I
kappa I
B I
transcriptional O
activity O
, O
the O
unresponsive O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
expressed O
no O
AP B
- I
1 I
and O
only O
weak O
NF B
- I
kappa I
B I
transcriptional O
activity O
. O

In O
contrast O
to O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP B
- I
1 I
and O
high O
NF B
- I
kappa I
B I
transcriptional O
activity O
, O
the O
unresponsive O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
expressed O
no O
AP B
- I
1 I
and O
only O
weak O
NF B
- I
kappa I
B I
transcriptional O
activity O
. O

We O
previously O
reported O
that O
ER O
- O
27191 O
( O
4 O
- O
[ O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
- O
hexahydro O
- O
7 O
, O
7 O
, O
10 O
, O
10 O
- O
tetramethyl O
- O
1 O
- O
( O
3 O
- O
pyridylmethyl O
) O
anthra O
[ O
1 O
, O
2 O
- O
b O
] O
pyrrol O
- O
3 O
- O
yl O
] O
benzoic O
acid O
) O
is O
a O
potent O
antagonist O
of O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
ER O
- O
35795 O
( O
( O
2E O
, O
4E O
, O
6E O
) O
- O
7 O
- O
[ O
1 O
- O
( O
1 O
- O
methylethyl O
) O
- O

8 O
- O
chloro O
- O
1 O
, O
2 O
, O
3 O
, O
4 O
- O
tetrahydroquinolin O
- O
6 O
- O
yl O
] O
- O
6 O
- O
fluoro O
- O
3 O
- O
methyl O
- O
2 O
, O
4 O
, O
6 O
- O
nonatrienoic O
acid O
) O
is O
a O
novel O
retinoid B
X I
receptor I
( O
RXR B
) O
- O
specific O
agonist O
. O

Targeting O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP B
- I
1 I
) O
into O
lipid O
rafts O
inhibits O
CD3 B
- O
induced O
T O
cell O
activation O
. O

To O
study O
the O
mechanism O
by O
which O
protein B
tyrosine I
phosphatases I
( O
PTPs B
) O
regulate O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B
in O
subdomains O
of O
plasma O
membrane O
. O

In O
Jurkat O
T O
cells O
, O
approximately O
5 O
- O
- O
10 O
% O
of O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP B
- I
1 I
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP B
- I
2 I
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

In O
Jurkat O
T O
cells O
, O
approximately O
5 O
- O
- O
10 O
% O
of O
Src B
homology I
2 I
domain I
- I
containing I
tyrosine I
phosphatase I
( O
SHP B
- I
1 I
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP B
- I
2 I
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP B
- I
1 I
into O
lipid O
rafts O
by O
using O
the O
N B
- I
terminal I
region I
of I
Lck I
( O
residues B
1 I
- I
- I
14 I
) O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck B
/ I
SHP I
- I
1 I
chimera I
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B
- O
induced O
tyrosine O
phosphorylation O
of O
CD3 B
zeta I
/ I
epsilon I
, O
IL O
- O
2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF B
- I
AT I
. O

An O
instructive O
component O
in O
T O
helper O
cell O
type O
2 O
( O
Th2 O
) O
development O
mediated O
by O
GATA B
- I
3 I
. O

Although O
interleukin B
( I
IL I
) I
- I
12 I
and O
IL B
- I
4 I
polarize O
naive O
CD4 O
( O
+ O
) O
T O
cells O
toward O
T O
helper O
cell O
type O
1 O
( O
Th1 O
) O
or O
Th2 O
phenotypes O
, O
it O
is O
not O
known O
whether O
cytokines B
instruct O
the O
developmental O
fate O
in O
uncommitted O
progenitors O
or O
select O
for O
outgrowth O
of O
cells O
that O
have O
stochastically O
committed O
to O
a O
particular O
fate O
. O

We O
observe O
IL B
- I
4 I
- O
dependent O
redirection O
of O
phenotype O
in O
cells O
that O
have O
already O
committed O
to O
a O
non O
- O
IL O
- O
4 O
- O
producing O
fate O
, O
inconsistent O
with O
predictions O
of O
the O
selective O
model O
. O

In O
vitro O
- O
activated O
human O
lupus O
T O
cells O
express O
normal O
estrogen B
receptor I
proteins I
which O
bind O
to O
the O
estrogen B
response I
element I
. O

In O
vitro O
- O
activated O
human O
lupus O
T O
cells O
express O
normal O
estrogen B
receptor I
proteins I
which O
bind O
to O
the O
estrogen B
response I
element I
. O

The O
value O
of O
TNFalpha B
and O
IL B
- I
10 I
in O
the O
culture O
medium O
of O
monocytes O
was O
measured O
and O
each O
mRNA O
expression O
was O
assayed O
. O

The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein B
kinase I
C I
( O
PKC B
) O
and O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
were O
also O
evaluated O
. O

GM O
decreased O
the O
TNFalpha B
production O
of O
LPS O
- O
stimulated O
monocytes O
as O
shown O
by O
the O
inhibition O
of O
mRNA O
expression O
and O
increased O
the O
IL B
- I
10 I
production O
of O
LPS O
- O
stimulated O
monocytes O
. O

Monocyte B
chemoattractant I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
is O
a O
potent O
chemokine B
that O
stimulates O
the O
migration O
of O
monocytes O
into O
the O
intima O
of O
the O
arterial O
wall O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
homocysteine O
on O
MCP B
- I
1 I
production O
in O
endothelial O
cells O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 B
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 B
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

The O
p38 B
MAP I
kinase I
as O
well O
as O
other O
members O
of O
the O
p38 O
MAP O
kinase O
pathway O
, O
including O
MKK3 B
, O
MKK6 B
, O
ATF B
- I
2 I
and O
Elk B
- I
1 I
, O
were O
activated O
in O
homocysteine O
- O
treated O
cells O
. O

Homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 B
MAP I
kinase I
inhibitor O
( O
SB203580 O
) O
suggesting O
that O
the O
p38 B
MAP I
kinase I
pathway O
might O
be O
involved O
in O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
. O

Homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 B
MAP I
kinase I
inhibitor O
( O
SB203580 O
) O
suggesting O
that O
the O
p38 B
MAP I
kinase I
pathway O
might O
be O
involved O
in O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
. O

Homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 B
MAP I
kinase I
inhibitor O
( O
SB203580 O
) O
suggesting O
that O
the O
p38 B
MAP I
kinase I
pathway O
might O
be O
involved O
in O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
. O

Homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 B
MAP I
kinase I
inhibitor O
( O
SB203580 O
) O
suggesting O
that O
the O
p38 B
MAP I
kinase I
pathway O
might O
be O
involved O
in O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
. O

In O
contrast O
, O
staurosporine O
, O
a O
protein B
kinase I
C I
inhibitor O
, O
had O
no O
effect O
on O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
. O

In O
contrast O
, O
staurosporine O
, O
a O
protein B
kinase I
C I
inhibitor O
, O
had O
no O
effect O
on O
homocysteine O
- O
induced O
MCP B
- I
1 I
expression O
. O

In O
conclusion O
, O
our O
results O
indicate O
that O
homocysteine O
stimulates O
MCP B
- I
1 I
expression O
in O
endothelial O
cells O
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B
( O
APO B
- I
1 I
, O
CD95 B
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B
expression O
and O
marked O
susceptibility O
to O
Fas B
- O
induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL O
- O
4R O
engagement O
, O
inhibits O
Fas B
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B
- O
resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B
- O
stimulated O
targets O
. O

Surface B
immunoglobulin I
and O
IL B
- I
4R I
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B
- O
resistance O
that O
differentially O
depend O
on O
PKC B
and O
STAT6 B
, O
respectively O
. O

Further O
, O
surface O
immunoglobulin O
signaling O
for O
inducible O
Fas B
- O
resistance O
bypasses O
Btk B
, O
requires O
NF B
- I
kappaB I
, O
and O
entails O
new O
macromolecular O
synthesis O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B
- O
resistance O
include O
the O
known O
anti B
- I
apoptotic I
gene I
products I
, O
Bcl B
- I
xL I
and O
FLIP B
, O
and O
a O
novel O
anti B
- I
apoptotic I
gene I
that O
encodes O
FAIM B
( O
Fas B
Apoptosis I
Inhibitory I
Molecule I
) O
. O

faim B
was O
identified O
by O
differential O
display O
and O
exists O
in O
two O
alternatively O
spliced O
forms O
; O
faim B
- I
S I
is O
broadly O
expressed O
, O
but O
faim O
- O
L O
expression O
is O
tissue O
- O
specific O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
( O
SDF1 B
alpha I
) O
and O
its O
cognate O
chemokine B
receptor I
CXCR4 I
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic O
progenitor O
cells O
and O
lymphocytes O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter B
gene I
construct I
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter B
gene I
construct I
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

AP B
- I
1 I
induction O
was O
dependent O
on O
the O
integrity O
of O
the O
ras O
/ O
Mek O
pathway O
indicating O
that O
this O
pathway O
was O
activated O
in O
the O
DP O
thymocytes O
. O

The O
goal O
of O
this O
study O
was O
to O
determine O
whether O
stimulation O
of O
T O
cells O
through O
CD2 B
recapitulates O
aspects O
of O
cytokine B
- O
induced O
T O
- O
cell O
activation O
by O
use O
of O
STAT B
transcription I
factors I
. O

MATERIALS O
AND O
METHODS O
: O
T O
cells O
were O
treated O
with O
anti B
- I
CD2 I
antibodies I
or O
cells O
bearing O
the O
natural O
CD2 B
ligand I
CD58 I
, O
after O
which O
signaling O
through O
STAT B
transcription I
factors I
was O
assessed O
. O

MATERIALS O
AND O
METHODS O
: O
T O
cells O
were O
treated O
with O
anti B
- I
CD2 I
antibodies I
or O
cells O
bearing O
the O
natural O
CD2 B
ligand I
CD58 I
, O
after O
which O
signaling O
through O
STAT B
transcription I
factors I
was O
assessed O
. O

Transcription O
of O
key O
target O
genes O
such O
as O
IRF1 B
and O
c B
- I
fos I
proceeds O
with O
delayed O
kinetics O
following O
CD2 O
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT O
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 O
ligation O
. O

CONCLUSION O
: O
Stimulation O
of O
T O
cells O
through O
cell B
- I
surface I
molecules I
such O
as O
CD2 B
involves O
activation O
of O
STAT B
transcription I
factors I
, O
thus O
recapitulating O
elements O
of O
cytokine O
signaling O
. O

NFAT B
transcription I
factors I
play O
critical O
roles O
in O
gene O
transcription O
during O
immune O
responses O
. O

To O
investigate O
further O
the O
two O
most O
prominent O
NFAT B
family I
members I
, O
NFATc1 B
and O
NFATc2 B
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O

Doubly O
deficient O
T O
cells O
displayed O
cell O
surface O
markers O
of O
activation O
yet O
were O
significantly O
deficient O
in O
the O
development O
of O
multiple O
effector O
functions O
, O
including O
Th B
cytokine I
production O
, O
surface B
effector I
molecule I
expression O
, O
and O
cytolytic O
activity O
. O

We O
show O
that O
dispersion O
of O
PML O
bodies O
by O
Z B
requires O
a O
portion O
of O
the O
transcriptional B
activation I
domain I
of O
Z B
but O
not O
the O
DNA O
- O
binding O
function O
. O

We O
also O
found O
that O
Z B
itself O
is O
SUMO O
- O
1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z B
competes O
with O
PML B
for O
limiting O
amounts O
of O
SUMO B
- I
1 I
. O

To O
elucidate O
whether O
troglitazone O
exerts O
an O
antiinflammatory O
effect O
in O
humans O
, O
in O
vivo O
, O
we O
investigated O
the O
suppression O
of O
nuclear B
factor I
kappaB I
( O
NFkappaB B
) O
in O
mononuclear O
cells O
( O
MNC O
) O
by O
this O
drug O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

Plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B
, O
sICAM B
, O
MCP B
- I
1 I
, O
PAI B
- I
1 I
, O
CRP B
, O
and O
IL B
- I
10 I
. O

Plasma O
TNF B
- I
alpha I
, O
sICAM B
- I
1 I
, O
MCP B
- I
1 I
, O
and O
PAI B
- I
1 I
concentrations O
fell O
significantly O
at O
week O
4 O
. O

Plasma O
TNF B
- I
alpha I
, O
sICAM B
- I
1 I
, O
MCP B
- I
1 I
, O
and O
PAI B
- I
1 I
concentrations O
fell O
significantly O
at O
week O
4 O
. O

Plasma O
TNF B
- I
alpha I
, O
sICAM B
- I
1 I
, O
MCP B
- I
1 I
, O
and O
PAI B
- I
1 I
concentrations O
fell O
significantly O
at O
week O
4 O
. O

Plasma O
TNF B
- I
alpha I
, O
sICAM B
- I
1 I
, O
MCP B
- I
1 I
, O
and O
PAI B
- I
1 I
concentrations O
fell O
significantly O
at O
week O
4 O
. O

Plasma O
IL B
- I
10 I
concentration O
increased O
significantly O
, O
whereas O
plasma B
CRP I
concentrations O
decreased O
. O

The O
involvement O
of O
the O
tyrosine B
kinases I
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases B
. O

These O
results O
show O
that O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine O
- O
dependent O
NF B
- I
kappa I
B I
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B
kinases I
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF B
- I
kappa I
B I
. O

Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
T O
cells O
, O
is O
an O
activator O
of O
NF B
- I
kappa I
B I
through O
tyrosine O
phosphorylation O
of O
I B
kappa I
B I
- I
alpha I
. O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

Our O
previous O
studies O
have O
implicated O
the O
nuclear O
transcription O
factor O
kappa O
B O
( O
NF B
kappa I
B I
) O
in O
the O
regulation O
of O
adhesion B
molecule I
expression O
in O
endothelial O
cells O
exposed O
to O
anoxia O
- O
reoxygenation O
( O
A O
/ O
R O
) O
or O
a O
redox O
imbalance O
. O

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein B

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein B

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B
kappa I
B I
activation O
by O
examining O
I O
kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B
in O
response O
to O
A O
/ O
R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B
, O
and O
E B
- I
selectin I
- O
mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B
tyrosine I
kinase I
( O
PTK B
) O
, O
protein B

tyrosine I
phosphatase I
( O
PTPase B
) O
and O
/ O
or O
protein B
kinase I
C I
( O
PKC B
) O
. O

The O
results O
demonstrate O
that O
both O
A O
/ O
R O
and O
redox O
imbalance O
led O
to O
I O
kappa O
B O
alpha O
degradation O
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 B
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF B
kappa I
B I
and O
subsequent O
nuclear O
translocation O
of O
the O
activated B
p65 I
subunit I
. O

The O
results O
demonstrate O
that O
both O
A O
/ O
R O
and O
redox O
imbalance O
led O
to O
I O
kappa O
B O
alpha O
degradation O
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 B
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF B
kappa I
B I
and O
subsequent O
nuclear O
translocation O
of O
the O
activated B
p65 I
subunit I
. O

Collectively O
, O
these O
findings O
indicate O
that O
A O
/ O
R O
- O
induced O
E O
- O
selectin O
expression O
and O
neutrophil O
- O
endothelial O
cell O
adhesion O
are O
mediated O
by O
both O
PKC B
and O
PTK B
, O
which O
signal O
rapid O
activation O
of O
NF B
kappa I
B I
. O

This O
A O
/ O
R O
- O
induced O
NF B
kappa I
B I
signaling O
response O
appears O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
intracellular O
redox O
imbalance O
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B
, O
TNF B
receptor I
1 I
or O
the O
aromatic B
hydrocarbon I
receptor I
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase B
- I
9 I
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B
, O
TNF B
receptor I
1 I
or O
the O
aromatic B
hydrocarbon I
receptor I
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase B
- I
9 I
. O

Apoptosis O
induced O
by O
DMA O
- O
2 O
, O
4 O
- O
D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B
, O
TNF B
receptor I
1 I
or O
the O
aromatic B
hydrocarbon I
receptor I
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase B
- I
9 I
. O

While O
an O
inhibitor O
of O
caspase B
- I
9 I
, O
as O
well O
as O
caspase B
- I
9 I
and O
caspase O
- O
3 O
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase B
- I
3 I
had O
a O
moderate O
inhibitory O
effect O
. O

While O
an O
inhibitor O
of O
caspase B
- I
9 I
, O
as O
well O
as O
caspase B
- I
9 I
and O
caspase O
- O
3 O
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase B
- I
3 I
had O
a O
moderate O
inhibitory O
effect O
. O

While O
an O
inhibitor O
of O
caspase B
- I
9 I
, O
as O
well O
as O
caspase B
- I
9 I
and O
caspase O
- O
3 O
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase B
- I
3 I
had O
a O
moderate O
inhibitory O
effect O
. O

Unlike O
Fas B
- O
mediated O
apoptosis O
, O
the O
initiator B
caspase I
, O
caspase B
- I
8 I
, O
was O
not O
involved O
in O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
. O

Transfection O
of O
Jurkat O
cells O
with O
Bcl B
- I
2 I
prevented O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
led O
to O
a O
complete O
blockage O
of O
apoptosis O
. O

Inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
mediated O
by O
SOCS1 B
. O

Interleukin B
6 I
( O
IL B
- I
6 I
) O
is O
a O
cytokine B
produced O
by O
immune O
and O
nonimmune O
cells O
and O
exhibits O
functional O
pleiotropy O
and O
redundancy O
. O

IL B
- I
6 I
plays O
an O
important O
role O
in O
the O
differentiation O
of O
several O
cell O
types O
. O

Here O
, O
we O
describe O
a O
novel O
function O
of O
IL B
- I
6 I
: O
the O
negative O
regulation O
of O
CD4 B
+ O
Th1 O
cell O
differentiation O
. O

While O
IL B
- I
6 I
- O
directed O
CD4 B
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL B
- I
4 I
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
independent O
of O
IL B
- I
4 I
. O

While O
IL B
- I
6 I
- O
directed O
CD4 B
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL B
- I
4 I
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
independent O
of O
IL B
- I
4 I
. O

While O
IL B
- I
6 I
- O
directed O
CD4 B
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL B
- I
4 I
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
independent O
of O
IL B
- I
4 I
. O

While O
IL B
- I
6 I
- O
directed O
CD4 B
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL B
- I
4 I
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL B
- I
6 I
is O
independent O
of O
IL B
- I
4 I
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Inhibition O
of O
IFNgamma B
receptor O
- O
mediated O
signals O
by O
IL B
- I
6 I
prevents O
autoregulation O
of O
IFNgamma B
gene I
expression O
by O
IFNgamma B
during O
CD4 O
+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Thus O
, O
IL B
- I
6 I
promotes O
CD4 B
+ O
Th2 O
differentiation O
and O
inhibits O
Th1 O
differentiation O
by O
two O
independent O
molecular O
mechanisms O
. O

Additionally O
, O
sequence O
variation O
at O
C B
/ I
EBP I
site I
I I
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B
nuclear I
factor I
kappa I
B I
site I
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B
transcription I
factor I
( O
ATF B
) O
/ O
cyclic B
AMP I
response I
element I
binding I
protein I
( O
CREB B
) O
, O
has O
been O
shown O
to O
affect O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
activity O
. O

First O
, O
low O
amounts O
of O
CREB B
- I
1 I
and O
C B
/ I
EBP I
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site O
consisting O
of O
a O
half O
site O
from O
both O
the O
ATF B
/ I
CREB I
and I
C I
/ I
EBP I
binding I
sites I
. O

First O
, O
low O
amounts O
of O
CREB B
- I
1 I
and O
C B
/ I
EBP I
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site O
consisting O
of O
a O
half O
site O
from O
both O
the O
ATF B
/ I
CREB I
and I
C I
/ I
EBP I
binding I
sites I
. O

In O
addition O
, O
CREB B
- I
1 I
homodimers I
bind O
to O
the O
ATF B
/ I
CREB I
site I
and O
recruit O
C B
/ I
EBP I
dimers I
to O
their O
cognate O
weak B
binding I
sites I
. O

This O
interaction O
is O
reciprocal O
, O
since O
C B
/ I
EBP I
dimer I
binding O
to O
a O
strong O
C B
/ I
EBP I
site I
leads O
to O
enhanced O
CREB B
- I
1 I
recruitment O
to O
ATF B
/ I
CREB I
sites I
that O
are O
weakly O
bound O
by O
CREB B
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF B
/ I
CREB I
binding I
site I
affected O
basal O
LTR B
activity O
as O
well O
as O
LTR B
function O
following O
interleukin B
- I
6 I
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C O
/ O
EBP O
activation O
. O

In O
contrast O
, O
ASA O
did O
not O
affect O
IL B
- I
13 I
, O
interferon B
- I
gamma I
, O
and O
IL B
- I
2 I
expression O
. O

In O
contrast O
, O
ASA O
did O
not O
affect O
IL B
- I
13 I
, O
interferon B
- I
gamma I
, O
and O
IL B
- I
2 I
expression O
. O

In O
contrast O
, O
ASA O
did O
not O
affect O
IL B
- I
13 I
, O
interferon B
- I
gamma I
, O
and O
IL B
- I
2 I
expression O
. O

ASA O
inhibited O
IL B
- I
4 I
, O
but O
not O
IL B
- I
2 I
, O
promoter O
- O
driven O
chloramphenicol O
acetyltransferase O
expression O
in O
transiently O
transfected O
Jurkat O
T O
cells O
. O

ASA O
inhibited O
IL B
- I
4 I
, O
but O
not O
IL B
- I
2 I
, O
promoter O
- O
driven O
chloramphenicol O
acetyltransferase O
expression O
in O
transiently O
transfected O
Jurkat O
T O
cells O
. O

The O
structurally O
unrelated O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
indomethacin O
and O
flurbiprofen O
did O
not O
affect O
cytokine O
gene O
expression O
in O
T O
cells O
, O
whereas O
the O
weak O
cyclo O
- O
oxygenase O
inhibitor O
salicylic O
acid O
was O
at O
least O
as O
effective O
as O
ASA O
in O
inhibiting O
IL B
- I
4 I
expression O
and O
promoter O
activity O
. O

It O
is O
concluded O
that O
anti O
- O
inflammatory O
salicylates O
, O
by O
means O
of O
a O
previously O
unrecognized O
mechanism O
of O
action O
, O
can O
influence O
the O
nature O
of O
adaptive O
immune O
responses O
by O
selectively O
inhibiting O
the O
expression O
of O
IL B
- I
4 I
, O
a O
critical O
effector O
of O
these O
responses O
, O
in O
CD4 O
+ O
T O
cells O
. O

Molecular O
and O
cellular O
mediators O
of O
interleukin B
- I
1 I
- O
dependent O
acute O
inflammatory O
arthritis O
. O

OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated B
bovine I
serum I
albumin I
( O
mBSA B
) O
and O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
. O

OBJECTIVE O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated B
bovine I
serum I
albumin I
( O
mBSA B
) O
and O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
. O

Flow O
cytometry O
and O
RNase O
protection O
were O
used O
to O
analyze O
IL B
- I
1 I
- O
dependent O
events O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

CONCLUSION O
: O
Arthritis O
induced O
by O
mBSA B
/ O
IL B
- I
1 I
is O
strain O
specific O
and O
dependent O
on O
CD4 O
+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB B
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody B
. O

IL B
- I
1 I
contributes O
to O
leukocyte O
recruitment O
to O
the O
synovium O
and O
directly O
induces O
chemokine O
mRNA O
production O
by O
synovial O
cells O
. O

This O
model O
of O
acute O
monarticular O
arthritis O
is O
particularly O
suitable O
for O
further O
investigations O
into O
cell O
- O
mediated O
immunity O
in O
arthritis O
and O
the O
role O
of O
IL B
- I
1 I
. O

Expression O
and O
function O
of O
a O
stem B
cell I
promoter I
for O
the O
murine B
CBFalpha2 I
gene I
: O
distinct O
roles O
and O
regulation O
in O
natural O
killer O
and O
T O
cell O
development O
. O

Expression O
and O
function O
of O
a O
stem B
cell I
promoter I
for O
the O
murine B
CBFalpha2 I
gene I
: O
distinct O
roles O
and O
regulation O
in O
natural O
killer O
and O
T O
cell O
development O
. O

Importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3 B
- I
K I
mediates O
the O
proliferation O
of O
infected O
B O
lymphocytes O
is O
through O
the O
induction O
of O
a O
granulocyte B
- I
monocyte I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
- O
dependent O
autocrine O
loop O
. O

Importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3 B
- I
K I
mediates O
the O
proliferation O
of O
infected O
B O
lymphocytes O
is O
through O
the O
induction O
of O
a O
granulocyte B
- I
monocyte I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
- O
dependent O
autocrine O
loop O
. O

PI3 B
- I
K I
induction O
of O
GM B
- I
CSF I
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3 B
- I
K I
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP B
- I
1 I
and O
NF B
- I
kappaB I
, O
which O
characterizes O
Theileria O
- O
infected O
leucocytes O
. O

PI3 B
- I
K I
induction O
of O
GM B
- I
CSF I
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3 B
- I
K I
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP B
- I
1 I
and O
NF B
- I
kappaB I
, O
which O
characterizes O
Theileria O
- O
infected O
leucocytes O
. O

PI3 B
- I
K I
induction O
of O
GM B
- I
CSF I
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3 B
- I
K I
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP B
- I
1 I
and O
NF B
- I
kappaB I
, O
which O
characterizes O
Theileria O
- O
infected O
leucocytes O
. O

PI3 B
- I
K I
induction O
of O
GM B
- I
CSF I
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3 B
- I
K I
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP B
- I
1 I
and O
NF B
- I
kappaB I
, O
which O
characterizes O
Theileria O
- O
infected O
leucocytes O
. O

PI3 B
- I
K I
induction O
of O
GM B
- I
CSF I
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3 B
- I
K I
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP B
- I
1 I
and O
NF B
- I
kappaB I
, O
which O
characterizes O
Theileria O
- O
infected O
leucocytes O
. O

Stimulation O
of O
B O
cells O
by O
surface B
immunoglobulin I
( O
sIg B
) O
triggering O
, O
or O
through O
the O
mitogenic O
combination O
of O
phorbol O
ester O
and O
calcium O
ionophore O
, O
is O
accompanied O
by O
activation O
of O
STAT B
transcription I
factors I
. O

In O
contrast O
, O
IL B
- I
10 I
alone O
appeared O
to O
account O
for O
STAT3 O
activation O
resulting O
from O
B O
cell O
stimulation O
with O
phorbol O
ester O
and O
calcium O
ionophore O
. O

In O
keeping O
with O
these O
results O
, O
soluble O
IL B
- I
6 I
and O
IL B
- I
10 I
were O
found O
in O
supernatant O
fluid O
obtained O
from O
stimulated O
B O
cells O
. O

In O
keeping O
with O
these O
results O
, O
soluble O
IL B
- I
6 I
and O
IL B
- I
10 I
were O
found O
in O
supernatant O
fluid O
obtained O
from O
stimulated O
B O
cells O
. O

However O
, O
other O
conserved B
sequence I
motifs I
, O
that O
differ O
between O
Ig B
variable I
gene I
families I
, O
are O
required O
for O
normal O
promoter O
function O
. O

One O
example O
is O
an O
E B
- I
box I
of O
the O
E47 B
/ I
E12 I
type I
( I
5 I
' I
- I
CAGCTG I
- I
3 I
' I
) I
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B
and I
murine I
Ig I
- I
kappa I
gene I
subgroups I
/ I
families I
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine B
families I
. O

Furthermore O
, O
AP B
- I
4 I
, O
unlike O
E47 B
, O
did O
not O
act O
as O
a O
transactivator B
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B
promoters I
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B
element I
has O
been O
mutated O
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5 B
' I
- I
CAGCTG I
- I
3 I
' I
motif I
among O
human B
and I
murine I
kappa I
promoters I
, O
we O
propose O
that O
AP B
- I
4 I
is O
the O
major B
ligand I
for O
Ig B
- I
kappa I
promoter I
E I
- I
boxes I
. O

Translocation O
of O
antigenic O
peptides O
into O
the O
cytosol O
of O
antigen O
presenting O
cells O
facilitates O
proteosomal O
processing O
and O
loading O
into O
Class B
I I
molecules I
for O
MHC O
presentation O
on O
the O
cell O
surface O
. O

The O
DNA B
binding I
domain I
of O
the O
Drosophila B
transcription I
factor I
( O
Antennapedia B
) O
, O
a O
60 B
amino I
acid I
protein I
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B
to O
enhance O
their O
immunogenicity O
. O

The O
DNA B
binding I
domain I
of O
the O
Drosophila B
transcription I
factor I
( O
Antennapedia B
) O
, O
a O
60 B
amino I
acid I
protein I
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B
to O
enhance O
their O
immunogenicity O
. O

The O
ability O
of O
the O
hybrid O
peptide O
to O
be O
processed O
and O
presented O
by O
APCs O
was O
similar O
, O
whether O
the O
SIINFEKL O
sequence O
was O
appended O
at O
the O
C B
- I
terminus I
or O
N B
- I
terminus I
of O
the O
Antennapedia O
peptide O
. O

The O
ability O
of O
the O
hybrid O
peptide O
to O
be O
processed O
and O
presented O
by O
APCs O
was O
similar O
, O
whether O
the O
SIINFEKL O
sequence O
was O
appended O
at O
the O
C B
- I
terminus I
or O
N B
- I
terminus I
of O
the O
Antennapedia O
peptide O
. O

Protein B
Kinase I
A I
( O
PKA B
) O
, O
a O
cAMP B
kinase I
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B
cytokine I
activity O
, O
was O
increased O
in O
EBV O
- O
CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

Additionally O
, O
IL O
- O
4 O
- O
mediated O
signal O
transduction O
and O
activation O
of O
transcription O
( O
STAT B
- I
6 I
) O
phosphorylation O
was O
slightly O
increased O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV O
- O
CTL O
generation O
, O
and O
TH2 B
associated O
PKA B
, O
CCR3 B
, O
and O
STAT B
- I
6 I
phosphorylation O
are O
enhanced O
by O
BMC O
. O

Reduction O
in O
DNA O
binding O
activity O
of O
the O
transcription B
factor I
Pax B
- I
5a I
in O
B O
lymphocytes O
of O
aged O
mice O
. O

The O
transcription B
factor I
Pax B
- I
5 I
is O
a O
key O
regulator O
of O
B O
cell O
development O
. O

Pax B
- I
5a I
/ I
B I
cell I
- I
specific I
activator I
protein I
and O
an O
alternatively B
spliced I
isoform I
, I
Pax I
- I
5d I
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation B
domain I
in O
Pax B
- I
5d I
. O

In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
protein O
was O
observed O
in O
aged O
B O
cells O
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax B
- I
5a I
and I
5d I
proteins O
were O
present O
in O
both O
age O
groups O
. O

In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
protein O
was O
observed O
in O
aged O
B O
cells O
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax B
- I
5a I
and I
5d I
proteins O
were O
present O
in O
both O
age O
groups O
. O

The O
observed O
decrease O
in O
Pax B
- I
5a I
binding O
activity O
correlated O
with O
changes O
in O
expression O
of O
two O
Pax B
- I
5 I
target I
genes I
in O
aged O
B O
cells O
. O

Expression O
of O
the O
Ig B
J I
chain I
and O
the O
secreted O
form O
of O
Ig B
mu I
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax B
- I
5a I
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Expression O
of O
the O
Ig B
J I
chain I
and O
the O
secreted O
form O
of O
Ig B
mu I
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax B
- I
5a I
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J B
chain I
, O
and O
secretion O
of O
IgM B

Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J B
chain I
, O
and O
secretion O
of O
IgM B

Proliferative O
responses O
of O
lymphoid O
cells O
to O
IL B
- I
2 I
and O
IL B
- I
4 I
depend O
on O
activation O
of O
the O
cells O
, O
but O
the O
mechanism O
( O
s O
) O
by O
which O
activation O
enhances O
cellular O
competence O
to O
respond O
to O
cytokines B
is O
not O
fully O
understood O
. O

Proliferative O
responses O
of O
lymphoid O
cells O
to O
IL B
- I
2 I
and O
IL B
- I
4 I
depend O
on O
activation O
of O
the O
cells O
, O
but O
the O
mechanism O
( O
s O
) O
by O
which O
activation O
enhances O
cellular O
competence O
to O
respond O
to O
cytokines B
is O
not O
fully O
understood O
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

However O
, O
transgenic O
cells O
exhibited O
a O
dramatic O
defect O
in O
Stat5A O
activation O
treatment O
with O
IL B
- I
2 I
, O
and O
a O
similar O
defect O
was O
observed O
for O
IL B
- I
4 I
- O
induced O
Stat5 B
. O

However O
, O
transgenic O
cells O
exhibited O
a O
dramatic O
defect O
in O
Stat5A O
activation O
treatment O
with O
IL B
- I
2 I
, O
and O
a O
similar O
defect O
was O
observed O
for O
IL B
- I
4 I
- O
induced O
Stat5 B
. O

In O
contrast O
, O
T O
lymphoid O
cells O
with O
inhibition O
of O
NF B
- I
kappaB I
showed O
normal O
insulin O
receptor O
substrate O
- O
2 O
phosphorylation O
and O
only O
a O
modest O
decrease O
in O
Stat6 O
activation O
and O
insulin O
receptor O
substrate O
- O
1 O
phosphorylation O
after O
IL O
- O
4 O
stimulation O
. O

Here O
we O
find O
that O
Egr2 B
and O
Egr3 B
are O
NFAT B
target I
genes I
. O

High O
glucose O
- O
induced O
intercellular B
adhesion I
molecule I
- I
1 I
( O
ICAM B
- I
1 I
) O
expression O
through O
an O
osmotic O
effect O
in O
rat O
mesangial O
cells O
is O
PKC O
- O
NF O
- O
kappa O
B O
- O
dependent O
. O

Up O
- O
regulation O
of O
ICAM B
- I
1 I
protein O
and O
mRNA O
was O
also O
found O
in O
IL B
- I
1 I
- I
beta I
and O
TNF B
- I
alpha I
- O
stimulated O
mesangial O
cells O
. O

Up O
- O
regulation O
of O
ICAM B
- I
1 I
protein O
and O
mRNA O
was O
also O
found O
in O
IL B
- I
1 I
- I
beta I
and O
TNF B
- I
alpha I
- O
stimulated O
mesangial O
cells O
. O

CONCLUSION O
/ O
INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B
adhesion I
molecule I
- I
1 I
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule O
- O
1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up O
- O
regulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B
kinase I
C I
nuclear B
factor I
- I
kappa I
B I
( O
PKC B
- O
NF B
- I
kappa I
B I
) O
pathway O
. O

Combined O
corticosteroid O
/ O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G B
- I
CSF I
: O
Activated O
glucocorticoid B
receptors I
synergize O
with O
G B
- I
CSF I
signals O
. O

Combined O
corticosteroid O
/ O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G B
- I
CSF I
: O
Activated O
glucocorticoid B
receptors I
synergize O
with O
G B
- I
CSF I
signals O
. O

Combined O
corticosteroid O
/ O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G B
- I
CSF I
: O
Activated O
glucocorticoid B
receptors I
synergize O
with O
G B
- I
CSF I
signals O
. O

More O
than O
90 O
% O
of O
patients O
with O
severe O
congenital O
neutropenia O
( O
SCN O
) O
respond O
to O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G B
- I
CSF I
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular B
domain I
of O
the O
G B
- I
CSF I
receptor I
( O
GCSF B
- I
R I
) O
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G B
- I
CSF I
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular B
domain I
of O
the O
G B
- I
CSF I
receptor I
( O
GCSF B
- I
R I
) O
. O

The O
in O
vitro O
effect O
of O
G B
- I
CSF I
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow O
mononuclear O
cells O
, O
by O
proliferation O
studies O
of O
the O
murine O
myeloid O
cell O
line O
32D O
expressing O
the O
patient O
' O
s O
mutated B
G I
- I
CSFR I
, O
and O
by O
measuring O
STAT5 O
activation O
in O
nuclear O
extracts O
from O
stimulated O
cells O
. O

Clonogenic O
assays O
of O
the O
patient O
' O
s O
marrow O
mononuclear O
cells O
incorporating O
either O
G B
- I
CSF I
or O
hydrocortisone O
produced O
little O
neutrophil O
growth O
. O

In O
contrast O
, O
inclusion O
of O
both O
G B
- I
CSF I
and O
hydrocortisone O
in O
the O
cytokine B
` I
` I
cocktail I
' I
' I
markedly O
increased O
the O
neutrophil O
numbers O
. O

Proliferation O
of O
32D O
cells O
expressing O
the O
mutated B
receptor I
and O
STAT5 O
activation O
were O
improved O
by O
a O
combination O
of O
G B
- I
CSF I
and O
dexamethasone O
. O

These O
data O
provide O
insight O
into O
SCN O
unresponsive O
to O
standard O
G B
- I
CSF I
treatment O
and O
to O
the O
potential O
corrective O
action O
of O
combined O
treatment O
with O
G B
- I
CSF I
and O
corticosteroids O
through O
synergistic O
activation O
of O
STAT5 B
. O

These O
data O
provide O
insight O
into O
SCN O
unresponsive O
to O
standard O
G B
- I
CSF I
treatment O
and O
to O
the O
potential O
corrective O
action O
of O
combined O
treatment O
with O
G B
- I
CSF I
and O
corticosteroids O
through O
synergistic O
activation O
of O
STAT5 B
. O

We O
have O
studied O
in O
cultured O
human O
mesangial O
cells O
( O
CHMC O
) O
several O
effects O
of O
9 O
- O
cis O
retinoic O
acid O
( O
9 O
- O
cRA O
) O
, O
an O
activator O
of O
both O
retinoic B
acid I
receptors I
( O
RARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
. O

We O
have O
studied O
in O
cultured O
human O
mesangial O
cells O
( O
CHMC O
) O
several O
effects O
of O
9 O
- O
cis O
retinoic O
acid O
( O
9 O
- O
cRA O
) O
, O
an O
activator O
of O
both O
retinoic B
acid I
receptors I
( O
RARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS O
- O
stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B
adhesion I
molecules I
, O
fibronectin B
and O
osteopontin B
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
and O
vascular B
adhesion I
molecule I
- I
1 I
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

Transcripts O
to O
RAR B
- I
alpha I
, O
RAR B
- I
beta I
and O
RXR B
- I
alpha I
increased O
after O
incubation O
with O
9 O
- O
cRA O
whereas O
RXR B
- I
gamma I
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B
and O
RXRs B
in O
9 O
- O
cRA O
- O
anti O
- O
inflammatory O
effects O
. O

Expression O
of O
mammalian B
defensin I
genes I
. O

CD3 B
/ I
CD28 I
- O
promoted O
CREB B
- O
CBP B
interaction O
was O
dependent O
on O
p38 B
mitogen I
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( I
CaMK I
) I
IV I
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal O
- O
regulated O
kinase O
pathway O
. O

Extracellular B
signal I
- I
regulated I
kinase I
, I
CaMKIV I
, O
and O
p38 B
MAPK I
were O
also O
the O
kinases O
involved O
in O
CREB B
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3 B
/ I
CD28 I
. O

The O
murine B
IL I
- I
2 I
promoter I
contains O
distal B
regulatory I
elements I
responsive O
to O
the O
Ah B
receptor I
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH B
- I
PAS I
transcription I
factor I
family I
. O

The O
minimal B
promoter I
necessary O
for O
this O
expression O
lies O
proximal O
, O
between O
- O
300 O
and O
the O
transcription B
start I
site I
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B
receptor I
( O
AHR B
) O
, O
a O
member O
of O
the O
bHLH B
- I
PAS I
family I
of I
transcription I
factors I
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL B
- I
2 I
in O
murine O
fetal O
thymocytes O
. O

We O
show O
here O
that O
these O
DNA B
motifs I
, O
the O
so O
- O
called O
dioxin B
response I
elements I
, O
after O
binding O
to O
the O
liganded B
AHR I
are O
sufficient O
to O
transactivate O
luciferase O
expression O
in O
a O
reporter O
gene O
system O
. O

Thus O
, O
the O
IL B
- I
2 I
promoter I
region I
contains O
novel O
distal B
regulatory I
elements I
that O
can O
be O
addressed O
by O
the O
AHR B
to O
induce O
IL B
- I
2 I
and O
can O
cooperate O
with O
the O
proximal B
promoter I

Thus O
, O
the O
IL B
- I
2 I
promoter I
region I
contains O
novel O
distal B
regulatory I
elements I
that O
can O
be O
addressed O
by O
the O
AHR B
to O
induce O
IL B
- I
2 I
and O
can O
cooperate O
with O
the O
proximal B
promoter I

Visualization O
of O
Syk B
- I
antigen I
receptor I
interactions O
using O
green B
fluorescent I
protein I
: O
differential O
roles O
for O
Syk B
and O
Lyn B
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

The O
cross O
- O
linking O
of O
the O
B B
cell I
Ag I
receptor I
( O
BCR B
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor O
- O
associated O
, O
protein B
tyrosine I
kinases I
of O
both O
the O
Src B
and I
Syk I
families I
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green B
fluorescent I
protein I
. O

Peptides O
representing O
potential O
epitope B
regions I
of O
the O
VP16 B
protein I
from O
HSV O
- O
2 O
were O
loaded O
onto O
recombinant B
DQ0602 I
molecules I
to O
generate O
a O
panel O
of O
Ag B
- I
specific I
DQ0602 I
tetramers I
. O

In O
contrast O
to O
the O
tumor O
cells O
( O
L O
& O
H O
cells O
) O
of O
lymphocyte O
predominant O
Hodgkin O
disease O
( O
LPHD O
) O
, O
Hodgkin O
and O
Reed O
- O
Sternberg O
( O
HRS O
) O
cells O
of O
classical O
Hodgkin O
disease O
( O
cHD O
) O
are O
unable O
to O
transcribe O
immunoglobulin B
, O
despite O
the O
presence O
of O
rearranged B
immunoglobulin I
genes I
. O

Furthermore O
, O
the O
reintroduction O
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
and O
Oct2 B
into O
cultured O
HRS O
cells O
restored O
the O
activity O
of O
cotransduced O
immunoglobulin B
promoter I
constructs I
. O

Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin B
V I
genes I
in O
cHD O
but O
is O
most O
likely O
due O
to O
a O
down O
- O
regulation O
of O
Oct2 B
and O
/ O
or O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
. O

Paraffin O
- O
embedded O
tissues O
from O
23 O
cutaneous O
lesions O
and O
a O
single O
lymph O
node O
biopsy O
from O
patients O
diagnosed O
with O
MF O
were O
evaluated O
for O
p65 O
( O
Rel O
A O
) O
expression O
by O
using O
a O
monoclonal B
mouse I
antibody I
that O
detects O
the O
activated O
form O
of O
p65 B
( I
Rel I
A I
) I
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

The O
binding B
complex I
induced O
by O
Tax B
in O
CTLL O
- O
2 O
contained O
JunD B
and O
Fra B
- I
2 I
. O

Activation O
of O
transcription O
through O
the O
AP B
- I
1 I
site I
in O
Jurkat O
cells O
by O
JunD B
and O
/ O
or O
Fra B
- I
2 I
was O
weak O
. O

c B
- I
Jun I
, O
JunB B
, O
and O
c B
- I
Fos I
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax B
. O

c B
- I
Jun I
, O
JunB B
, O
and O
c B
- I
Fos I
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax B
. O

OBJECTIVE O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF O
) O
on O
DNA O
binding O
activity O
of O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
the O
Mono O
Mac O
6 O
monocytic O
/ O
macrophage O
cell O
line O
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O

RESULTS O
: O
Induction O
of O
NF B
- I
kappaB I
DNA O
binding O
by O
the O
p65 B
( I
RelA I
) I
/ I
p50 I
heterodimer I
was O
observed O
in O
response O
to O
incubation O
of O
Mono O
Mac O
6 O
cells O
with O
SF O
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA O
, O
4 O
of O
5 O
with O
OA O
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O

Unexpectedly O
, O
a O
slowly O
migrating O
SF O
inducible O
NF B
- I
kappaB I
- O
binding O
complex O
was O
observed O
in O
EMSA O
of O
Mono O
Mac O
6 O
cells O
after O
incubation O
with O
SF O
from O
5 O
of O
8 O
RA O
and O
2 O
of O
5 O
OA O
subjects O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF B
- I
alpha I
or O
IL B
- I
6 I
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF B
- I
alpha I
, O
IL O
- O
1beta O
, O
TNF B
- I
alpha I
/ O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
platelet B
derived I
growth I
factor I
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

CONCLUSION O
: O
Biological O
activity O
of O
TNF B
- I
alpha I
in O
SF O
from O
RA O
and O
OA O
subjects O
is O
capable O
of O
inducing O
p65 B
/ I
p50 I
NF I
- I
kappaB I
DNA O
binding O
activity O
in O
macrophages O
. O

A O
property O
of O
SF O
that O
is O
independent O
of O
TNF B
- I
alpha I
and O
other O
cytokines B
is O
responsible O
for O
the O
induction O
of O
a O
novel O
slowly O
migrating O
NF B
- I
kappaB I
- I
binding I
complex I
. O

Only O
PPAR O
- O
gamma O
agonists O
( O
thiazolidinediones O
) O
, O
and O
not O
PPAR O
- O
alpha O
agonists O
, O
mimicked O
the O
effect O
of O
15d O
- O
PGJ O
( O
2 O
) O
on O
B O
- O
lineage O
cells O
, O
indicating O
that O
the O
mechanism O
by O
which O
15d O
- O
PGJ O
( O
2 O
) O
negatively O
affects O
B O
- O
lineage O
cells O
involves O
in O
part O
PPAR B
- I
gamma I
. O

To O
better O
define O
the O
role O
of O
ATF B
- I
2 I
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant B
ATF I
- I
2 I
protein I
were O
challenged O
with O
lipopolysaccharide O
( O
LPS O
) O
, O
anti B
- I
CD3 I
antibody I
or O
virus O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

Stimulation O
of O
T O
lymphocytes O
by O
anti B
- I
CD3 I
antibody I
also O
showed O
less O
induction O
of O
IL B
- I
1 I
and O
IL B
- I
6 I
in O
ATF O
- O
2 O
mutant O
tissues O
. O

Stimulation O
of O
T O
lymphocytes O
by O
anti B
- I
CD3 I
antibody I
also O
showed O
less O
induction O
of O
IL B
- I
1 I
and O
IL B
- I
6 I
in O
ATF O
- O
2 O
mutant O
tissues O
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti B
- I
CD3 I
antibody I
in O
vitro O
demonstrated O
reduced O
induction O
of O
c B
- I
Jun I
, O
JunB B
, O
JunD B
and O
Fra B
- I
2 I
. O

ATF O
- O
2 O
mutant O
thymocytes O
treated O
with O
anti B
- I
CD3 I
antibody I
in O
vitro O
demonstrated O
reduced O
induction O
of O
c B
- I
Jun I
, O
JunB B
, O
JunD B
and O
Fra B
- I
2 I
. O

ATF B
- I
2 I
is O
essential O
for O
maximal O
immediate O
induction O
of O
adhesion B
molecules I
and O
cytokine B
genes I
, O
but O
at O
later O
time O
points O
may O
even O
protect O
against O
overactive O
immune O
responses O
. O

LIGHT B
is O
a O
recently O
identified O
member O
of O
the O
TNF B
superfamily I
and O
its O
receptors O
, O
herpesvirus B
entry I
mediator I
and O
lymphotoxin B
beta I
receptor I
, O
are O
found O
in O
T O
cells O
and O
stromal O
cells O
. O

LIGHT B
is O
a O
recently O
identified O
member O
of O
the O
TNF B
superfamily I
and O
its O
receptors O
, O
herpesvirus B
entry I
mediator I
and O
lymphotoxin B
beta I
receptor I
, O
are O
found O
in O
T O
cells O
and O
stromal O
cells O
. O

Blockade O
of O
LIGHT B
by O
its O
soluble B
receptors I
, O
lymphotoxin B
beta I
receptor I
- I
Ig I
or O
HVEM B
- I
Ig I
, O
inhibits O
the O
induction O
of O
DC O
- O
mediated O
primary O
allogeneic O
T O
cell O
response O
. O

Furthermore O
, O
engagement O
of O
LIGHT B
costimulates O
human O
T O
cell O
proliferation O
, O
amplifies O
the O
NF O
- O
kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O

Furthermore O
, O
engagement O
of O
LIGHT B
costimulates O
human O
T O
cell O
proliferation O
, O
amplifies O
the O
NF O
- O
kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN B
- I
gamma I
, O
but O
not O
IL B
- I
4 I
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O

Activity O
of O
the O
distal B
region I
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long B
terminal I
repeat I
( O
LTR B
) O
, O
which O
contains O
binding B
sites I
for O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

To O
determine O
the O
biological O
relevance O
of O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
in O
HIV O
- O
1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant O
- O
negative O
mutant O
of O
Ets B
- I
1 I
( O
dnEts B
- I
1 I
) O
on O
HIV O
- O
1 O
infection O
of O
T O
cells O
. O

To O
determine O
the O
biological O
relevance O
of O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
in O
HIV O
- O
1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant O
- O
negative O
mutant O
of O
Ets B
- I
1 I
( O
dnEts B
- I
1 I
) O
on O
HIV O
- O
1 O
infection O
of O
T O
cells O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly B
active I
USF I
- I
1 I
/ I
Ets I
- I
1 I
complex I
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV O
- O
1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF B
- I
1 I
and O
Ets B
- I
1 I
with O
the O
HIV B
- I
1 I
LTR I
may O
provide O
a O
new O
target O
for O
anti O
- O
HIV O
- O
1 O
gene O
therapy O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly B
active I
USF I
- I
1 I
/ I
Ets I
- I
1 I
complex I
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV O
- O
1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF B
- I
1 I
and O
Ets B
- I
1 I
with O
the O
HIV B
- I
1 I
LTR I
may O
provide O
a O
new O
target O
for O
anti O
- O
HIV O
- O
1 O
gene O
therapy O
. O

A O
brief O
incubation O
with O
the O
T B
( I
H I
) I
2 I
cytokines I
IL B
- I
4 I
and O
IL B
- I
5 I
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc B
. O

A O
brief O
incubation O
with O
the O
T B
( I
H I
) I
2 I
cytokines I
IL B
- I
4 I
and O
IL B
- I
5 I
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc B
. O

BLyS B
BINDS O
TO O
B O
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES O
ACTIVATION O
OF O
THE O
TRANSCRIPTION B
FACTORS I
NF B
- I
kappaB I
AND O
ELF B
- I
1 I
. O

BLyS B
BINDS O
TO O
B O
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES O
ACTIVATION O
OF O
THE O
TRANSCRIPTION B
FACTORS I
NF B
- I
kappaB I
AND O
ELF B
- I
1 I
. O

B B
lymphocyte I
stimulator I
( O
BLyS B
) O
is O
a O
novel O
member O
of O
the O
TNF B
family I
of I
proteins I
expressed O
by O
myeloid O
cells O
as O
membrane O
- O
bound O
and O
soluble O
forms O
. O

Similar O
to O
other O
TNF B
family I
members I
, O
BLyS B
is O
present O
in O
solution O
as O
a O
homotrimer B
as O
determined O
by O
gel O
filtration O
chromatography O
and O
light O
scattering O
analysis O
. O

BLyS B
binding O
to O
B O
cells O
is O
specific O
as O
other O
TNF B
family I
members I
tested O
did O
not O
compete O
for O
( O
125 O
) O
I O
- O
BLyS B
binding O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

In O
addition O
we O
report O
that O
BLyS B
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF B
- I
kappaB I
and O
the O
Ets B
family I
transcription I
factor I
, O
ELF B
- I
1 I
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo B
- I
like I
kinase I
( O
PLK B
) O
. O

The O
Nef B
protein I
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell B
surface I
proteins I
, O
and O
associate O
with O
many O
intracellular B
proteins I
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O

It O
is O
composed O
of O
a O
fusion O
between O
full B
- I
length I
Nef I
and O
the O
estrogen B
receptor I
hormone I
- I
binding I
domain I
( O
Nef B
- I
ER I
) O
. O

The O
Nef B
- I
ER I
is O
kept O
in O
an O
inactive O
state O
due O
to O
steric O
hindrance O
, O
and O
addition O
of O
the O
membrane O
- O
permeable O
drug O
4 O
- O
hydroxytamoxifen O
( O
4 O
- O
HT O
) O
, O
which O
binds O
to O
the O
ER B
domain I
, O
leads O
to O
inducible O
activation O
of O
Nef B
- I
ER I
within O
cells O
. O

The O
Nef B
- I
ER I
is O
kept O
in O
an O
inactive O
state O
due O
to O
steric O
hindrance O
, O
and O
addition O
of O
the O
membrane O
- O
permeable O
drug O
4 O
- O
hydroxytamoxifen O
( O
4 O
- O
HT O
) O
, O
which O
binds O
to O
the O
ER B
domain I
, O
leads O
to O
inducible O
activation O
of O
Nef B
- I
ER I
within O
cells O
. O

We O
demonstrate O
that O
Nef B
- I
ER I
inducibly O
associates O
with O
the O
62 B
- I
kDa I
Ser I
/ I
Thr I
kinase I
and O
is O
localized O
to O
specific O
membrane O
microdomains O
( O
lipid O
rafts O
) O
only O
after O
activation O
. O

Using O
this O
inducible O
Nef B
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 B
and O
HLA B
- I
A2 I
downmodulation O
in O
a O
SupT1 O
T O
- O
cell O
line O
. O

Half O
- O
maximal O
downmodulation O
of O
cell B
surface I
CD4 I
required O
very O
little O
active O
Nef B
- I
ER I
and O
occurred O
as O
early O
as O
4 O
h O
after O
addition O
of O
4 O
- O
HT O
. O

Half O
- O
maximal O
downmodulation O
of O
cell B
surface I
CD4 I
required O
very O
little O
active O
Nef B
- I
ER I
and O
occurred O
as O
early O
as O
4 O
h O
after O
addition O
of O
4 O
- O
HT O
. O

In O
contrast O
, O
50 O
% O
downmodulation O
of O
HLA B
- I
A2 I
by O
Nef B
required O
16 O
to O
24 O
h O
and O
about O
50 O
- O
to O
100 O
- O
fold O
- O
greater O
concentrations O
of O
4 O
- O
HT O
. O

These O
data O
suggest O
that O
HLA B
- I
A2 I
downmodulation O
may O
require O
certain O
threshold O
levels O
of O
active O
Nef B
. O

The O
differential O
timing O
of O
CD4 B
and O
HLA B
- I
A2 I
downmodulation O
may O
have O
implications O
for O
HIV O
pathogenesis O
and O
immune O
evasion O
. O

Since O
MIP B
- I
2 I
is O
a O
potent O
PMN O
chemoattractant O
and O
MIP B
- I
1alpha I
is O
a O
potent O
macrophage O
/ O
monocyte O
chemoattractant O
has O
been O
well O
known O
. O

Since O
MIP B
- I
2 I
is O
a O
potent O
PMN O
chemoattractant O
and O
MIP B
- I
1alpha I
is O
a O
potent O
macrophage O
/ O
monocyte O
chemoattractant O
has O
been O
well O
known O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP O
- O
2 O
mRNA O
expression O
, O
suggesting O
that O
MIP B
- I
2 I
is O
involved O
in O
the O
development O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP B
- I
1alpha I
mRNA I
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP B
- I
1alpha I
, O
adherent O
to O
the O
lining O
surface O
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP O
- O
2 O
mRNA O
expression O
, O
suggesting O
that O
MIP B
- I
2 I
is O
involved O
in O
the O
development O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP B
- I
1alpha I
mRNA I
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP B
- I
1alpha I
, O
adherent O
to O
the O
lining O
surface O
of O
the O
airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

The O
promotor B
region I
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

The O
promotor B
region I
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

The O
promotor B
region I
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF B
- I
kappaB I
, O
not O
AP B
- I
1 I
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP B
- I
2 I
mRNA I
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF B
- I
kappaB I
, O
not O
AP B
- I
1 I
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP B
- I
2 I
mRNA I
. O

p65 B
( I
Rel I
A I
) I
and O
p50 B
protein I
appears O
to O
be O
involved O
in O
MIP O
- O
2 O
NF B
- I
kappaB I
binding O
. O

Taken O
together O
, O
our O
studies O
suggest O
that O
MIP B
- I
2 I
is O
an O
important O
mediator O
of O
NaVO3 O
- O
induced O
pulmonary O
inflammation O
in O
the O
rat O
model O
. O

In O
addition O
, O
elevated O
MIP B
- I
2 I
mRNA I
levels O
are O
accompanied O
by O
increased O
NF B
- I
kappaB I
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP B
- I
2 I
transcriptional O
regulation O
through O
NF B
- I
kappaB I
. O

In O
addition O
, O
elevated O
MIP B
- I
2 I
mRNA I
levels O
are O
accompanied O
by O
increased O
NF B
- I
kappaB I
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP B
- I
2 I
transcriptional O
regulation O
through O
NF B
- I
kappaB I
. O

In O
addition O
, O
elevated O
MIP B
- I
2 I
mRNA I
levels O
are O
accompanied O
by O
increased O
NF B
- I
kappaB I
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP B
- I
2 I
transcriptional O
regulation O
through O
NF B
- I
kappaB I
. O

In O
this O
study O
we O
analysed O
the O
induction O
of O
factors O
involved O
in O
cytokine O
signal O
transduction O
, O
such O
as O
STAT B
1 I
proteins I
and O
IRF B
- I
1 I
mRNA I
, O
in O
normal O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
exposed O
to O
HIV O
- O
infected O
cells O
, O
and O
the O
induction O
of O
apoptosis O
. O

This O
effect O
was O
prevented O
by O
neutralizing O
antibodies O
against O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
. O

This O
effect O
was O
prevented O
by O
neutralizing O
antibodies O
against O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B
against O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B
against O
IFN B
- I
gamma I
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B
against O
tumour B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B
against O
IFN B
- I
gamma I
. O

All O
these O
findings O
suggest O
that O
uninfected O
PBMC O
can O
undergo O
activation O
of O
signal O
transduction O
and O
apoptosis O
after O
exposure O
to O
bystander O
HIV O
- O
infected O
cells O
, O
subsequent O
to O
the O
induction O
of O
cytokines B
such O
as O
IFNs B
and O
TNF B
- I
alpha I
. O

We O
investigated O
the O
role O
of O
protein B
kinase I
C I
theta I
( O
PKCtheta B
) O
in O
the O
activation O
of O
the O
NF B
- I
kappaB I
cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

Expression O
of O
dominant B
- I
active I
PKCtheta I
also O
had O
stimulatory O
effects O
on O
the O
CD28 B
response I
element I
of O
the O
IL B
- I
2 I
promoter I
. O

T O
- O
cell O
- O
mediated O
regulation O
of O
osteoclastogenesis O
by O
signalling O
cross O
- O
talk O
between O
RANKL B
and O
IFN B
- I
gamma I
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

This O
inhibition O
of O
osteoclastogenesis O
is O
rescued O
by O
overexpressing O
TRAF6 B
in O
precursor O
cells O
, O
which O
indicates O
that O
TRAF6 B
is O
the O
target O
critical O
for O
the O
IFN B
- I
gamma I
action O
. O

Furthermore O
, O
we O
provide O
evidence O
that O
the O
accelerated O
degradation O
of O
TRAF6 B
requires O
both O
its O
ubiquitination O
, O
which O
is O
initiated O
by O
RANKL B
, O
and O
IFN B
- I
gamma I
- O
induced O
activation O
of O
the O
ubiquitin O
- O
proteasome O
system O
. O

Our O
study O
shows O
that O
there O
is O
cross O
- O
talk O
between O
the O
tumour B
necrosis I
factor I
and O
IFN B
families I
of O
cytokines B
, O
through O
which O
IFN B
- I
gamma I
provides O
a O
negative O
link O
between O
T O
- O
cell O
activation O
and O
bone O
resorption O
. O

Our O
study O
shows O
that O
there O
is O
cross O
- O
talk O
between O
the O
tumour B
necrosis I
factor I
and O
IFN B
families I
of O
cytokines B
, O
through O
which O
IFN B
- I
gamma I
provides O
a O
negative O
link O
between O
T O
- O
cell O
activation O
and O
bone O
resorption O
. O

The O
role O
of O
the O
chemokine B
binding O
stromal B
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B
( O
TPO B
) O
have O
not O
been O
determined O
. O

In O
this O
study O
it O
was O
found O
that O
SDF B
- I
1 I
, O
unlike O
TPO B
, O
does O
not O
stimulate O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cell O
proliferation O
or O
differentiation O
or O
have O
an O
antiapoptotic O
effect O
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl B
- I
inositol I
3 I
- I
kinase I
( O
PI B
- I
3K I
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP B
- I
9 I
and O
VEGF B
, O
the O
inhibition O
of O
MAPK B
p42 I
/ I
44 I
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl B
- I
inositol I
3 I
- I
kinase I
( O
PI B
- I
3K I
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP B
- I
9 I
and O
VEGF B
, O
the O
inhibition O
of O
MAPK B
p42 I
/ I
44 I
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Accordingly O
, O
PI B
- I
3K I
is O
involved O
in O
TPO B
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen B
and O
vitronectin B
, O
and O
SDF B
- I
1 I
- O
mediated O
migration O
. O

Accordingly O
, O
PI B
- I
3K I
is O
involved O
in O
TPO B
- O
mediated O
inhibition O
of O
apoptosis O
, O
TPO O
- O
and O
SDF O
- O
1 O
- O
regulated O
adhesion O
to O
fibrinogen B
and O
vitronectin B
, O
and O
SDF B
- I
1 I
- O
mediated O
migration O
. O

This O
study O
expands O
the O
understanding O
of O
the O
role O
of O
SDF B
- I
1 I
and O
TPO B
in O
normal O
human O
megakaryopoiesis O
and O
indicates O
the O
molecular O
basis O
of O
the O
observed O
differences O
in O
cellular O
responses O
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL B
- I
6 I
gene I
trascription I
factors I
( O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
) O
and O
IL O
- O
6 O
gene O
expression O
: O
role O
of O
alpha3beta1 B
and I
alpha6beta4 I
integrins I
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL B
- I
6 I
gene I
trascription I
factors I
( O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
) O
and O
IL O
- O
6 O
gene O
expression O
: O
role O
of O
alpha3beta1 B
and I
alpha6beta4 I
integrins I
. O

In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
gene B
transcription I
factors I
and O
enhanced O
IL O
- O
6 O
production O
. O

In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
gene B
transcription I
factors I
and O
enhanced O
IL O
- O
6 O
production O
. O

In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL6 I
gene B
transcription I
factors I
and O
enhanced O
IL O
- O
6 O
production O
. O

Identification O
and O
characterization O
of O
SKAT B
- I
2 I
, O
a O
novel O
Th2 B
- I
specific I
zinc I
finger I
gene I
. O

We O
have O
identified O
a O
novel O
Kruppel B
- I
type I
zinc I
finger I
( I
ZF I
) I
gene I
, O
SKAT B
- I
2 I
, O
which O
is O
selectively O
expressed O
by O
murine O
Th2 O
cells O
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2 O
- O
type O
ZF O
tandemly O
arrayed O
at O
its O
C B
terminus I
and O
N B
- I
terminal I
SCAN B
box I
and O
KRAB B
domains I
. O

SKAT B
- I
2 I
is O
tissue O
restricted O
in O
expression O
at O
the O
RNA O
level O
, O
detectable O
only O
in O
brain O
and O
at O
low O
levels O
in O
kidney O
and O
spleen O
and O
few O
hematopoietic O
cell O
lines O
. O

By O
in O
situ O
hybridization O
, O
SKAT B
- I
2 I
expression O
was O
found O
to O
peak O
in O
antigen O
- O
stimulated O
CD4 O
( O
+ O
) O
T O
cells O
after O
2 O
- O
3 O
days O
of O
culture O
under O
Th2 O
but O
not O
Th1 O
biasing O
conditions O
. O

This O
pattern O
of O
expression O
closely O
mirrored O
that O
of O
GATA B
- I
3 I
in O
the O
same O
cells O
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
/ O
ionomycin O
- O
stimulated O
EL4 O
cells O
, O
SKAT B
- I
2 I
was O
found O
to O
up O
- O
regulate O
the O
activity O
of O
the O
IL B
- I
4 I
but I
not I
the I
IL I
- I
5 I
promoter I
, O
contrasting O
with O
the O
ability O
of O
GATA B
- I
3 I
to O
activate O
both O
promoters B
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
/ O
ionomycin O
- O
stimulated O
EL4 O
cells O
, O
SKAT B
- I
2 I
was O
found O
to O
up O
- O
regulate O
the O
activity O
of O
the O
IL B
- I
4 I
but I
not I
the I
IL I
- I
5 I
promoter I
, O
contrasting O
with O
the O
ability O
of O
GATA B
- I
3 I
to O
activate O
both O
promoters B
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT B
- I
2 I
, O
thus O
SKAT B
- I
2 I
is O
a O
novel O
Th2 B
- I
specific I
gene I
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine B
genes I
in O
T O
cells O
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT B
- I
2 I
, O
thus O
SKAT B
- I
2 I
is O
a O
novel O
Th2 B
- I
specific I
gene I
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine B
genes I
in O
T O
cells O
. O

hsp70 B
interacting I
protein I
Hip I
does O
not O
affect O
glucocorticoid B
receptor I
folding O
by O
the O
hsp90 O
- O
based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG B
- I
1 I
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

In O
the O
five O
- O
protein O
system O
, O
Hip B
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B
co I
- I
chaperone I
BAG I
- I
1 I
, O
and O
cotransfection O
of O
Hip B
with O
BAG B
- I
1 I
opposes O
BAG B
- I
1 I
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

We O
conclude O
that O
Hip B
is O
not O
a O
component O
of O
the O
assembly O
machinery O
but O
that O
it O
could O
play O
a O
regulatory O
role O
in O
opposition O
to O
BAG B
- I
1 I
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

We O
previously O
showed O
that O
Tax B
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
at O
the O
mRNA O
level O
in O
T O
cells O
. O

Our O
present O
results O
suggest O
that O
activation O
of O
AP B
- I
1 I
occurs O
through O
Tax O
- O
dependent O
and O
- O
independent O
mechanisms O
in O
HTLV O
- O
1 O
- O
infected O
T O
cells O
, O
which O
may O
play O
some O
roles O
in O
dysregulated O
phenotypes O
of O
HTLV O
- O
1 O
- O
infected O
cells O
. O

In O
addition O
, O
caspase B
- I
3 I
, O
an O
executioner O
of O
apoptosis O
, O
was O
activated O
and O
its O
substrate O
, O
poly B
( I
ADP I
- I
ribose I
) I
polymerase I
( O
PARP B
) O
, O
was O
cleaved O
during O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
- O
induced O
apoptosis O
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

In O
contrast O
, O
when O
these O
cells O
were O
cultured O
in O
IL B
- I
3 I
, O
higher O
levels O
of O
these O
adhesion B
molecules I
were O
detected O
. O

In O
contrast O
when O
the O
Raf O
- O
responsive O
cells O
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM B
- I
CSF I
, O
in O
the O
absence O
of O
deltaRaf B
: I
ER I
activation O
, O
increased O
levels O
of O
the O
CD11b B
and I
CD18 I
molecules I
were O
detected O
. O

In O
contrast O
when O
the O
Raf O
- O
responsive O
cells O
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM B
- I
CSF I
, O
in O
the O
absence O
of O
deltaRaf B
: I
ER I
activation O
, O
increased O
levels O
of O
the O
CD11b B
and I
CD18 I
molecules I
were O
detected O
. O

Retinoic O
acid O
( O
RA O
) O
inhibited O
3H O
- O
thymidine O
incorporation O
in O
response O
to O
GM B
- I
CSF I
. O

Cyclic O
AMP O
activates O
p38 B
mitogen I
- I
activated I
protein I
kinase I
in O
Th2 O
cells O
: O
phosphorylation O
of O
GATA B
- I
3 I
and O
stimulation O
of O
Th2 O
cytokine O
gene O
expression O
. O

Elevation O
of O
intracellular O
cAMP O
in O
T O
cells O
, O
induced O
by O
agents O
such O
as O
IL B
- I
1alpha I
or O
PGs B
, O
inhibits O
T O
cell O
activation O
. O

Here O
we O
report O
that O
cAMP O
- O
induced O
effects O
in O
Th2 O
cells O
occur O
independently O
of O
the O
protein B
kinase I
A I
pathway O
, O
which O
is O
the O
major O
mediator O
of O
cAMP O
- O
induced O
signaling O
events O
in O
most O
cell O
types O
. O

We O
show O
that O
in O
Th2 O
cells O
, O
cAMP O
promotes O
the O
production O
of O
both O
IL B
- I
5 I
and O
IL B
- I
13 I
, O
which O
play O
distinct O
but O
critical O
roles O
in O
asthma O
pathogenesis O
. O

We O
show O
that O
in O
Th2 O
cells O
, O
cAMP O
promotes O
the O
production O
of O
both O
IL B
- I
5 I
and O
IL B
- I
13 I
, O
which O
play O
distinct O
but O
critical O
roles O
in O
asthma O
pathogenesis O
. O

Thus O
, O
Th2 O
- O
specific O
GATA B
- I
3 I
expression O
and O
p38 B
mitogen I
- I
activated I
protein I
kinase I
activation O
together O
provide O
a O
molecular O
basis O
for O
the O
differential O
effects O
of O
cAMP O
in O
the O
two O
T O
helper O
cell O
subsets O
. O

Characterization O
of O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
dependent O
on O
the O
human B
IL I
- I
13 I
receptor I
alpha I
chain I
1 I
: O
redundancy O
of O
requirement O
of O
tyrosine O
residue O
for O
STAT3 O
activation O
. O

Characterization O
of O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
dependent O
on O
the O
human B
IL I
- I
13 I
receptor I
alpha I
chain I
1 I
: O
redundancy O
of O
requirement O
of O
tyrosine O
residue O
for O
STAT3 O
activation O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
are O
pleiotropic B
cytokines I
whose O
biological O
activities O
overlap O
with O
each O
other O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
are O
pleiotropic B
cytokines I
whose O
biological O
activities O
overlap O
with O
each O
other O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human B
IL I
- I
13R I
alpha I
1 I
, O
and O
analyzed O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
using O
an O
IL B
- I
13R I
alpha I
1 I
- O
transfected O
human O
B O
cell O
line O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human B
IL I
- I
13R I
alpha I
1 I
, O
and O
analyzed O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
using O
an O
IL B
- I
13R I
alpha I
1 I
- O
transfected O
human O
B O
cell O
line O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

Expression O
of O
IL B
- I
13R I
alpha I
1 I
evoked O
STAT3 B
activation O
by O
IL B
- I
4 I
and O
IL B
- I
13 I
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL B
- I
13R I
alpha I
1 I
was O
highly O
expressed O
, O
IL B
- I
4 I
and O
IL B
- I
13 I
induced O
STAT3 B
activation O
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 B
. O

These O
results O
suggest O
that O
STAT3 B
activation O
is O
involved O
with O
IL B
- I
4 I
and O
IL B
- I
13 I
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL B
- I
13R I
alpha I
1 I
to O
activate O
STAT3 B
. O

We O
recently O
reported O
that O
tyrphostin O
AG O
- O
490 O
selectively O
blocked O
IL O
- O
2 O
activation O
of O
Jak3 B
/ I
Stat5 I
and O
growth O
of O
murine O
T O
cell O
lines O
. O

In O
contrast O
, O
AG O
- O
490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50 B
/ I
p65 I
components I
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
activated O
by O
the O
HTLV B
- I
1 I
- I
encoded I
phosphoprotein I
, I
Tax I
. O

Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
induced O
B O
- O
cell O
growth O
transformation O
, O
a O
central O
feature O
of O
the O
virus O
' O
strategy O
for O
colonizing O
the O
human O
B O
- O
cell O
system O
, O
requires O
full O
virus O
latent O
gene O
expression O
and O
is O
initiated O
by O
transcription O
from O
the O
viral B
promoter I
Wp I
. O

In O
reporter O
assays O
with O
mutant B
Wp I
constructs I
, O
the O
loss O
of O
factor O
binding O
to O
any O
one O
of O
these O
sites O
severely O
impaired O
promoter O
activity O
in O
B O
cells O
, O
while O
the O
wild B
- I
type I
promoter I
could O
be O
activated O
in O
non O
- O
B O
cells O
by O
ectopic O
BSAP O
expression O
. O

We O
show O
here O
that O
the O
other O
Lck B
- I
binding I
domain I
, O
residues O
104 O
- O
113 O
, O
binds O
to O
the O
carboxyl B
- I
terminal I
half I
of O
Lck B
and O
that O
this O
binding O
does O
not O
require O
the O
Lck B
SH3 I
domain I
. O

The O
transient O
expression O
of O
Tip B
in O
T O
cells O
was O
found O
to O
stimulate O
both O
Stat3 B
- O
dependent O
and O
NF B
- I
AT I
- O
dependent O
transcription O
. O

In O
contrast O
, O
ablation O
of O
either O
Lck B
- I
binding I
domain I
abolished O
the O
ability O
of O
Tip B
to O
stimulate O
NF B
- I
AT I
- O
dependent O
transcription O
. O

The O
expression O
of O
constitutively O
active O
MAP B
/ I
ERK I
kinase I
kinase I
1 I
( O
MEKK1 B
) O
inhibited O
RXRE O
- O
dependent O
transcription O
, O
whereas O
dominant B
negative I
MEKK1 I
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK B
signaling O
pathways O
in O
the O
process O
. O

In O
contrast O
, O
expression O
of O
constitutively B
active I
MEK1 I
, O
which O
activates O
ERK B
pathway O
, O
enhanced O
RXRE O
- O
dependent O
activation O
. O

The O
proteasome B
regulates O
receptor O
- O
mediated O
endocytosis O
of O
interleukin B
- I
2 I
. O

Recent O
studies O
have O
increasingly O
implicated O
the O
proteasome B
in O
the O
regulation O
of O
cell B
surface I
receptors I
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Therefore O
, O
a O
functional O
proteasome B
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL B
- I
2R I
/ I
ligand I
complex I
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL B
- I
2 I
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O

OBJECTIVE O
: O
The O
transcription B
factor I
NF I
- I
E2 I
, O
a O
heterodimeric B
protein I
complex I
composed O
of O
p45 B
and O
small O
Maf B
family I
proteins I
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

OBJECTIVE O
: O
The O
transcription B
factor I
NF I
- I
E2 I
, O
a O
heterodimeric B
protein I
complex I
composed O
of O
p45 B
and O
small O
Maf B
family I
proteins I
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

MATERIALS O
AND O
METHODS O
: O
Human B
p45 I
mRNAs I
have O
two O
alternative O
isoforms O
, O
aNF B
- I
E2 I
and O
fNF B
- I
E2 I
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative B
promoters I
. O

MATERIALS O
AND O
METHODS O
: O
Human B
p45 I
mRNAs I
have O
two O
alternative O
isoforms O
, O
aNF B
- I
E2 I
and O
fNF B
- I
E2 I
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative B
promoters I
. O

MATERIALS O
AND O
METHODS O
: O
Human B
p45 I
mRNAs I
have O
two O
alternative O
isoforms O
, O
aNF B
- I
E2 I
and O
fNF B
- I
E2 I
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative B
promoters I
. O

Although O
both O
isomers O
were O
expressed O
in O
human O
erythroid O
- O
megakaryocytic O
cell O
lines O
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF B
- I
E2 I
, O
suggesting O
that O
fNF B
- I
E2 I
promoter I
is O
more O
erythroid O
specific O
. O

Functional O
analysis O
of O
fNF B
- I
E2 I
promoter I
showed O
that O
the O
promoter O
is O
active O
only O
in O
erythroid O
- O
megakaryocytic O
cells O
and O
that O
the O
double B
GATA I
sit I
e O
in O
the O
proximal O
region O
is O
necessary O
for O
its O
efficient O
activity O
. O

OBJECTIVE O
: O
Tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
induces O
a O
variety O
of O
cellular O
responses O
, O
some O
of O
them O
being O
at O
least O
seemingly O
contradictory O
. O

Thus O
, O
we O
set O
out O
to O
find O
differences O
in O
the O
modes O
of O
proliferative O
and O
apoptotic O
responses O
to O
TNF B
- I
alpha I
. O

MATERIALS O
AND O
METHODS O
: O
We O
screened O
a O
panel O
of O
acute O
myeloid O
leukemia O
- O
derived O
cell O
lines O
for O
TNF B
- I
alpha I
- O
responsiveness O
. O

In O
two O
lines O
( O
OCI O
- O
AML O
- O
1 O
, O
OCI O
- O
AML O
- O
11 O
) O
, O
TNF B
- I
alpha I
acted O
as O
an O
apoptotic O
agent O
; O
in O
others O
( O
HU O
- O
3 O
, O
M O
- O
07e O
, O
TF O
- O
1 O
) O
, O
it O
had O
the O
opposite O
effect O
, O
preventing O
apoptosis O
and O
inducing O
proliferation O
. O

Direct O
and O
indirect O
signaling O
mechanisms O
, O
including O
NF B
- I
kappaB I
activation O
and O
cytokine O
synthesis O
, O
were O
analyzed O
. O

RESULTS O
: O
All O
cell O
lines O
tested O
expressed O
TNF B
- I
alpha I
receptors I
I I
and I
II I
and O
responded O
to O
TNF B
- I
alpha I
by O
upregulation O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

In O
contrast O
to O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
TNF B
- I
alpha I
did O
not O
activate O
the O
MAP B
kinase I
and O
p70S6 O
kinase O
pathways O
. O

In O
contrast O
to O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
TNF B
- I
alpha I
did O
not O
activate O
the O
MAP B
kinase I
and O
p70S6 O
kinase O
pathways O
. O

Nevertheless O
, O
inhibitors O
of O
these O
pathways O
clearly O
reduced O
the O
TNF B
- I
alpha I
- O
induced O
cell O
growth O
, O
indicating O
that O
TNF O
- O
alpha O
- O
proliferative O
cells O
produced O
a O
growth O
factor O
that O
induced O
proliferation O
upon O
stimulation O
of O
the O
above O
pathways O
. O

Anti B
- I
GM I
- I
CSF I
antibodies I
inhibited O
the O
TNF B
- I
alpha I
- O
induced O
growth O
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM B
- I
CSF I
. O

Anti B
- I
GM I
- I
CSF I
antibodies I
inhibited O
the O
TNF B
- I
alpha I
- O
induced O
growth O
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM B
- I
CSF I
. O

Supporting O
this O
notion O
, O
TNF B
- I
alpha I
- O
induced O
upregulation O
of O
GM B
- I
CSF I
mRNA I
levels O
and O
protein O
secretion O
in O
the O
TNF B
- I
alpha I
- O
proliferative O
, O
but O
not O
in O
the O
TNF O
- O
alpha O
- O
apoptotic O
cell O
lines O
. O

Supporting O
this O
notion O
, O
TNF B
- I
alpha I
- O
induced O
upregulation O
of O
GM B
- I
CSF I
mRNA I
levels O
and O
protein O
secretion O
in O
the O
TNF B
- I
alpha I
- O
proliferative O
, O
but O
not O
in O
the O
TNF O
- O
alpha O
- O
apoptotic O
cell O
lines O
. O

CONCLUSION O
: O
These O
data O
identify O
GM B
- I
CSF I
synthesis O
as O
an O
early O
and O
essential O
step O
in O
TNF O
- O
alpha O
- O
induced O
proliferation O
. O

We O
show O
for O
the O
first O
time O
that O
TNF O
- O
alpha O
- O
treated O
cell O
lines O
producing O
no O
or O
only O
minimal O
amounts O
of O
GM B
- I
CSF I
demonstrate O
an O
apoptotic O
phenotype O
, O
while O
cell O
lines O
with O
high O
GM B
- I
CSF I
expression O
rates O
can O
escape O
from O
growth O
arrest O
or O
even O
apoptosis O
. O

We O
show O
for O
the O
first O
time O
that O
TNF O
- O
alpha O
- O
treated O
cell O
lines O
producing O
no O
or O
only O
minimal O
amounts O
of O
GM B
- I
CSF I
demonstrate O
an O
apoptotic O
phenotype O
, O
while O
cell O
lines O
with O
high O
GM B
- I
CSF I
expression O
rates O
can O
escape O
from O
growth O
arrest O
or O
even O
apoptosis O
. O

In O
this O
context O
, O
we O
discuss O
arguments O
pointing O
at O
NF B
- I
kappaB I
as O
regulator O
of O
GM B
- I
CSF I
synthesis O
and O
thus O
indirectly O
as O
regulator O
for O
the O
escape O
of O
TNF B
- I
alpha I
- O
induced O
apoptosis O

In O
this O
context O
, O
we O
discuss O
arguments O
pointing O
at O
NF B
- I
kappaB I
as O
regulator O
of O
GM B
- I
CSF I
synthesis O
and O
thus O
indirectly O
as O
regulator O
for O
the O
escape O
of O
TNF B
- I
alpha I
- O
induced O
apoptosis O

In O
this O
context O
, O
we O
discuss O
arguments O
pointing O
at O
NF B
- I
kappaB I
as O
regulator O
of O
GM B
- I
CSF I
synthesis O
and O
thus O
indirectly O
as O
regulator O
for O
the O
escape O
of O
TNF B
- I
alpha I
- O
induced O
apoptosis O

Synovium O
, O
obtained O
from O
knee O
joints O
of O
rheumatoid O
patients O
undergoing O
surgery O
, O
was O
incubated O
with O
clostridiopeptidase B
A I
and O
trypsin B
- I
EDTA I
to O
obtain O
cell O
suspensions O
. O

We O
concluded O
from O
this O
, O
that O
one O
or O
more O
of O
the O
cell O
types O
present O
in O
synovial O
tissue O
contain O
a O
specific B
steroid I
receptor I
, O
but O
that O
this O
is O
lacking O
in O
synovial O
fluid O
polymorphonuclear O
leucocytes O
. O

Csk B
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B
family I
kinases I
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum B
response I
element I
and O
Fyn O
- O
mediated O
enhancement O
of O
IL B
- I
2 I
promoter I
activity O
. O

Csk B
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B
family I
kinases I
, O
down O
- O
regulated O
Fyn O
- O
and O
Lck O
- O
mediated O
stimulation O
of O
the O
serum B
response I
element I
and O
Fyn O
- O
mediated O
enhancement O
of O
IL B
- I
2 I
promoter I
activity O
. O

As O
with O
the O
prototypical O
NF B
- I
kappa I
B I
p50 I
- I
p65 I
heterodimer I
, O
this O
novel O
p65 B
homodimeric I
form I
of O
NF B
- I
kappa I
B I
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear O
compartment O
following O
cellular O
stimulation O
. O

Site O
- O
directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein B
kinase I
A I
( O
RRPS B
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91 O
- O
amino O
- O
acid O
segment O
of O
the O
Rel B
homology I
domain I
that O
mediates O
self O
- O
association O
. O

Site O
- O
directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein B
kinase I
A I
( O
RRPS B
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91 O
- O
amino O
- O
acid O
segment O
of O
the O
Rel B
homology I
domain I
that O
mediates O
self O
- O
association O
. O

Effects O
of O
IL B
- I
4 I
and O
Fc B
gamma I
receptor I
II I
engagement O
on O
Egr B
- I
1 I
expression O
during O
stimulation O
of O
B O
lymphocytes O
by O
membrane O
immunoglobulin O
crosslinking O
. O

Effects O
of O
IL B
- I
4 I
and O
Fc B
gamma I
receptor I
II I
engagement O
on O
Egr B
- I
1 I
expression O
during O
stimulation O
of O
B O
lymphocytes O
by O
membrane O
immunoglobulin O
crosslinking O
. O

Egr B
- I
1 I
is O
an O
immediate B
early I
gene I
that O
is O
rapidly O
upregulated O
in O
response O
to O
mitogenic O
signals O
induced O
by O
antigen O
receptor O
crosslinking O
on O
murine O
B O
lymphocytes O
. O

Egr B
- I
1 I
is O
an O
immediate B
early I
gene I
that O
is O
rapidly O
upregulated O
in O
response O
to O
mitogenic O
signals O
induced O
by O
antigen O
receptor O
crosslinking O
on O
murine O
B O
lymphocytes O
. O

It O
has O
been O
shown O
that O
levels O
of O
Egr B
- I
1 I
expression O
are O
closely O
correlated O
with O
B O
cell O
proliferation O
in O
several O
models O
of O
B O
cell O
activation O
and O
tolerance O
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

However O
, O
the O
correlation O
between O
Egr O
- O
1 O
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL B
- I
4 I
is O
added O
as O
a O
co O
- O
mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG B
anti I
- I
Ig I
or O
submitogenic O
concentrations O
of O
Fab B
' I
2 I
anti I
- I
Ig I
. O

No O
corresponding O
increases O
in O
Egr B
- I
1 I
mRNA I
levels O
are O
observed O
when O
IL B
- I
4 I
is O
added O
. O

Therefore O
, O
IL B
- I
4 I
overcomes O
Fc O
receptor O
- O
mediated O
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr B
- I
1 I
mRNA I
induction O
, O
as O
demonstrated O
earlier O
for O
c B
- I
myc I
mRNA I
in O
this O
system O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
, O
a O
cytokine B
with O
pleiotropic O
biological O
effects O
, O
is O
produced O
by O
a O
variety O
of O
cell O
types O
in O
response O
to O
induction O
by O
diverse O
stimuli O
. O

In O
this O
paper O
, O
TNF B
- I
alpha I
mRNA I
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine O
T O
cell O
clone O
by O
stimulation O
with O
T B
cell I
receptor I
( O
TCR B
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

Nevertheless O
, O
gel O
retardation O
analysis O
indicated O
that O
the O
AP B
- I
1 I
activity O
detected O
in O
untreated O
cells O
was O
drastically O
reduced O
during O
the O
commitment O
stage O
of O
DMSO O
- O
induced O
HL O
- O
60 O
differentiation O
towards O
granulocytes O
. O

Treatment O
of O
HL O
- O
60 O
cells O
with O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
, O
another O
monocytic O
differentiation O
agent O
, O
induced O
a O
weak O
, O
but O
appreciable O
, O
increase O
in O
AP B
- I
1 I
activity O
. O

In O
contrast O
, O
when O
HL O
- O
60 O
cells O
were O
treated O
with O
retinoic O
acid O
, O
a O
granulocytic O
differentiation O
inducer O
, O
no O
enhanced O
AP O
- O
1 O
binding O
activity O
was O
observed O
, O
and O
only O
a O
weak O
increase O
in O
jun B
D I
mRNA I
level O
was O
detected O
. O

These O
data O
indicate O
that O
formation O
of O
AP B
- I
1 I
is O
not O
required O
for O
the O
induction O
of O
HL O
- O
60 O
differentiation O
towards O
granulocytes O
, O
whereas O
induction O
of O
monocytic O
differentiation O
is O
correlated O
with O
an O
increase O
in O
AP B
- I
1 I
activity O
. O

These O
data O
indicate O
that O
formation O
of O
AP B
- I
1 I
is O
not O
required O
for O
the O
induction O
of O
HL O
- O
60 O
differentiation O
towards O
granulocytes O
, O
whereas O
induction O
of O
monocytic O
differentiation O
is O
correlated O
with O
an O
increase O
in O
AP B
- I
1 I
activity O
. O

The O
differential O
expression O
of O
AP B
- I
1 I
activity O
may O
be O
critical O
in O
the O
differentiation O
of O
HL O
- O
60 O
cells O
towards O
monocytic O
or O
granulocytic O
lineages O

Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs B
alpha I
, O
Gi B
alpha I
1 I
, O
and O
p21ras B
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O

Stimulation O
probably O
was O
mediated O
by O
CLE0 B
- I
binding I
proteins I
because O
depletion O
of O
these O
proteins O
specifically O
reduced O
GM B
- I
CSF I
transcription O
. O

One O
of O
the O
binding B
factors I
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription B
factor I
AP1 I
. O

By O
using O
a O
reporter O
- O
based O
expression O
approach O
, O
a O
T B
- I
cell I
- I
specific I
enhancer I
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T B
- I
cell I
- I
restricted I
hypersensitive I
sites I
in O
the O
last O
intron O
of O
the O
CD8 B
alpha I
gene I
. O

DNA O
sequence O
analysis O
of O
the O
minimal B
enhancer I
revealed O
a O
striking O
cluster O
of O
consensus B
binding I
sites I
for O
Ets B
- I
1 I
, I
TCF I
- I
1 I
, I
CRE I
, I
GATA I
- I
3 I
, I
LyF I
- I
1 I
, I
and I
bHLH I
proteins I
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
addition O
, O
the O
5 B
' I
end I
of O
the O
enhancer B
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA B
- I
3 I
, I
bHLH I
, I
and I
LyF I
- I
1 I
binding I
sites I
. O

Comparison O
of O
the O
CD8 B
alpha I
enhancer I
with O
other O
recently O
identified O
T B
- I
cell I
- I
specific I
regulatory I
elements I
suggests O
that O
a O
common O
set O
of O
transcription B
factors I
regulates O
several O
T B
- I
cell I
genes I
. O

Interleukin B
3 I
( O
IL B
- I
3 I
) O
is O
a O
hematopoietic B
stem I
- I
cell I
growth I
and I
differentiation I
factor I
that O
is O
expressed O
solely O
in O
activated O
T O
and O
NK O
cells O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

Combination O
IL B
- I
2 I
and O
IL B
- I
4 I
reduces O
glucocorticoid O
receptor O
- O
binding O
affinity O
and O
T O
cell O
response O
to O
glucocorticoids O
. O

Combination O
IL B
- I
2 I
and O
IL B
- I
4 I
reduces O
glucocorticoid O
receptor O
- O
binding O
affinity O
and O
T O
cell O
response O
to O
glucocorticoids O
. O

We O
examined O
the O
possibility O
that O
certain O
cytokines O
, O
specifically O
IL B
- I
2 I
and O
IL B
- I
4 I
, O
could O
affect O
T O
cell O
response O
to O
glucocorticoids O
. O

We O
examined O
the O
possibility O
that O
certain O
cytokines O
, O
specifically O
IL B
- I
2 I
and O
IL B
- I
4 I
, O
could O
affect O
T O
cell O
response O
to O
glucocorticoids O
. O

PBMC O
from O
normal O
donors O
incubated O
for O
48 O
h O
in O
the O
presence O
of O
combination O
IL B
- I
2 I
+ O
IL B
- I
4 I
had O
nuclear O
GR O
with O
significantly O
reduced O
binding O
affinity O
( O
GR O
Kd O
= O
36 O
. O
1 O
+ O
/ O
- O
1 O
. O
63 O
nM O
, O
mean O
+ O
/ O
- O
SEM O
; O
p O
= O
0 O
. O
0001 O
) O
as O
compared O
with O
PBMC O
incubated O
with O
medium O
alone O
( O
GR O
Kd O
= O
6 O
. O
74 O
+ O
/ O
- O
0 O
. O
46 O
nM O
) O
. O

PBMC O
from O
normal O
donors O
incubated O
for O
48 O
h O
in O
the O
presence O
of O
combination O
IL B
- I
2 I
+ O
IL B
- I
4 I
had O
nuclear O
GR O
with O
significantly O
reduced O
binding O
affinity O
( O
GR O
Kd O
= O
36 O
. O
1 O
+ O
/ O
- O
1 O
. O
63 O
nM O
, O
mean O
+ O
/ O
- O
SEM O
; O
p O
= O
0 O
. O
0001 O
) O
as O
compared O
with O
PBMC O
incubated O
with O
medium O
alone O
( O
GR O
Kd O
= O
6 O
. O
74 O
+ O
/ O
- O
0 O
. O
46 O
nM O
) O
. O

However O
, O
when O
PBMC O
were O
incubated O
with O
IL B
- I
2 I
alone O
or O
IL B
- I
4 I
alone O
, O
no O
change O
in O
GR O
- O
binding O
affinity O
was O
observed O
. O

However O
, O
when O
PBMC O
were O
incubated O
with O
IL B
- I
2 I
alone O
or O
IL B
- I
4 I
alone O
, O
no O
change O
in O
GR O
- O
binding O
affinity O
was O
observed O
. O

More O
importantly O
, O
the O
alteration O
in O
PBMC O
GR O
- O
binding O
affinity O
with O
IL B
- I
2 I
+ O
IL B
- I
4 I
was O
associated O
with O
a O
functional O
change O
in O
T O
cell O
response O
to O
methylprednisolone O
MPN O
, O
i O
. O
e O
. O
, O
a O
reduced O
inhibitory O
effect O
of O
MPN O
on O
PMA O
/ O
ionomycin O
- O
induced O
T O
cell O
proliferation O
. O

More O
importantly O
, O
the O
alteration O
in O
PBMC O
GR O
- O
binding O
affinity O
with O
IL B
- I
2 I
+ O
IL B
- I
4 I
was O
associated O
with O
a O
functional O
change O
in O
T O
cell O
response O
to O
methylprednisolone O
MPN O
, O
i O
. O
e O
. O
, O
a O
reduced O
inhibitory O
effect O
of O
MPN O
on O
PMA O
/ O
ionomycin O
- O
induced O
T O
cell O
proliferation O
. O

These O
effects O
of O
IL B
- I
2 I
+ O
IL B
- I
4 I
on O
PBMC O
GR B
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co O
- O
incubation O
with O
IFN B
- I
gamma I
. O

These O
effects O
of O
IL B
- I
2 I
+ O
IL B
- I
4 I
on O
PBMC O
GR B
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co O
- O
incubation O
with O
IFN B
- I
gamma I
. O

These O
effects O
of O
IL B
- I
2 I
+ O
IL B
- I
4 I
on O
PBMC O
GR B
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co O
- O
incubation O
with O
IFN B
- I
gamma I
. O

The O
altered O
PBMC O
GR O
binding O
from O
patients O
with O
SR O
asthma O
reversed O
to O
normal O
when O
incubated O
with O
medium O
alone O
, O
but O
was O
sustained O
with O
IL B
- I
2 I
+ O
IL B
- I
4 I
. O

The O
altered O
PBMC O
GR O
binding O
from O
patients O
with O
SR O
asthma O
reversed O
to O
normal O
when O
incubated O
with O
medium O
alone O
, O
but O
was O
sustained O
with O
IL B
- I
2 I
+ O
IL B
- I
4 I
. O

Furthermore O
, O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
4 I
were O
blocked O
by O
IFN B
- I
gamma I
. O

Furthermore O
, O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
4 I
were O
blocked O
by O
IFN B
- I
gamma I
. O

Furthermore O
, O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
4 I
were O
blocked O
by O
IFN B
- I
gamma I
. O

We O
analyzed O
the O
5 B
' I
transcription I
control I
sequences I
of O
the O
human B
CD4 I
gene I
. O

We O
located O
the O
transcription B
initiation I
site I
and O
showed O
that O
the O
CD4 B
core I
promoter I
( O
positions B
- I
40 I
to I
+ I
16 I
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator B
positioning I
consensus I
sequence I
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B
virus I
40 I
enhancer I
. O

We O
located O
the O
transcription B
initiation I
site I
and O
showed O
that O
the O
CD4 B
core I
promoter I
( O
positions B
- I
40 I
to I
+ I
16 I
) O
lacks O
a O
classical O
` O
` O
TATA O
' O
' O
or O
initiator B
positioning I
consensus I
sequence I
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B
virus I
40 I
enhancer I
. O

The O
transcriptional O
activity O
of O
the O
CD4 B
gene I
promoter I
correlated O
with O
CD4 O
expression O
in O
various O
cell O
types O
. O

Interestingly O
, O
the O
CD4 B
core I
promoter I
also O
displayed O
a O
tissue O
- O
specific O
transcriptional O
activity O
. O

Within O
this O
fragment O
, O
three O
nucleic O
acid O
sequences O
are O
completely O
conserved O
in O
the O
murine B
CD4 I
gene I
. O

Another O
ETS B
consensus I
sequence I
is O
located O
1060 O
nt O
upstream O
. O

Moreover O
, O
in O
CD4 O
- O
cells O
, O
overexpression O
of O
Ets B
- I
1 I
or O
Ets B
- I
2 I
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B
promoter I
and O
core B
promoter I
. O

Moreover O
, O
in O
CD4 O
- O
cells O
, O
overexpression O
of O
Ets B
- I
1 I
or O
Ets B
- I
2 I
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B
promoter I
and O
core B
promoter I
. O

These O
data O
indicate O
that O
Ets B
transcription I
factors I
play O
a O
central O
role O
in O
controlling O
CD4 O
gene O
expression O
, O
by O
binding O
to O
both O
a O
classical B
remote I
site I
and O
an O
unusual O
proximal B
activator I
sequence I

These O
data O
indicate O
that O
Ets B
transcription I
factors I
play O
a O
central O
role O
in O
controlling O
CD4 O
gene O
expression O
, O
by O
binding O
to O
both O
a O
classical B
remote I
site I
and O
an O
unusual O
proximal B
activator I
sequence I

Although O
glucocorticoids O
are O
not O
cytolytic O
for O
and O
do O
not O
inhibit O
the O
growth O
of O
the O
IM O
- O
9 O
line O
of O
cultured O
human O
lymphoblasts O
, O
these O
cells O
have O
a O
high O
steroid O
- O
binding O
capacity O
. O

We O
have O
used O
IM O
- O
9 O
cells O
in O
order O
to O
examine O
whether O
unoccupied B
glucocorticoid I
receptors I
are O
inactivated O
and O
activated O
in O
intact O
cells O
. O

The O
leukocyte O
migration O
inhibition O
response O
to O
certain O
breast B
cancer I
- I
related I
antigens I
( O
MCF B
- I
7 I
and O
MuMTV B
) O
: O
their O
potential O
as O
discriminants O
. O

In O
a O
paired O
- O
antigen O
study O
using O
MuMTV B
and O
MCF B
- I
7 I
, O
75 O
% O
of O
the O
breast O
cancer O
patients O
responded O
, O
versus O
18 O
% O
of O
the O
normal O
women O
( O
P O
less O
than O
0 O
. O
0050 O
) O
. O

The O
overall O
responses O
to O
MuMTV B
and O
MCF B
- I
7 I
were O
analyzed O
with O
reference O
to O
certain O
prognostic O
factors O
, O
but O
showed O
no O
relation O
to O
age O
, O
menstrual O
status O
, O
estrogen O
receptor O
status O
, O
or O
stage O
of O
disease O
. O

The O
above O
reactions O
suggest O
that O
a O
large O
proportion O
of O
breast O
cancer O
patients O
exhibit O
presensitization O
to O
antigenfs O
found O
in O
MuMTV B
and O
MCF B
- I
7 I
, O
which O
may O
be O
cross O
- O
reactive O
with O
antigens O
in O
the O
primary O
cancer O
. O

The O
human B
TNF I
promoter I
contains O
four O
potential O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
- I
binding I
sites I
, O
with O
the O
strongest O
binding O
seen O
for O
the O
- O
605 O
motif O
. O

Nuclear O
extracts O
from O
unstimulated O
cells O
of O
the O
human O
monocytic O
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific B
binding I
protein I
( O
complex B
II I
) O
, O
consistent O
with O
a O
constitutive B
p50 I
homodimer I
. O

Nuclear O
extracts O
from O
unstimulated O
cells O
of O
the O
human O
monocytic O
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific B
binding I
protein I
( O
complex B
II I
) O
, O
consistent O
with O
a O
constitutive B
p50 I
homodimer I
. O

Binding O
activity O
of O
other O
nuclear B
factors I
that O
recognize O
the O
SP O
- O
1 O
and O
c O
/ O
EBP O
motifs O
of O
the O
human B
TNF I
promoter I
is O
not O
affected O
by O
such O
treatment O
. O

Comparing O
regions O
of O
the O
Epstein B
- I
Barr I
virus I
ZEBRA I
protein I
which O
function O
as O
transcriptional B
activating I
sequences I
in O
Saccharomyces O
cerevisiae O
and O
in O
B O
cells O
. O

Two O
of O
the O
three O
regions O
of O
the O
native O
ZEBRA B
protein I
act O
together O
to O
mediate O
activation O
when O
assayed O
on O
ZEBRA B
binding I
sites I
. O

However O
, O
when O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL B
4 O
and O
assayed O
on O
GAL4 B
binding I
sites I
, O
regions B
YII I
and I
YIII I
were O
each O
sufficient O
to O
confer O
activation O
in O
S O
. O
cerevisiae O
. O

However O
, O
when O
fused O
to O
the O
DNA B
binding I
domain I
of O
GAL B
4 O
and O
assayed O
on O
GAL4 B
binding I
sites I
, O
regions B
YII I
and I
YIII I
were O
each O
sufficient O
to O
confer O
activation O
in O
S O
. O
cerevisiae O
. O

Thus O
, O
the O
behavior O
of O
ZEBRA B
in O
human O
B O
cells O
and O
S O
. O
cerevisiae O
suggests O
that O
the O
protein O
contains O
universal B
activation I
motifs I
that O
interact O
with O
conserved O
components O
of O
the O
transcription O
machinery O
. O

Functional O
interaction O
of O
the O
v B
- I
Rel I
and I
c I
- I
Rel I
oncoproteins I
with O
the O
TATA B
- I
binding I
protein I
and O
association O
with O
transcription B
factor I
IIB I
. O

Rel B
family I
proteins I
regulate O
the O
expression O
of O
genes O
linked O
to O
kappa O
B O
- O
binding O
motifs O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

We O
also O
demonstrate O
that O
TPB B
interaction O
with O
Rel B
activation I
regions I
leads O
to O
synergistic O
activation O
of O
transcription O
of O
a O
kappa B
B I
- I
linked I
reporter I
gene I
. O

Combined O
with O
the O
observation O
that O
the O
mouse B
c I
- I
Rel I
and I
human I
RelA I
proteins I
also O
interact O
with O
TBP B
and O
TFIIB B
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B
transcription I
factors I
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B
family I
proteins I
. O

Combined O
with O
the O
observation O
that O
the O
mouse B
c I
- I
Rel I
and I
human I
RelA I
proteins I
also O
interact O
with O
TBP B
and O
TFIIB B
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B
transcription I
factors I
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B
family I
proteins I
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine B
nucleotide I
binding I
protein I
, O
p21ras B
, O
which O
is O
coupled O
to O
the O
TCR B
by O
a O
protein B
tyrosine I
kinase I
dependent O
mechanism O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

Here O
we O
show O
that O
, O
as O
in O
chickens O
, O
multiple O
members O
of O
the O
GATA B
factor I
family I
are O
expressed O
in O
human O
and O
murine O
erythroid O
cells O
. O

During O
the O
early O
stages O
of O
chicken O
embryogenesis O
( O
well O
before O
blood O
island O
formation O
) O
, O
each O
of O
the O
GATA B
family I
members I
is O
transcribed O
with O
a O
unique O
temporal O
and O
spatial O
pattern O
. O

In O
the O
primitive O
erythroid O
lineage O
, O
transcription O
of O
the O
embryonic B
epsilon I
- I
globin I
gene I
parallels O
GATA O
- O
1 O
expression O
while O
the O
switch O
to O
beta O
- O
globin O
transcription O
in O
definitive O
erythroid O
cells O
is O
directly O
preceded O
by O
a O
pronounced O
increase O
in O
GATA B
- I
3 I
accumulation O
. O

Molecular O
regulation O
of O
human B
interleukin I
2 I
and O
T O
- O
cell O
function O
by O
interleukin B
4 I
. O

The O
two O
major O
types O
and O
their O
principal O
products O
, O
interleukin B
4 I
and O
interferon B
gamma I
( O
IL B
- I
4 I
and O
IFN B
- I
gamma I
) O
, O
are O
reciprocally O
negatively O
interactive O
. O

The O
two O
major O
types O
and O
their O
principal O
products O
, O
interleukin B
4 I
and O
interferon B
gamma I
( O
IL B
- I
4 I
and O
IFN B
- I
gamma I
) O
, O
are O
reciprocally O
negatively O
interactive O
. O

To O
analyze O
the O
molecular O
mechanism O
of O
IL O
- O
4 O
- O
mediated O
suppression O
of O
cell O
- O
mediated O
immunity O
we O
studied O
its O
effects O
on O
expression O
of O
interleukin B
2 I
( O
IL B
- I
2 I
) O
and O
IFN B
- I
gamma I
. O

To O
analyze O
the O
molecular O
mechanism O
of O
IL O
- O
4 O
- O
mediated O
suppression O
of O
cell O
- O
mediated O
immunity O
we O
studied O
its O
effects O
on O
expression O
of O
interleukin B
2 I
( O
IL B
- I
2 I
) O
and O
IFN B
- I
gamma I
. O

IL B
- I
4 I
pretreatment O
of O
Jurkat O
cells O
prior O
to O
stimulation O
resulted O
in O
a O
decrease O
in O
transcription O
of O
the O
IL2 B
gene I
. O

IL B
- I
4 I
suppressed O
IL O
- O
2 O
and O
IFN O
- O
gamma O
mRNA O
levels O
in O
primary O
human O
T O
cells O
, O
and O
addition O
of O
anti B
- I
CD28 I
antibodies I
relieved O
this O
suppression O
. O

Using O
enhancer B
- I
reporter I
constructs I
, O
IL B
- I
4 I
specifically O
down O
- O
regulated O
the O
NFIL B
- I
2B I
element I
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL B
- I
2B I
binding I
site I
indicated O
that O
IL B
- I
4 I
inhibited O
the O
NFIL B
- I
2B I
complex I
and O
that O
the O
NFIL B
- I
2B I
DNA I
binding I
factor I
is O
distinct O
from O
AP B
- I
1 O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
regulate O
development O
and O
function O
of O
T O
- O
cell O
subsets O
involved O
in O
cell O
- O
mediated O
immunity O
in O
part O
by O
inhibiting B
factors I
required O
for O
transcription O
of O
the O
IL2 B
gene I

The O
suggestion O
is O
offered O
that O
the O
immunologic O
response O
to O
self B
- I
antigens I
exposed O
by O
disease O
or O
trauma O
may O
be O
suppressed O
by O
corticosteroid O
to O
offset O
the O
likelihood O
of O
autoimmune O
attack O
. O

Protein B
tyrosine I
kinase I
activation O
is O
required O
for O
lipopolysaccharide O
induction O
of O
cytokines B
in O
human O
blood O
monocytes O
. O

Bacterial O
LPS O
induce O
production O
of O
cytokines B
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
, O
and O
TNF B
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O

Bacterial O
LPS O
induce O
production O
of O
cytokines B
such O
as O
IL B
- I
1 I
, O
IL B
- I
6 I
, O
and O
TNF B
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O

Protein B
kinase I
C I
inhibition O
by O
staurosporine O
reduced O
LPS O
induction O
of O
TNF B
- I
alpha I
, O
whereas O
it O
had O
no O
effects O
on O
IL B
- I
6 I
and O
IL O
- O
1 O
beta O
. O

Protein B
kinase I
C I
inhibition O
by O
staurosporine O
reduced O
LPS O
induction O
of O
TNF B
- I
alpha I
, O
whereas O
it O
had O
no O
effects O
on O
IL B
- I
6 I
and O
IL O
- O
1 O
beta O
. O

Protein B
kinase I
C I
inhibition O
by O
staurosporine O
reduced O
LPS O
induction O
of O
TNF B
- I
alpha I
, O
whereas O
it O
had O
no O
effects O
on O
IL B
- I
6 I
and O
IL O
- O
1 O
beta O
. O

Inhibition O
of O
protein B
kinase I
A I
by O
H89 O
reduced O
IL B
- I
6 I
mRNA I
levels O
but O
did O
not O
detectably O
change O
IL O
- O
1 O
beta O
or O
TNF O
- O
alpha O
mRNA O
levels O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B
kinase I
C I
and O
protein B
kinase I
A I
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B
, O
whereas O
PTK B
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B
and O
NF B
- I
kappa I
B I
activation O
in O
monocytes O
. O

Many O
liberated O
NF B
- I
kappa I
B I
dimers I
reached O
the O
nucleus O
, O
where O
increased O
c B
- I
rel I
, O
p65 O
and O
p50 O
were O
detected O
by O
immunoblotting O
and O
by O
DNA O
binding O
assays O
. O

Some O
liberated B
dimers I
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B
kappa I
B I
alpha I
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B
kappa I
B I
alpha I
and O
not O
of O
c B
- I
rel I
or O
p65 B
. O

No O
effect O
of O
LPS O
treatment O
was O
detected O
on O
p105 B
or O
p100 B
, O
which O
also O
retain O
rel B
family I
members I
in O
the O
cytoplasm O
. O

Identification O
of O
a O
killer B
cell I
- I
specific I
regulatory I
element I
of O
the O
mouse B
perforin I
gene I
: O
an O
Ets O
- O
binding O
site O
- O
homologous O
motif O
that O
interacts O
with O
Ets B
- I
related I
proteins I
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell O
- O
type O
- O
specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA O
- O
protein O
interactions O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
mouse B
perforin I
gene I
( O
Pfp B
) O
. O

Within O
this O
segment O
, O
a O
9 O
- O
mer O
motif O
( O
5 O
' O
- O
ACAGGAAGT O
- O
3 O
' O
, O
residues B
- I
505 I
to I
- I
497 I
; O
designated O
NF O
- O
P O
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets B
proto I
- I
oncoprotein I
- I
binding I
site I
, O
was O
found O
to O
interact O
with O
two O
proteins O
, O
NF B
- I
P1 I
and O
NF B
- I
P2 I
. O

Within O
this O
segment O
, O
a O
9 O
- O
mer O
motif O
( O
5 O
' O
- O
ACAGGAAGT O
- O
3 O
' O
, O
residues B
- I
505 I
to I
- I
497 I
; O
designated O
NF O
- O
P O
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets B
proto I
- I
oncoprotein I
- I
binding I
site I
, O
was O
found O
to O
interact O
with O
two O
proteins O
, O
NF B
- I
P1 I
and O
NF B
- I
P2 I
. O

NF B
- I
P2 I
appears O
to O
be O
induced O
by O
reagents O
known O
to O
up O
- O
regulate O
the O
perforin O
message O
level O
and O
is O
present O
exclusively O
in O
killer O
cells O
. O

Electrophoretic O
mobility O
shift O
assay O
and O
UV O
cross O
- O
linking O
experiments O
revealed O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
may O
possess O
common O
DNA B
- I
binding I
subunits I
. O

Electrophoretic O
mobility O
shift O
assay O
and O
UV O
cross O
- O
linking O
experiments O
revealed O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
may O
possess O
common O
DNA B
- I
binding I
subunits I
. O

However O
, O
the O
larger O
native O
molecular O
mass O
of O
NF B
- I
P1 I
suggests O
that O
NF B
- I
P1 I
contains O
an O
additional O
non B
- I
DNA I
- I
binding I
subunit I
( O
s O
) O
. O

However O
, O
the O
larger O
native O
molecular O
mass O
of O
NF B
- I
P1 I
suggests O
that O
NF B
- I
P1 I
contains O
an O
additional O
non B
- I
DNA I
- I
binding I
subunit I
( O
s O
) O
. O

In O
view O
of O
the O
homology O
between O
the O
NF B
- I
P I
motif I
and O
other O
Ets B
proto I
- I
oncoprotein I
- I
binding I
sites I
, O
it O
is O
postulated O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
belong O
to O
the O
Ets B
protein I
family I
. O

In O
view O
of O
the O
homology O
between O
the O
NF B
- I
P I
motif I
and O
other O
Ets B
proto I
- I
oncoprotein I
- I
binding I
sites I
, O
it O
is O
postulated O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
belong O
to O
the O
Ets B
protein I
family I
. O

In O
view O
of O
the O
homology O
between O
the O
NF B
- I
P I
motif I
and O
other O
Ets B
proto I
- I
oncoprotein I
- I
binding I
sites I
, O
it O
is O
postulated O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
belong O
to O
the O
Ets B
protein I
family I
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

This O
potent O
activation O
does O
not O
require O
accessory O
cells O
, O
such O
as O
monocytes O
, O
but O
depends O
on O
persistent O
interleukin B
2 I
( O
IL B
- I
2 I
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25 B
/ I
IL I
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
chain I
gene I
. O

The O
transcription B
factor I
NF I
- I
kappa I
B I
participates O
in O
the O
regulation O
of O
both O
IL B
- I
2 I
and I
IL I
- I
2R I
alpha I
genes I
, O
as O
well O
as O
multiple B
cellular I
genes I
involved O
in O
T O
- O
cell O
proliferation O
. O

As O
the O
role O
of O
p50 B
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF B
- I
kappa I
B1 I
( O
p50 B
/ I
p105 I
) O
gene O
regulation O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
and O
Western O
and O
Northern O
blot O
analyses O
, O
we O
studied O
NF B
- I
kappa I
B1 I
gene I
expression O
during O
T O
- O
cell O
stimulation O
via O
CD2 B
+ I
CD28 I
. O

Vitamin B
D I
receptor I
quantitation O
in O
human O
blood O
mononuclear O
cells O
in O
health O
and O
disease O
. O

Vitamin B
D I
receptor I
( O
VDR O
) O
concentration O
was O
quantitated O
in O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
from O
patients O
with O
absorptive O
hypercalciuria O
( O
AH O
) O
and O
patients O
with O
high O
1 O
, O
25 O
( O
OH O
) O
2D3 O
due O
to O
acquired O
or O
transient O
disease O
states O
and O
the O
results O
compared O
to O
those O
in O
normal O
subjects O
. O

The O
synergistic O
induction O
of O
tyrosine O
phosphorylation O
by O
H2O2 O
plus O
vanadate O
included O
physiologically O
relevant O
proteins O
such O
as O
PLC B
gamma I
1 I
. O

Although O
treatment O
of O
cells O
with O
H2O2 O
alone O
did O
not O
affect O
the O
activity O
of O
src B
family I
kinases I
, O
treatment O
with O
H2O2 O
plus O
vanadate O
led O
to O
activation O
of O
the O
p56lck B
and I
p59fyn I
tyrosine I
kinases I
. O

Induction O
of O
tyrosine O
phosphorylation O
by O
ROI O
may O
thus O
lead O
to O
many O
of O
the O
pleiotropic O
effects O
of O
ROI O
in O
lymphoid O
cells O
, O
including O
downstream O
activation O
of O
PLC B
gamma I
1 I
and O
NF B
- I
kappa I
B I

The O
influence O
of O
human B
serum I
albumin I
and O
sex B
hormone I
binding I
globulin I
( O
SHBG B
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

Multiple O
closely O
- O
linked O
NFAT B
/ I
octamer I
and O
HMG B
I I
( I
Y I
) I
binding I
sites I
are O
part O
of O
the O
interleukin O
- O
4 O
promoter O
. O

We O
show O
here O
that O
the O
immediate B
upstream I
region I
( O
from O
position O
- O
12 O
to O
- O
270 O
) O
of O
the O
murine B
interleukin I
4 I
( I
Il I
- I
4 I
) I
gene I
harbors O
a O
strong O
cell O
- O
type O
specific O
transcriptional B
enhancer I
. O

In O
T O
lymphoma O
cells O
, O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
/ I
enhancer I
is O
stimulated O
by O
phorbol O
esters O
, O
Ca O
+ O
+ O
ionophores O
and O
agonists O
of O
protein B
kinase I
A I
and O
inhibited O
by O
low O
doses O
of O
the O
immunosuppressant O
cyclosporin O
A O
. O

Whereas O
the O
binding O
of O
NFAT B
- I
1 I
and O
Octamer B
factors I
enhance O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
, O
the O
binding O
of O
HMG O
I O
( O
Y O
) O
suppresses O
its O
activity O
and O
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il B
- I
4 I
transcription O
in O
resting O
T O
lymphocytes O
. O

Whereas O
the O
binding O
of O
NFAT B
- I
1 I
and O
Octamer B
factors I
enhance O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
, O
the O
binding O
of O
HMG O
I O
( O
Y O
) O
suppresses O
its O
activity O
and O
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il B
- I
4 I
transcription O
in O
resting O
T O
lymphocytes O
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC B
- I
specific I
phospholipase I
C I
( O
PC B
- I
PLC I
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC B
- I
PLC I
induces O
functional O
activation O
of O
NF B
- I
kappa I
B I
and O
increases O
human B
immunodeficiency I
virus I
( I
HIV I
) I
enhancer I
activity O
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC B
- I
specific I
phospholipase I
C I
( O
PC B
- I
PLC I
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC B
- I
PLC I
induces O
functional O
activation O
of O
NF B
- I
kappa I
B I
and O
increases O
human B
immunodeficiency I
virus I
( I
HIV I
) I
enhancer I
activity O
. O

Induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor B
necrosis I
factor I
or O
interleukin B
1 I
. O

Induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor B
necrosis I
factor I
or O
interleukin B
1 I
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T O
- O
cell O
lines O
, O
induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
resulted O
in O
clear O
induction O
of O
luciferase B
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B
kappa I
B I
enhancers I
or O
wild O
type O
, O
but O
not O
kappa O
B O
- O
mutated O
, O
HIV B
long I
terminal I
repeat I
constructs I
. O

HIV O
replication O
was O
increased O
by O
PC B
- I
PLC I
in O
chronically O
infected O
monocytes O
and O
T O
lymphocytes O
. O

Interaction O
of O
IL B
- I
2 I
with O
its O
high B
affinity I
membrane I
receptor I
complex I
( O
IL B
- I
2R I
) O
present O
on O
activated O
T O
lymphocytes O
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O

Interaction O
of O
IL B
- I
2 I
with O
its O
high B
affinity I
membrane I
receptor I
complex I
( O
IL B
- I
2R I
) O
present O
on O
activated O
T O
lymphocytes O
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O

Glucocorticoids O
inhibit O
IL B
- I
2 I
production O
by O
inhibiting O
TCR O
- O
mediated O
signal O
transduction O
. O

We O
asked O
whether O
they O
also O
inhibit O
the O
action O
of O
IL B
- I
2 I
by O
inhibiting O
signal O
transduction O
through O
IL B
- I
2R I
. O

We O
asked O
whether O
they O
also O
inhibit O
the O
action O
of O
IL B
- I
2 I
by O
inhibiting O
signal O
transduction O
through O
IL B
- I
2R I
. O

Human O
peripheral O
blood O
T O
cells O
, O
stimulated O
with O
PMA O
for O
48 O
h O
( O
PMA O
blasts O
) O
, O
were O
incubated O
with O
IL B
- I
2 I
in O
the O
presence O
of O
incremental O
dosages O
of O
dexamethasone O
( O
Dex O
; O
10 O
( O
- O
5 O
) O
- O
10 O
( O
- O
9 O
) O
M O
) O
. O

In O
addition O
, O
Scatchard O
plot O
analysis O
of O
125I B
- I
labeled I
IL I
- I
2 I
showed O
that O
Dex O
did O
not O
affect O
the O
binding O
of O
IL B
- I
2 I
, O
thus O
suggesting O
that O
inhibition O
is O
due O
to O
a O
postreceptor O
effect O
. O

IL O
- O
2 O
- O
dependent O
IL O
- O
2R O
alpha O
expression O
in O
PMA O
blasts O
and O
NF B
- I
kB I
induction O
in O
resting O
human O
T O
cells O
were O
also O
inhibited O
by O
Dex O
. O

These O
results O
demonstrate O
that O
glucocorticoids O
inhibit O
preactivated O
T O
cells O
by O
down O
- O
regulating O
signal O
transduction O
through O
IL B
- I
2R I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

